Molecular determinants of astrocyte morpho-functional changes in Alzheimer’s disease by Ulzheimer, Norah Elisa
1 
 
Molecular determinants of astrocyte morpho-functional 
changes in Alzheimer’s disease 
 
 
 
by 
 
 
 
 
 
Norah Elisa Ulzheimer 
 
 
 
 
 
 
 
 
 
 
 
 
A thesis submitted in partial fulfilment of the requirements for the degree of              
Doctor of Philosophy at the University of Central Lancashire  
 
 
 
 
 
 
 
 
June 2019 
2 
 
STUDENT DECLARATION FORM    
 
Type of Award   Doctor of Philosophy 
 
School    Pharmacy & Biomedical Sciences 
 
 
1. Concurrent registration for two or more academic awards 
  
 I declare that while registered as a candidate for the research degree, I have not been 
a registered candidate or enrolled student for another award of the University or other 
academic or professional institution 
 
  
 
2. Material submitted for another award 
 
 I declare that no material contained in the thesis has been used in any other submission 
for an academic award and is solely my own work 
 
  
 
3.  Collaboration 
 
 Where a candidate’s research programme is part of a collaborative project, the thesis 
must indicate in addition clearly the candidate’s individual contribution and the extent 
of the collaboration.  Please state below: 
 N/A 
  
4. Use of a Proof-reader 
 
 No proof-reading service was used in the compilation of this thesis. 
 
 
Signature of Candidate    
 
Print name:   Norah Elisa Ulzheimer 
 
 
  
3 
 
Abstract 
As people are living longer, neurodegenerative disorders such as Alzheimer’s disease 
(AD) are becoming more prevalent but the pursuit for treatments has yet to deliver 
satisfactory results. By the time AD is diagnosed, the typical hallmarks of neurofibrillary 
tangles and senile plaques are present and cognitive decline has occurred, pointing future 
research towards the early stages of the disease. Indeed, recent research has unearthed 
cell-autonomous atrophy of astrocytes in the early stages of AD, characterised by 
decreased cell size and loss of processes. This aberrant astrocyte morphology was present 
in both sporadic and familial AD models and manifests independently of senile plaques. 
These findings challenge the neuron-centric view of AD, granting glial cells an 
undeniable role in neurodegeneration. The exact mechanisms underlying aberrant 
astrocyte morphology are entirely unexplained. This thesis explores how the Cas-
proteins, previously identified by genome-wide association studies as genetic risk-factors 
for late-onset AD, NEDD9 and CASS4 act as regulators of astrocyte morphology and 
function. This could potentially unearth mechanisms that lead to astrocyte atrophy in AD.  
This was achieved by transiently transfecting primary human cortical astrocytes in vitro 
with vectors mediating the overexpression or siRNA-induced knock-down of either 
NEDD9 or CASS4. Concurrent expression of GFP, which localised throughout the entire 
cell, permitted the visualisation of complete cellular morphologies, including fine 
processes. Morphological analysis by visual binning into morphological subtypes or 3D 
reconstruction followed by morphometric quantifications (e.g. surface area, volume) 
revealed that overexpression or knock-down of either NEDD9 or CASS4 induced 
significant changes in astrocyte morphology compared to controls and, specifically, 
depletion of the proteins lead to astrocyte atrophy, mimicking a phenotype previously 
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found in other studies of AD models. Moreover, manipulation of Cas-protein levels 
induced altered expression and sub-cellular distribution of key astrocyte functional 
markers, including glial fibrillary acid protein (GFAP) and the calcium-binding protein, 
S100B; further mimicking the pathological phenotype reported in human iPSC astrocyte 
models of AD. 
Hence, it appears that both NEDD9 and CASS4 are capable of inducing morphological 
and functional changes in human astrocytes and may therefore contribute to astrocyte 
pathology in AD. This implies that the Cas-proteins or binding partners are potentially 
contributing to astrocyte atrophy in AD. This thesis delivers ample grounds for further 
research which could identify yet unexplored pathways, which could be used for new 
early diagnostic tests or therapeutic measures. 
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1 Chapter 1 – Introduction 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD), first described by Alois Alzheimer (Alzheimer, 1910), is a 
progressive neurodegenerative disorder and the leading cause of dementia worldwide 
(Feigin 2019). The World Health Organisation (WHO) reported 81.1 million cases of 
Alzheimer’s disease last year and estimates 152 million people will be suffering from 
dementia by 2050 (Patterson, 2018). These figures and the associated cost of health care 
demonstrate the need for continuing research into AD. 
AD in its familial or sporadic form manifests over several years; ranging from short-term 
memory loss to severe cognitive decline, ultimately leading to complete loss of bodily 
functions and thus death. Pathophysiologically, AD is characterised by synaptic 
dysfunction, accumulation of β-amyloid (Aβ) aggregates (“senile plaques”) and 
intracellular neurofibrillary tangles of hyperphosphorylated tau, and eventual neuronal 
loss (Braak et al., 1989, Hardy and Selkoe, 2002, Holtzman et al., 2011). 
Neurodegeneration arises in the entorhinal cortex, advances to the hippocampus and 
finally manifests in the frontal, temporal and parietal lobes, leading to extensive loss of 
grey matter (Karas et al., 2004, Thompson et al., 2003, Janke et al., 2001).  
Hypotheses on how exactly AD begins and progresses are plentiful, with most centred on 
the archetypical hallmark of extracellular Aβ plaques. This aberrant protein interferes 
with cell signalling, particularly intracellular calcium signalling, and protein synthesis, 
ultimately leading to inflammatory and stress responses and thus cell death (Abramov et 
al., 2003). The amyloid hypothesis posits that Aβ aggregates trigger the onset of AD. 
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First suggested by Glenner in 1984, this hypothesis was widely accepted (Glenner et al., 
1984, Masters et al., 1985, Hardy and Allsop, 1991) and over three decades, research has 
focused on senile plaques as a therapeutic target (Braak et al., 1989, Chen et al., 2000, 
Haass and Selkoe, 2007, Hsiao et al., 1996). Unfortunately, treatments targeted to Aβ 
have yet to yield satisfactory clinical results, prompting criticism within the field that a 
shift in the focus of AD research is necessary and overdue (Golde et al., 2011, Castello 
et al., 2014, Moreno-Treviño et al., 2015, Kametani and Hasegawa, 2018). 
There are several pitfalls with amyloid deposits as diagnostic and therapeutic targets for 
AD. Aβ plaques are also found in the healthy aging brain, in the absence of pathologies, 
diminishing diagnostic value of amyloid plaques (Davis et al., 1999, Fagan et al., 2009). 
Furthermore, the appearance of senile plaques correlates poorly with cognitive decline; 
hence the anti-Aβ treatments developed to date have only been used at the symptomatic 
stage, when cognitive decline has already occurred, hence limiting their curative potential 
(Rygiel, 2016, Kametani and Hasegawa, 2018). Moreover, it has been suggested that 
plaque formation might actually be a protective mechanism to corral the highly toxic 
soluble Aβ species to a larger insoluble mass (Gandy et al., 2010, Lublin and Gandy, 
2010); and prevention of this mechanism might actually exacerbate AD pathology. 
The second hallmark of AD, tau neurofibrillary tangles (NFT) appear to provide a 
superior diagnostic and therapeutic target. Tau is a soluble phosphoprotein 
predominantly, but not exclusively, found in neurons of the healthy brain (Weingarten et 
al., 1975), where it interacts with and stabilises microtubules. Tau activity is regulated by 
splicing (six isoforms) and post translational modifications, such as phosphorylation 
(Lindwall and Cole, 1984, Alonso et al., 1994, Wray et al., 2008). In AD, tau is 
hyperphosphorylated, which is believed to induce insoluble aggregates (Bancher et al., 
1989, Hanger et al., 1991, Kopke et al., 1993). Hyperphosphorylated tau is not only a 
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hallmark of AD but occurs in several neurodegenerative diseases (tauopathies), such as 
Pick disease, progressive supranuclear palsy and Parkinsonism with fronto-temporal 
dementia (Irwine, 2017, Goetz et al., 2018). Hyperphophorylated tau is believed to 
propagate from cell to cell in a prion-like manner (Clavaguera et al., 2009, Nonaka et al., 
2010, Goedert and Spillantini, 2017) and correlates with cognitive impairment (Braak and 
Braak, 1991, Bejanin et al., 2017), giving tau accumulation superior diagnostic value than 
Aβ. Although significant progress has been made, the exact mechanisms involved in the 
generation of aggregated tau remain unknown, hampering efforts to utilise tau as a 
therapeutic target (Himmelstein et al., 2012, Kametani and Hasegawa, 2018).  
The microtubule associated protein tau (MAPT) gene encodes tau and several tauopathies 
can be traced back to mutations in the MAPT gene, such as Pick’s disease (Pollock et al., 
1986, Sergeant et al., 2005). Although abnormal phosphorylation of tau is an early 
hallmark of neurodegeneration, AD is the most common secondary tauopathy with no 
known mutations of MAPT (Simic et al., 2016, Terry, RD., 1996). Moreover, the exact 
mechanisms leading to these hallmarks are yet to be fully elucidated. Hence, there is a 
renewed research focus on understanding the causes and pathogenesis of AD in a bid to 
reveal alternative therapeutic and diagnostic targets.  
 
1.2 Established risk genes of Alzheimer’s disease 
The vast majority of cases of AD are of a sporadic or late (>65 years) onset (LOAD) in 
nature. Much of what is known is based on the familial or early-onset form of AD 
(EOAD), which accounts for less than 2% of AD cases (Rosenthal and Kamboh, 2014). 
Almost all cases of EOAD are familial in nature and can be traced to several known 
mutations within three genes, APP (amyloid precursor protein), PSEN1 and PSEN2 
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(presenilins 1 and 2) (Bagyinszky et al., 2016, Lanoiselee et al., 2017, Sherrington et al., 
1995, Campion et al., 1999). Previously thought to be idiopathic, it is now understood 
that late-onset Alzheimer’s disease (LOAD) also entails a genetic component and several 
genes which confer increased risk of developing the disease have been identified (Bertram 
et al., 2008, Piaceri et al., 2013). 
The most widely established and strongest genetic risk for LOAD is the ε4 allele of the 
APOE gene. Encoding apolipoprotein E (ApoE), a vital component and regulator of lipid 
metabolism and involved in Aβ clearance. The ε4 allele has been shown to correlate with 
an increased risk of both familial/early and sporadic/late forms of AD (Chartier-Harlin et 
al., 1994, Kim et al., 2009, Corder et al., 1993, Morris et al., 2010). While this is a major 
advancement for our understanding of LOAD risk, only around half of individuals 
developing LOAD carry the APOE ε4 allele (Huang et al., 2004, Naj et al., 2011), raising 
the question of the aetiology in the rest of LOAD cases.  
 
1.3 Emerging Alzheimer’s disease risk genes 
In a quest to elucidate the pathogenesis of LOAD, genome-wide association studies 
(GWAS) were used to search for LOAD risk genes (Lambert et al., 2009; Harold et al., 
2009; Seshadri et al., 2010; Naj et al., 2011; Hollingworth et al., 2011; Lee et al., 2011; 
Reitz et al., 2013) These studies have led to the identification of almost 30 susceptibility 
loci harbouring single nucleotide polymorphisms (SNPs) which correlate with an 
enhanced risk of developing LOAD. Since the identification of these risk genes, very few 
studies have attempted to define how they might actually influence LOAD development. 
Those which have been published have focused on functions and pathways known to be 
affected or altered in LOAD. These include genes implicated with the immune system, 
24 
 
CD33, CR1, HLA-DRB1-DRB5, MS4A, MEF2C, TREM2 (Bradshaw et al., 2013, Kok et 
al., 2011, Lambert et al., 2013, Antúnez et al., 2011, Tang et al., 2016, Jonsson et al., 
2013); lipid transport and cholesterol metabolism, ABCA7, CLU, PLD3, SORL1 
(Hollingworth et al., 2011, Harold et al., 2009, Cruchaga et al., 2014, K et al., 2008) and 
endocytosis BIN1, PICALM, CD2AP, EPHA1, SLC24A4/RIN3 (Chapuis et al., 2013, 
Harold et al., 2009, Chen et al., 2015, Lambert et al., 2013, Rosenthal and Kamboh, 
2014). 
 
Among the identified LOAD risk loci are polymorphic variants within NEDD9 (Neural 
precursor cell expressed developmentally down-regulated protein 9) and CASS4 (Cas 
Scaffolding Protein Family Member 4) (Li et al., 2008, Lambert et al., 2013). Follow-up 
studies showed that one SNP in NEDD9 (rs760678) and three SNPs in CASS4 
(rs7274581, rs16979934 and rs6024870) had the strongest association with LOAD 
development (Li et al., 2008, Fu et al., 2012, Xing et al., 2011, Wang et al., 2012, 
Rosenthal and Kamboh, 2014). These polymorphisms appear in non-coding regions of 
NEDD9 and CASS4, including transcription factor binding sites and intron splice sites, 
hence it is predicted that these SNPs confer altered (likely reduced) expression of these 
proteins in carrier individuals (Beck et al., 2014). 
Interestingly, both NEDD9 and CASS4 are members of the same Cas-proteins family, 
one which has not previously been linked to AD. That both of these paralogous proteins, 
together with a shared interacting partner in the form of Protein Tyrosine Kinase 2 Beta 
(PTK2B), were identified by multiple groups working independently is intriguing and 
would be expected to generate significant interest. However very few studies have 
focused on NEDD9 or CASS4 involvement in LOAD or its functions in normal brain 
physiology. This may be owed to low frequencies of the risk variants in populations, as 
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NEDD9 rs760678 occurs with an average frequency of 34% and CASS4 variants are even 
less common with rs7274581 (10%), rs16979934 (5%), and rs6024870 less than 1% 
(Wang et al., 2012, Xing et al., 2011, Laumet et al., 2010, Lin et al., 2017). Although 
more studies are needed, so far, NEDD9 and CASS4 SNPs have been shown to correlate 
with only a low risk of developing LOAD (Chaudhry et al., 2015, Rosenthal et al., 2014, 
Wang et al., 2015) and are less frequently found than other risk variants, such as APOE. 
However, at the beginning of this thesis, the Cas-proteins were the only proteins, 
implicated as LOAD ‘risk genes’, involved in cell morphology and hence of interest in 
the investigation of astrocyte atrophy. 
1.4 Cas-proteins 
The Cas-protein, NEDD9/CasL/Hef1 (Law et al., 1996, Minegishi et al., 1996), 
CASS4/HEPL (Singh et al., 2008), p130Cas/BCAR1 (Sakai et al., 1994) and EFS/Sin 
(Ishino et al., 1995) make up a family of scaffolding proteins and are highly involved in 
signalling pathways, acting as central ‘nodes’ for various processes including cell growth, 
cell survival, migration and adhesion (Beck et al., 2014).  
Although lacking enzymatic activity, Cas-proteins harbour four distinct domains, 
including the SH3 (Src homology 3) which facilitates the binding of protein substrates 
such as the tyrosine kinases protein tyrosine kinase 2 Beta (PTK2B) and focal adhesion 
kinase (FAK), Figure 1.1 (Tikhmyanova et al., 2010). Adjacent to the SH3 domain is a 
highly conserved largely unstructured substrate binding domain containing varying 
numbers of YxxP motifs, which create binding sites upon phosphorylation for partners 
with SH2 domains; predominantly adaptor molecules such as the proto-oncogene Crk 
(Roselli et al., 2010, Sawada et al., 2006), Next is a highly variable four-helix bundle 
which provides further docking sites for other interacting partners such as molecular 
chaperones and signalling adaptor proteins (Briknarova et al., 2005, Vuori et al., 1996). 
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Finally, at the C-terminus is highly conserved and might mediate homo- or 
heterodimerization with other Cas-proteins (Law et al., 1999) and is predicted to mediate 
binding to a raft of other proteins including those containing helix-loop-helix domains 
and E3 ubiquitin ligases (Tikhmyanova et al., 2010, Singh et al., 2007).  
 
Figure 1.1 General structure of the Cas-proteins family members 
All Cas-proteins comprise four distinct similarly structured domains including 
an SH3 domain, unstructured substrate binding domain, four-helix bundle and 
C-terminal domain (A). B indicates where some of the key Cas-proteins 
interacting partners have been found to bind. Note, while CASS4 and NEDD9 
retain this overall domain structure, not all identified binding proteins are 
known to interact with these two family members. (Tikhmyanova et al., 2010) 
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Despite their overall structural similarities, the individual domains do vary somewhat 
between Cas-protein family members and hence so do their ability to bind other proteins. 
Moreover, their varied tissue-specific expression and subcellular localisations suggests 
that each of the Cas-protein may be capable of contributing to distinct cellular processes 
(Law et al., 1996, Singh et al., 2008, Tikhmyanova et al., 2010). 
 
 Neural precursor cell expressed developmentally down-regulated 
protein 9 (NEDD9) 
NEDD9 (also known as HEF1) is abundantly expressed in many tissues (Fashena et al., 
2002, Minegishi et al., 1996, Aquino et al., 2008, Chang et al., 2012), although expression 
levels are thought to vary greatly (Law et al., 1998). NEDD9 (isoform 1) has a molecular 
weight of 93kDa, which occurs as two larger, phosphorylated versions of 105kDa and 
115kDa (Singh et al., 2007) and three cleaved isoforms of the protein 65, 55 and 28kDa 
have been identified and (Law et al., 2000); expression of these isoforms is cell cycle 
dependant (Fashena et al., 2002, Singh et al., 2007). 
Similar to other Cas-proteins, NEDD9 functions as a scaffold protein and regulates the 
assembly of signalling molecules in a number of cellular signalling cascades (Law et al., 
1996, Law et al., 1998, Pugacheva and Golemis, 2005, Manie et al., 1997). Binding 
partners of NEDD9 include kinases, such as aurora kinase A (AURKA), FAK and 
PTK2B; involved in apoptosis, adhesion, invasion and migration (Beck et al., 2014, Singh 
et al., 2007, Tikhmyanova et al., 2010). Kinase activation depends on NEDD9 expression 
levels, which themselves are cell cycle regulated (Law et al., 1998). Increased expression 
leads to phosphorylation of NEDD9 motifs by the proto-oncogene tyrosine-protein 
kinase, Src, to create additional docking sites for SH2 domain-containing partner proteins, 
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such as Crk. This results in the assembly of signalling complexes, capable of structurally 
rearranging the cytoskeleton (Aquino et al., 2008, Deneka et al., 2015, Manie et al., 
1997). Furthermore, believed to be anchored to focal adhesions and the cytoskeleton, 
NEDD9 has been shown to be sensitive to mechanical forces via its C-terminus; exposing 
yet more binding domains in response to cell stretching (Tamada et al., 2004). As such, 
NEDD9 is essential for the maintenance of structural plasticity (Dent, 2017, Haseleu et 
al., 2013) and plays an important role in translating internal and external signals to 
alterations in cellular morphology via regulation of the cytoskeleton (Law et al., 1998). 
Previously believed to be primarily cytoplasmic, NEDD9 is active in several cellular 
compartments (including the nucleus, Golgi and endoplasmic reticulum) and hence plays 
a role in coordinating signalling between them (O'Neill and Golemis, 2001, Singh et al., 
2007, Law et al., 1998). Evidence has been found that NEDD9 is able to couple cell cycle 
regulation to morphological alterations, notably adhesion and migration (Law et al., 1998, 
Dadke et al., 2006, Rousseau et al., 2015). Unsurprisingly therefore, NEDD9 has received 
a great deal of attention in regard to its role in cancer. 
By far the majority of published studies on NEDD9 have centred on its role in the 
progression of various cancers, revealing this Cas-protein to be a major determinant of 
cancer metastasis (Nikonova et al, 2014). Overexpression of NEDD9 has been shown to 
promote cancer cell migration and invasion (Gabbasov et al., 2018, Feng et al., 2015, Li 
et al., 2011, Izumchenko et al., 2009), and induce the growth of cellular processes in 
epithelial-derived cancer cells (Bargon et al., 2005). Related to the brain, NEDD9 has 
been identified as a regulator of invasion in glioblastoma, where a high expression of the 
protein correlates with a decrease in progression-free survival (Speranza et al., 2012). 
Other studies have also confirmed a correlation between high NEDD9 expression and 
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poor survival in glioma and neuroblastoma; whereby NEDD9 depletion decreases cell 
migration (Zhong et al., 2014, McLaughlin et al., 2014, Kondo et al., 2012).  
Outside of cancer, NEDD9 has been shown to regulate neural crest cell migration during 
embryogenesis, a process vital for proper brain development (Aquino et al., 2008, Merrill 
et al., 2004). Additionally, the same study proposed NEDD9 expression as a master 
switch for cell morphology; inducing cell rounding when depleted and elongation when 
highly expressed (Aquino et al., 2008), implicating NEDD9 expression in cell 
morphology. Moreover, via its activation of AURKA, NEDD9 plays a role in both 
centrosome formation and primary cilia disassembly (Pugacheva and Golemis, 2005, 
Pugacheva et al., 2007). Taken together, these studies clearly implicate NEDD9 as a 
major regulator of cell morphology determination. 
 
 Cas Scaffolding Protein Family Member 4 (CASS4) 
CASS4 (also known as HEPL) is the most recent addition to the Cas-proteins family 
(Singh et al., 2008). Sharing some structural homology with its paralogues, its activity is 
believed to be dependent on the presence of other Cas-protein, although this is not yet 
conclusively proven (Deneka et al., 2015). There are three known isoforms of CASS4 
87kDa (isoform 1), 74kDa (isoform 2) and 38kDa (isoform 3). It is not known if highly 
phosphorylated or cleaved isoforms, comparable to paralogue NEDD9, exist or if these 
are also cell cycle related. Very little is known about the biological functions of CASS4, 
but it is assumed to act in a similar manner to its paralogues. As for NEDD9, 
overexpression of CASS4 has been suggested to correlate with tumour severity and poor 
prognosis in cancers, although direct mechanistic studies are lacking (Li et al., 2016, Miao 
et al., 2013). Determination of discrete roles for CASS4 is complicated by the abundant 
cellular expression of other Cas-proteins, such as NEDD9 and BCAR1. Nonetheless, its 
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subcellular localisation implies CASS4 activity at focal adhesions, and interactions 
between CASS4 and FAK and Src kinases have been experimentally confirmed, despite 
CASS4 lacking a common site found in other Cas-proteins which facilitates Src binding 
(Hassan et al., 2018, Singh et al., 2008, Tikhmyanova et al., 2010). Furthermore, 
overexpression of CASS4 has been demonstrated to be sufficient to induce FAK 
phosphorylation, leading to cell spreading, albeit to a lesser degree than for NEDD9 (Li 
et al., 2016, Singh et al., 2008). Interestingly, CASS4 exerted a bimodal effect on cell 
migration; enhancing migration in a subset of cells, while impeding it in another. While 
the reason for this has not been explored, it may suggest that CASS4’s effects might 
depend upon the relative amounts of other Cas-proteins in each cell, further supporting 
the idea of cell type-specific roles. 
During the initial identification of CASS4, real-time PCR (RT-PCR) revealed high 
expression of CASS4 mRNA in spleen and lungs as well as in leukaemia and ovarian 
cancer cells (Singh et al., 2008). CASS4 mRNA expression, and particularly the protein 
expression has since been described in other tissues, including neuronal cells in the 
cerebral cortex and hippocampus (Kim et al., 2014) and in microglia (Skene and Grant, 
2016). Notwithstanding, a lack of basic knowledge regarding CASS4 tissue expression 
levels remains.  
 
 NEDD9 and CASS4 in Alzheimer’s disease 
Although a recent study employing the expression weighted cell-type enrichment method, 
found that CASS4 was the only protein with a lower expression in glial cells than 
expected in AD brain samples (Skene and Grant, 2016), there is no empirical data to 
confirm the expression levels of CASS4 in glial cells in LOAD.  
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CASS4 has been implicated as a modulator of tau in a drosophila model (Dourlen et al., 
2016) and meta-analysis of neuropathologic features of AD found CASS4 to be 
associated with tau neurofibrillary tangles in brains with AD (Beecham et al., 2014), 
which was confirmed in a population study of 601 participants (Makela et al., 2018).  
One recent study investigated the effect of NEDD9 on brain function using NEDD9 
knock-out mice (Knutson et al., 2016). These mice suffer extensive dendritic spine loss 
in the dentate gyrus and CA1 regions of the hippocampus and hence display significant 
deficits in learning ability in the Morris water maze test, mimicking some of the deficits 
usually seen in AD transgenic mouse models (Martinez-Coria et al., 2015, Stimmell et 
al., 2019). The study concluded that NEDD9 is essential for hippocampal spine 
maintenance, a role which is heavily influenced by astrocytes. 
Very few studies have explored the role of NEDD9 and CASS4 in LOAD and there is no 
knowledge of the Cas-protein expression or role in astrocytes. This thesis is the first 
attempt to establish NEDD9 and CASS4 expression in astrocytes, to identify a possible 
role of the proteins in cell morphology and how the risk variants may contribute to LOAD 
pathology. 
 
1.5 Astrocytes 
Astrocytes (also known as astroglia) are among the most heterogenous cells in the human 
brain. This subset of glial cells has several roles in the central nervous system (CNS). 
Astrocytes are critical during development, as they modulate synapse formation (Casse 
et al., 2018). These cells continue to support, maintain and influence synaptic function 
(Fields et al., 2015, Nishida and Okabe, 2007), they enwrap pre- and postsynaptic 
membranes, building a functional unit termed the tripartite synapse (Perrera et al., 2009), 
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which permits control of homeostasis in the neural tissue (Mohamet et al., 2018). 
Furthermore, these cells are part of the glymphatic pathway via the astrocyte endfeet, a 
connection to the vascular system, allowing transport and clearance of metabolites 
(Bushong et al., 2004, Perez-Alvarez et al., 2014, Nedergaard et al., 2002, Iadecola and 
Nedergaard, 2007); astrocyte endfeet are an integral part of the blood brain barrier (BBB). 
On the whole, astrocytes are essential for the proper functioning of neurones, are 
fundamental to memory formation and are crucial components in the adaptive plasticity 
of the CNS (Verkhratsky and Nedergaard, 2018).  
 Astrocyte morphology 
As the name suggests, astrocyte morphology is roughly stellate, typically consisting of a 
cell body with numerous, often branching, processes. As recognised by Ramón y Cajal 
over 100 years ago, astroglial morphologies are highly varied (Garcia-Lopez et al., 2010). 
These morphologies roughly correlate with neuroanatomical location and specific 
functions (Parpura et al., 2012, Zorec et al., 2015). Astrocytes can be generally 
categorised into the protoplasmic of the grey matter (Figure 1.3, A), which possess 
thicker, defined processes splitting into finer branches; and fibrous astrocytes of the white 
matter (Figure 1.3, B), morphologically differing by copious fibrous processes 
(Rodriguez et al., 2009, Sofroniew and Vinters, 2010). Additionally, several subtypes of 
the above have been identified, including interlaminar astrocytes (Colombo and Reisin, 
2004), varicose projection astroglia (Oberheim et al., 2009), Bergmann glia and Mϋller 
glia (Eroglu and Barres, 2010). It is generally accepted that further subpopulations of 
astrocytes are yet to be defined and likely play diverse roles in health and disease (Miller, 
2018). 
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Figure 1.2 Diagram showing gross morphologies of protoplasmic (A) and fibrous (B) 
astrocytes 
(Adapted from Carson et al., 2018) 
 
 
 Astrocyte function 
The unique morphology of astrocytes is integral to abundant functions in the central 
nervous system (CNS). Numerous processes allow them to form gap junctions with other 
astrocytes and connect to the vascular system via endfeet (Bushong et al., 2004, Perez-
Alvarez et al., 2014, Nedergaard et al., 2002, Iadecola and Nedergaard, 2007), permitting 
transport, clearance and release of ions, hormones, neuromodulators, metabolites and 
neurotransmitters, such as GABA, glutamate and D-serine (Cheung et al., 2015, 
Martineau et al., 2014, Parpura et al., 2012). This exchange, release and uptake of 
molecules is regulated via numerous transporters and by exocytosis (Parpura et al., 2012, 
Lalo et al., 2011, Walz, 2000). Importantly, astroglia have been shown to modulate 
synaptic function and plasticity by stimulating synaptogenesis and altering the structural 
characteristics of dendritic spines, including the stabilisation of individual dendritic 
protrusions and subsequent maturation into spines (Fields et al., 2015, Nishida and 
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Okabe, 2007). The above is dependent on the ability of astrocyte processes to directly 
contact synapses, coupling morphology to function (Hama et al., 2004). Hence, astrocyte 
processes are structurally interwoven with the pre- and post-synaptic membranes, 
forming a functional unit known as the tripartite synapse, Figure 1.3 (Perea et al., 2009). 
 
 
Figure 1.3 Scheme of the tripartite synapse 
Figure representing the transfer of information between neuronal elements and 
astrocyte at the tripartite synapse. (Perea et al., 2009) 
 
 
Despite some original scepticism within the research community, numerous studies have 
now shown that astrocytes actively influence synaptic activity (Baldwin and Eroglu, 
2018, Santello et al., 2019, Perez-Alvarez et al., 2014, Zorec et al., 2015). Astrocytes 
support and maintain the synaptic plasticity required for learning and memory formation 
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(Zovkic et al., 2013, Alberini et al., 2018). To fulfil synaptic requirements, astrocytes 
exhibit enormous structural plasticity, allowing these cells to remodel processes (Perez-
Alvarez et al., 2014). Such structural plasticity requires intracellular signalling inducing 
extensive cytoskeletal rearrangement (Bernardinelli et al., 2014, Heller and Rusakov, 
2015). 
 
 Astrocytes in Alzheimer’s disease 
Although astrocyte pathologies have long been ignored, aberrant astrocyte morphology 
and function have been reported for several neurological disorders, such as Amyotrophic 
Lateral Sclerosis, Parkinson’s disease and AD (Robinson et al., 2016, Pehar et al., 2017, 
Kohutnicka et al., 1998, Verkhratsky et al., 2014). Neurons are more susceptible to injury 
and rely on astroglial protection (Verkhratsky and Nedergaard, 2018), highlighting the 
importance of astrocytes in neurological disorders. As with healthy astrocytes, 
astrogliopathologies are equally as hetereogeneous and complex and astrocytes contribute 
to neurological diseases in several different ways. 
Pathological changes of astrocytes include remodelling, atrophy and hypertrophy 
(Verkhratsky et al., 2017). Hypertrophic astrocytes are characterised by enlarged somata 
and thicker membrane processes, which coincide with an upregulation of GFAP and 
vimentin (Pekny and Pekna, 2014, Zhang et al., 2017). Hypertrophic astrocytes are 
inherent to reactive astrogliosis and a direct consequence of brain injury (Schiweck et al., 
2018). Astrogliosis is scar forming defence mechanism to confine the affected area, 
increase neuroprotection and aid lesion regeneration (Pekny et al., 2016). Inhibition of 
pathways, triggering astrogliosis, such as the Signal transducer and activator of 
transcription 3 (STAT3) pathway, including downstream pro-inflammatory messengers 
such as interleukin 6 (IL6) or Leukaemia inhibitory factor (LIF), has been shown to result 
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in larger lesions (Herman et al., 2008, Sriram et al., 2004), indicating a neuroprotective 
role for astrogliosis. But reactive astrocytes have also been shown to lead to neurotoxicity 
after prolonged damage (Pekny and Pekna, 2014) as they show varying characteristics in 
different disorders (Matias et al., 2019). In neurodegenerative disorders, they are induced 
by microglia (Liddelow et al., 2017), suggesting that reactive/hypertrophic astrocytes are 
not a single manifestation, but rather a group of manifestations with differing roles, 
dependent on the cause of activation.  
In AD, hypertrophic astrocytes have been found in in vitro studies, human post-mortem 
brain samples and in animal models, such as the triple transgenic mouse model of AD 
(3xTg-AD), which contains three mutations associated with familial Alzheimer's disease 
(Olabarria et al., 2010, Verkhratsky et al., 2016, Vijayan et al., 1991, Perez-Nievas and 
Serrano-Pozo, 2018). In AD, hypertrophy/reactivity of astrocytes, believed to be induced 
by activated microglia in response to the presence of amyloid β plaques (Abramov et al., 
2003, Grolla et al., 2013). It is unclear how these astrocytes contribute to synaptic loss 
(Lidelow et al., 2017) but disruption of astrocyte calcium and glutamate signalling by 
amyloid plaques may play a role (Vincent et al., 2010). A similar mechanism of reactive 
astrocytes is also indicated in Parkinson’s disease, where accumulation of α-synuclein 
disrupts astrocyte glutamate transport (Gu et al., 2010) and Amyotrophic Lateral 
Syndrome (ALS), where aberrant glutamate signalling leads to cell death (Martorana et 
al., 2012). Astrogliosis being a robust hallmark of several neurodegenerative disorders, 
highly hypertrophic astrocytes manifest during the later, symptomatic stages of AD 
(Olabarria et al., 2010, Rodriguez-Arellano et al., 2016, Vijayan et al., 1991, Heneka et 
al., 2015).  
Recent studies focus on the presence of atrophic astrocytes in AD, as these have been 
shown to accumulate in amyloid plaques-free areas and prior to neurodegeneration 
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(Kulijewicz-Nawrot et al., 2012, Olabarria et al., 2010, Yeh et al., 2011) but have also 
been shown to be induced by intracerebral injection with Aβ oligomers in mice (Diniz et 
al., 2017). Astrocyte atrophy manifests during the early stages of AD, as found in the 
3xTg-AD mouse model, PDAPP-J20 transgenic mice (Pomilio et al., 2016, Kulijewicz-
Nawrot et al., 2012, Olabarria et al., 2010, Yeh et al., 2011). Most recently, AD-
associated astrocyte atrophy has been demonstrated in human induced pluripotent stem 
cell (iPSC)-derived astrocytes from both EOAD and LOAD patients (Jones et al., 2017), 
which revealed the same phenotypic changes in both forms of the disease. Atrophic 
astrocytes are characterised by reduced somata volumes and process shrinkage 
(Verkhratsky et al., 2010). What exactly leads to this aberrant astrocyte morphology 
remains unknown. As atrophic astrocytes present with a decreased level of glial fibrillary 
acidic protein (GFAP), as well as other cytoskeletal proteins (Jones et al., 2017, Olabarria 
et al., 2010, Rodriguez-Arellano et al., 2016), mechanisms involved in cytoskeletal 
structure and motility may be affected in AD. It remains unknown if atrophic astrocytes 
become hypertrophic during later stages of the disease, if either are brain region 
dependent or whether there is a relationship between hypertrophic and atrophic astrocytes 
at all; hypertrophic and atrophic astrocytes may well be completely independent 
manifestations in the AD brain. It could be hypothesised, that atrophic astrocytes become 
reactive/hypertrophic due to β-amyloid plaques, as atrophic cells lose functions and may 
thus be unable to deal with the plaque burden. Furthermore, the loss of membrane 
processes, as described by Jones et al. (2017) would suggest that these astrocytes are 
unable to retain contact with synapses, leading to loss of homeostasis and ultimately loss 
of these synapses. However, this remains speculative and requires more research as no 
study to date has revealed mechanisms leading to astrocyte atrophy or determined 
functional consequences. 
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As proper morphology is vital to astrocyte function, astrocyte dystrophy coincides with 
aberrant cell function. A study of AD animal models has identified dynamics of astroglial 
functional marker profiles during different stages of AD (3, 9, 18 and 24 months disease 
development). This study employed assessment of GFAP (intermediate filament, 
primarily expressed in astrocytes), glutamine synthetase (enzyme responsible for 
metabolic regulation of glutamate) and S100 calcium-binding protein B (s100β), in 
atrophic astrocytes, which were found to be distinctively expressed during different stages 
of the disease (Rodriguez et al., 2014). This appeared to be region-dependent; as atrophy 
appeared first (at 1 month of age) in the entorhinal cortex, around 6 months of age in the 
prefrontal cortex and ~12 months of age in the hippocampus, implicating how astrocyte 
morphology and function changes during disease development. Furthermore, a recent 
study by Jones et al. (2017), also established a change of key markers in iPSC derived 
astrocytes from AD patients, detecting decreased GFAP, glutamate transporters and GS 
in the iPSC astrocytes. Altered expression of key markers in AD astrocytes implicate 
aberrant function, which is particularly interesting as the iPSC astrocytes were 
investigated in an autonomous culture, hence free of any environmental influences, such 
as dysfunctional neurons or aberrant proteins. As these astrocytes showed aberrant 
morphology, a change in cytoskeletal proteins, such as GFAP, is a likely consequence. 
The decrease in glutamate transporters and GS indicates that these cells may have lost 
their ability to maintain glutamate homeostasis, which could lead to neurotoxicity and 
subsequently loss of synapses.  
A known altered function in astrocytes is abnormal calcium signalling (Abramov et al., 
2003, Grolla et al., 2013, Rodriguez-Arellano et al., 2016). Conflicting studies argue that 
abnormal Aβ is the cause of aberrant calcium signalling in astroglia (Alberdi et al., 2013, 
Abramov et al., 2003, González-Reyes et al., 2017), yet others report no effect (Casley et 
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al., 2009, Toivari et al., 2011). To date, nothing is known about the cause of aberrant 
calcium signalling in atrophic astrocytes, found during early stages of AD development. 
The aforementioned iPSC study also found that the calcium binding protein100β was not 
only reduced, but mislocated to the nucleus. Why or how such mislocation occurs and 
whether it is cause or effect of aberrant calcium signalling, remains to be fully elucidated 
and highlights how much about AD aetiology is yet to be discovered. The findings of 
Jones et al. (2017) provide a new role of astrocytes in AD. Identifying the underlying 
mechanisms leading to this manifestation could lead to the discovery of new therapeutic 
targets in the early stages of AD, prior to cognitive decline. This thesis proposes a possible 
mechanism leading to atrophic astrocytes.  
 
1.6 Aims and objectives 
This thesis aims to explore if altered expression of the Cas-proteins leads to AD-
associated aberrant morphology and function of astrocytes, predicated on a number of 
lines of evidence: 
• GWAS has identified both NEDD9 and CASS4 as risk factors for AD. 
• Although less frequent than other risk factors, NEDD9 and CASS4 are the only 
LOAD risk factors involved in cytoskeletal arrangement and thus morphology. 
• CASS4 and NEDD9 have both been shown to have roles in the control of cellular 
morphology and during preliminary experiments, it was found overexpression of 
both NEDD9 and CASS4 induced morphological changes in epithelial cells, 
including the generation of cellular processes atypical for this cell type 
(Ulzheimer and Jones, 2016; unpublished data), further confirming the impact of 
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Cas-protein expression on morphological changes and hence a possible role in 
aberrant astrocyte morphology in AD. 
• Astrocytic atrophy and process loss are early factors of AD pathology, exhibiting 
reduced cell size and loss of processes. This likely impairs the ability to support 
neurones and maintain synapses. The cause is unknown. 
• NEDD9 knockout mice display extensive hippocampal dendritic spine loss, 
suggesting that downregulation of the Cas-protein may also cause atrophy in 
astrocytes and hence play a part in AD.  
 
Specific objectives 
The overarching aim of this thesis is to find a therapeutic way of reverting atrophic 
astrocytes to a healthy phenotype. In order to achieve this, first, the unknown mechanisms 
leading to atrophy must be unearthed.   
Based on the above, the specific objectives of this thesis are as follows: 
1. To test if NEDD9 and CASS4 are expressed in normal human cortical astrocytes, 
glial cell lines using immunofluorescence and western blotting. As NEDD9 and 
CASS4 expression has not been tested in astrocytes to date, this thesis aims to 
establish robust expression of the proteins in the glial cells. 
2. To establish expression of NEDD9 and CASS4 in the adult brain. Although the 
Cas-proteins have been identified as LOAD risk genes, which signifies expression 
in the adult brain, previous studies had recorded low or no expression in the adult 
brain. As primary human astrocytes are foetal and human brain tissue was not 
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available for this thesis, expression of NEDD9 and CASS4 will be tested in adult 
mouse brain tissue to further validate this model. 
3. Construct overexpression and knock-down in vitro models of both NEDD9 and 
CASS4 in normal human astrocytes via transient transfection of CMV-driven 
plasmids for overexpression or siRNA-encoding plasmids for knock-down of the 
genes. Overexpression and knock-down will be validated via 
immunocytochemistry (measuring fluorescence intensity) and western blotting, 
followed by densitometry analysis. These models will be the foundation for the 
investigation into the effect of altered expression on astrocyte morphology and 
function. 
4. Investigate if altered expression of NEDD9 or CASS4 affects astrocyte 
morphology. This will be assessed via visual analysis (deconvolution microscopy) 
categorising of cell morphology to evaluate the distribution of morphologies 
under different transfection conditions. Additionally, 3D isoSurface renders of 
confocal Z-stacks will be constructed for morphometric quantitative analysis. This 
will establish how overexpression or downregulation of the Cas-proteins will 
affect astrocyte morphology and if these changes are implicated in LOAD 
pathology. 
5. Investigate whether altered expression of NEDD9 or CASS4 might affect 
astrocyte function. This will be assessed by immunostaining for astrocyte 
functional markers (GFAP, s100B, EAAT2, Actin, Tubulin), followed by 
comparison of fluorescence intensity under different transfection conditions and 
visual inspection of marker subcellular localisation. This will be the first step in 
functional assessment of the NEDD9/CASS4 overexpression and knockdown 
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models and give an indication of how the Cas-proteins may be involved altered 
astrocyte function in LOAD. 
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2 Chapter 2 – Materials and Method 
2.1 Materials 
Unless otherwise stated, all laboratory reagents were purchased from Fisher Scientific 
(Loughborough, UK). All solutions were made up with de-ionised water (dH2O).  
 
 Plasmids  
The pcEGFP-C1 expression vector was obtained from Clontech laboratories (Saint-
Germain-en-Laye, France). NEDD9 Lentiviral Vector (pLenti-GIII-CMV-GFP-2A-
Puro), CASS4 Lentiviral Vector (pLenti-GIII-CMV-GFP-2A-Puro), CASS4 set 
siRNA/shRNA/RNAi Lentivector, NEDD9 set siRNA/shRNA/RNAi Lentivector, 
Scrambled siRNA control vector and blank control vector were sourced from Applied 
Biological Materials Inc (Richmond, BC, Canada). Descriptions of the gene of interest 
encoded in each plasmid, tags and abbreviated names used throughout this thesis may be 
found in Table 2.1. A generic plasmid map for the pLenti-GIII-CMV-GFP-2A-Puro 
lentiviral expression vector backbone is outlined in Figure 2.1. 
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Table 2.1 Plasmids  
Official name Encoded 
Gene 
Description Tag Abbreviation 
pEGFP-C1 EGFP Induce expression of 
EGFP via CMV 
promoter 
EGFP (N-
terminal) 
GFP plasmid 
CASS4 Lentiviral Vector 
(Human) (CMV) (pLenti-
GIII-CMV-GFP-2A-Puro) 
CASS4 Induce 
overexpression of 
CASS4 via CMV 
promoter 
CopGFP CASS4 LV-
CMV 
NEDD9 Lentiviral Vector 
(Human) (CMV) (pLenti-
GIII-CMV-GFP-2A-Puro) 
NEDD9 Induce 
overexpression of 
NEDD9 via CMV 
promoter 
CopGFP NEDD9 LV-
CMV 
Blank pLenti-GIII-CMV-
GFP-2A-Puro 
Empty Blank vector control. 
Induce expression of 
CopGFP only via 
CMV promoter 
CopGFP Blank vector 
CASS4-set 
siRNA/shRNA/RNAi 
Lentivector (Human) 
siRNA 
against 
CASS4 
Knock down of 
CASS4 expression 
CopGFP CASS4 
siRNA 
NEDD9-set 
siRNA/shRNA/RNAi 
Lentivector (Human) 
siRNA 
against 
NEDD9 
Knock down of 
NEDD9 expression 
CopGFP NEDD9 
siRNA 
Scrambled siRNA GFP 
Lentivirus 
Scrambled 
siRNA 
Knock down control CopGFP Scramble  
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Figure 2.1 pLenti-CMV-GFP-2A-Puro-Blank plasmid map 
Vector map (Applied Biological Materials Inc); www.abmgood.com 
 
 
 
 
 Cell culture reagents 
The SVG p12 human foetal astrocyte cell line and the HeLa human epithelial cervical 
adenocarcinoma cell line were obtained from ATCC (Manassas, USA), while the 1321N1 
human astrocytoma cell line was obtained from European Collection of Authenticated 
Cell Cultures (Porton Down, UK). Normal human astrocytes (NHA) cells from three 
separate male donors were purchased from LONZA (Slough, UK). 
Media, cell culture reagents and supplements for cell lines were purchased from Fisher 
Scientific (Loughborough, UK). Media for primary cells (NHA) were purchased from 
Fisher Scientific (Loughborough, UK), while cell culture reagents and supplements for 
NHA culture (trypsin EDTA and trypsin neutralising solution) were purchased from 
LONZA (Slough, UK).  
Phosphate buffered saline (PBS) was made with 10 mM phosphate, 137 mM NaCl, 2.7 
mM KCl, the pH was adjusted to 7.4. 
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 SDS-PAGE and Western blotting buffers 
RIPA buffer was prepared containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5 % 
(w/v) sodiumdeoxycholate and 1 % (v/v) Triton X-100. Prior to use, Halt™ Protease 
Inhibitor Cocktail was added. 
Laemmli buffer was prepared containing 125 mM Tris-HCl, 4 % (v/v) SDS, 10 % (v/v) 
mercaptoethanol, 20 % (v/v) Glycerol and 0.004 % (w/v) bromophenol blue. The pH was 
adjusted to 6.8.  
SDS-PAGE running buffer was prepared containg 25 mM Tris base, 190 mM glycine and 
0.1 % (v/v) sodium dodecyl sulphate (SDS), aiming for a pH of 8.3.  
Western blot transfer buffer was prepared containing 2.5 mM Tris base and 19 mM 
glycine. Prior to use 20 % (v/v) methanol was added to the buffer. 
TBS-T was prepared containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1 % (v/v) 
Tween®. 
Blocking buffer was made fresh with TBS-T, containing 5 % (w/v) non-fat dry milk 
powder. 
  
48 
 
 
 Antibodies 
Primary and secondary antibodies used for immunocytochemistry (ICC) or Western blot 
(WB) are listed in Table 2.2, together with working dilution factors and sources. 
Table 2.2 Primary and scondary antibodies 
Target Species Isotype Clone Dilution Source 
CASS4 Rabbit IgG mono 1:100 (ICC), 
1:1000 (WB) 
Abcam, 
Cambridge, UK 
NEDD9 Mouse IgG1 mono 1:100 (ICC), 
1:1000 (WB) 
Abcam, 
Cambridge, UK 
GFAP Rabbit IgG poly 1:250 (ICC), 
1:5000 (WB) 
Sigma Aldrich, 
Irvine, UK 
β actin Mouse IgG1 mono 1:250 (ICC), 
1:5000 (WB) 
Abcam, 
Cambridge, UK 
α tubulin Rabbit IgG mono 1:250 (ICC), 
1:5000 (WB) 
Abcam, 
Cambridge, UK 
EAAT1 Rabbit IgG Poly 1:250 (ICC), 
1:5000 (WB) 
Abcam, 
Cambridge, UK 
S100B Rabbit IgG Mono 1:250 (ICC), 
1:5000 (WB) 
Abcam, 
Cambridge, UK 
Alexa Fluor 
555 
Goat IgG _ 1:500 (ICC) Abcam, 
Cambridge, UK 
Alexa Fluor 
555 
Goat IgG _ 1:500 (ICC) Abcam, 
Cambridge, UK 
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Anti-Mouse 
IgG H&L 
(HRP) 
Rabbit IgG Poly 1:5000 (WB) Abcam, 
Cambridge, UK 
Anti-Mouse 
IgG H&L 
(HRP) 
Goat IgG Poly 1:5000 (WB) Abcam, 
Cambridge, UK 
 
 
 
2.2 Molecular Biology 
 Bacterial work 
Aseptic technique was adhered to at all times when working with bacteria and when 
preparing any reagents or growth media for use with bacteria. 
 Lysogeny broth 
Lysogeny broth (LB) was prepared by adding Miller’s LB base powder to de-ionised 
water at a final concentration of 20 g/L and autoclaved. The sterile broth was then stored 
in sealed bottles at room temperature. Antibiotics were added to the broth immediately 
prior to use. 
 Agar plates 
LB agar plates were prepared as follows; 32 g/L of LB agar powder was added to de-
ionised water and autoclaved. When the agar solution was hand-hot, antibiotics were 
added and the mixed solution poured into 10cm petri dishes and allowed to set. After 
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setting, the agar plates were dried in a 37 °C oven and stored upside-down at 4 °C until 
use. 
 Super optimal broth with catabolite repression 
Super optimal broth with catabolite repression (SOC) consisted of LB broth 
supplemented with 2.5 mM KCl, 10 mM MgCl2.6H2O and 20 mM glucose. Supplements 
were filtered with 0.22 µm filter into autoclaved LB broth to avoid glucose burning. 
 Antibiotics 
Antibiotics were used where appropriate to select for transformed bacteria. All constructs 
used in this thesis contained kanamycin resistance genes. Hence, kanamycin sulphate 
(Sigma Aldrich, Gilingham, UK) was added to growth media where required at a 
concentration of 50 µg/ml. 
 Bacterial transformations 
Plasmids were amplified by transformation of STBL3 competent E.coli cells, obtained 
from Thermo Fisher, Altrincham, UK. Competent E.coli (50µl) were thawed on ice and 
100 ng of plasmid DNA was gently added. Following gentle swirling, the mixture 
incubated on ice for 30 minutes. The mixture was then heat-shocked for exactly two 
minutes at 42 °C before being placed on ice for a further two minutes to restore the cell 
membrane. 250 µl of warm SOC medium was added and the transformation mixture 
incubated at 37 °C, shaking at 225rpm for a minimum of one hour for recovery. 50-100 
µl of transformed cells were spread on agar plates, containing 50 µg/ml kanamycin. Plates 
were sealed with para-film and incubated upside-down overnight at 37 °C. 
 Plasmid purification 
In preparation for plasmid maxi-preps, single bacterial colonies were picked from fresh 
agar plates and added to 200 ml LB broth, containing 50µg/ml kanamycin. Each broth 
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was incubated at 37°C in a shaker (200-250rpm) for 24 hours. Plasmids were extracted 
from these overnight cultures using Hi-speed plasmid maxiprep kits (Qiagen, Crawley, 
UK) as per the manufacturer’s instructions. Such preparations provided, typically, 900 µl 
of plasmid DNA solution at a concentration of 150-1000 ng/µl. 
 Measuring DNA concentrations 
The concentration of purified DNA was determined using a NanoDrop ND-1000 
spectrophotometer (Labtech International Ltd., Ringmer, UK). Absorbance was measured 
at 260nm (A260) and concentration was estimated based upon an A260 of 1.0 being 
equivalent to 50 µg/ml double-stranded DNA. A260/280 ratios were also calculated to 
determine DNA purity, with ratios of >1.8 being deemed acceptable for transfections. 
2.3 Mammalian cell culture 
Expression of NEDD9 and CASS4 has not been confirmed in astrocytes. To establish 
which cell line expresses the proteins and would be best suited as a model for this thesis, 
several astrocyte cell lines were used. Expression of the Cas-proteins had been confirmed 
in cervical cancer, HeLa cells were thus used as positive control. 
 Cell culture 
The SVGp12 (human foetal astrocytes) and HeLa (human epithelial cervical 
adenocarcinoma) cell lines were maintained in Eagle's minimal essential medium, 
supplemented with 10 % (v/v) Foetal Bovine Serum (FBS), 2 mM L-glutamine, 1 % (v/v) 
non-essential amino acids (NEAA), 1 mM sodium pyruvate and 1 % (v/v) 
penicillin/streptomycin. 1321N1 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium, plus 10 % (v/v) FBS, 2 mM L-glutamine and 1 % (v/v) penicillin/streptomycin. 
All cell lines were incubated in a humidified incubator at 37 °C with 5 % CO2. Cells were 
grown in tissue culture-treated vented T75 culture flasks (ThermoFisher, Altrincham, 
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UK) and passaged at 80 % confluency (approximately twice weekly). Cells were rinsed 
with PBS to remove excess medium before the addition of 2 ml 1 % (v/v) trypsin in PBS. 
The flask was returned to the incubator for sufficient time for cells to begin to detach 
from the flasks (as determined by viewing down a tissue culture microscope). Trypsin 
activity was immediately quenched by the addition of 20 ml fresh complete culture 
medium. The cell/medium mix was centrifuged at 800 xg for 5 minutes to gently pellet 
cells. The supernatant was carefully discarded and the pellet gently re-suspended in fresh 
warm culture medium, prior to re-seeding into T75 flasks at a cell-appropriate density. 
Typically, 1:4 to 1:6 seeding ratios were appropriate for all cell lines to reach 80 % 
confluency in 3-4 days. Cell lines were only utilised up to a maximum number of 20 
passages. 
 Primary cell culture 
Normal (cortical) human astrocytes, obtained from LONZA (Slough, UK), were 
maintained in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (1:1), 
supplemented with 10 % (v/v) FBS and 2 mM L-glutamine. Culture medium was 
exchanged every other day and the volume increased as cells became more confluent. 
Cells were initially resurrected into T25 flasks until good growth was established, and 
thereafter grown in T75 flasks. Flasks were incubated with 5% CO2 in a humidified 
incubator at 37 °C and passaged when a confluency of 80 % was reached – typically once 
every two weeks. Cells were detached from flasks using 0.25 % (w/v) trypsin and 1 mM 
EDTA in Hank’s buffered saline solution, quenched with trypsin neutralising solution 
and centrifuged at 800 xg for 4 minutes. Supernatants were discarded and cells gently re-
suspended in fresh warm culture medium, counted and reseeded in T75 flasks at a seeding 
density of 5000 cells/cm2. Cell lines were only utilised up to a maximum number of 5 
passages.  
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 Transfections and puromycin selection 
Prior to transfection, cells were seeded directly onto sterile No. 1.5 glass cover slips 
(Scientific Laboratory Supplies Limited, Nottingham, UK) in 24-well tissue culture plates 
(Thermo Fisher, Altrincham, UK) and incubated at 37 °C for a minimum of 24 hours, 
until a confluency of 60-70 % was reached. Culture medium was exchanged on the 
morning of transfection. Transfection was achieved using the Lipofectamine™ 3000 
Transfection Reagent (Thermo Fisher, Altrincham, UK) for all plasmids at optimised 
concentrations, based on manufacturer’s guidelines. Culture medium was exchanged 6 
hours after transfection to avoid DNA-reagent complex-induced toxicity. pEGFP-C1, 
blank vector or scramble vector were used as positive transfection controls in all cases. 
Negative controls included non-transfected and Lipofectamine-only (no DNA) cells. 
Population enrichment for Western blotting was achieved by adding 5µg/ml puromycin 
to the cell growth medium 24 hours after transfection. The optimal concentration for 
puromycin selection was established with a puromycin kill curve experiment, whereby 
varying concentrations of puromycin (1-5µg/ml) were added to cells, followed by cell 
counts at 24, 48 and 72 hours to establish cell viability. Knock-down was achieved 48 
hours post transfection, but cells would detach by 72 hours; hence the ideal concentration 
would require sufficient enrichment of transfected cell populations sufficiently, 24 hours 
after supplementing medium with puromycin (48 hours post transfection). Non-
transfected cell numbers were sufficiently and consistently reduced with 5µg/ml 
puromycin after 24 hours, to validate knock-down via Western blotting. 
Transfection efficiency was established by counting GFP+ cells in >10 random fields of 
view in comparison to total cell numbers (DAPI channel), enabling calculation of 
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transfection efficiency percentage. This experiment was repeated with cells from three 
donors with three repeats within each experiment.  
2.4 Fixation and Immunocytochemistry 
Mammalian cells grown on coverslips were washed twice in PBS prior to fixation with 4 
% (v/v) formaldehyde in PBS for 10 minutes. Cells were then treated with 0.1 M glycine 
in PBS to quench formaldehyde cross-linking and permeabilised with 0.1% (v/v) Triton 
X-100 in PBS. Cells were blocked for 1 hour at 4 °C with 1 % (w/v) bovine serum albumin 
diluted in PBS (“blocking solution”) to prevent non-specific antibody binding. All 
antibodies were diluted in blocking solution. Primary antibodies were either applied for 
1 hour at room temperature or incubated at 4˚C overnight (for anti-NEDD9 and anti-
CASS4), as appropriate. In either case, coverslips were placed cell side-down onto a 50 
µl drop of diluted antibody placed on parafilm in a home-made humidity chamber. 
Subsequently coverslips were washed in excess PBS and a mixed solution of the 
appropriate fluorophone-conjugated secondary antibody diluted in PBS also containing 
0.1 µg/ml 4',6-diamidino-2-phenylindole (DAPI) was applied and incubated for 30 
minutes at room temperature in the dark. Immunostained cells were mounted onto glass 
microscope slides with ProLong Diamond mountant (Thermo Fisher, Altrincham, UK) 
and cured overnight at room temperature prior to being sealed with nail varnish. 
2.5 Cell fixation for flow cytometry 
Cells were fixed in solution with 4% (v/v) formaldehyde in PBS as described above. Cells 
were centrifuged at 800 xg for 5 minutes in between each step. Cell pellet was 
resuspended in primary antibody diluted 1 % (w/v) bovine serum albumin (in PBS) and 
incubated at 4˚C overnight. Cells were washed with PBS and centrifuged at 800 xg for 5 
minutes, followed by incubation with a secondary antibody, diluted in 1 % (w/v) bovine 
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serum albumin (in PBS), for one hour at room temperature. Cells were washed and 
centrifuged once more and stored in PBS at 4˚C until use (maximum of 24 hours). 
2.6 Mouse brain tissue 
Despite being identified as LOAD ‘risk genes’, NEDD9 and CASS4 expression had 
previously been questioned in the adult brain. Wild type adult mouse brain tissue was 
used to confirm NEDD9 and CASS4 expression in the adult brain, as human brain tissue 
was unavailable for this thesis. 
All mouse brain tissues were obtained for secondary use from Dr Donna Daly (University 
of Central Lancashire) and in accordance with local ethical approvals. Male C57BL/6 
wildtype mice were purchased from Charles River (Harlow, UK) and sacrificed aged 24 
weeks under Schedule 1 of the Animals (Scientific Procedures) Act 1986. Mouse brain 
tissues were excised and entorhinal cortices were flash frozen on dry ice by Mr Atte 
Räsänen (University of Central Lancashire). Brain tissue was lysed with CelLytic M 
(Sigma Aldrich, Gilingham, UK) according to manufacturer’s guidelines and stored at -
20 °C until use. 
 
2.7 Fluorescence microscopy and flow cytometry 
 Deconvolution microscopy 
Initial visualisation of immunofluorescently stained cells, morphological binning (see 
morphological analysis, Table 2.3) and transfection efficiency calculations were 
undertaken using a Zeiss cell observer Axio Z1 system, equipped with a colibri LED light 
source (25% intensity), AxioCam and ZEN software (Carl Zeiss, Cambridge, UK). Cells 
were visualised using 20x PL Apo (0.8 NA), 40x LD Plan-Neofluar (0.6 NA) and 63x PL 
Apo (1.4 NA) oil objectives and GFP/dsRed/DAPI filter sets. All images were taken with 
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the same exposure time (DAPI: 63 msec; GFP: 400 msec; dsRED: 800 msec). 
Deconvolution of images was carried out using the constrained iterative method with a 
maximum of 10 iterations. Total and GFP+ cells were counted from a minimum of 5 
fields of view at 20x magnification per coverslip to estimate mean transfection 
efficiencies.  
 
 Confocal microscopy 
Individual cell images for later morphometric analysis were collected on a Leica TCS 
SP8 AOBS inverted confocal microscope using a 100x Plan Fluotar (1.40 NA) objective 
and Hybrid photon detectors. Images were collected using the following detection mirror 
settings; DAPI 400-460 nm; Alexa Fluor 488 480-550 nm; Alexa Fluor 555, 555-590 nm 
using 488nm (5 % power), 594nm (10 % power) and 633 nm (10% power) laser lines 
respectively. Image acquisition confocal settings were identical for all experiments, as 
follows; pinhole - 1 airy unit, scan speed – 600 Hz unidirectional scan, confocal zoom – 
0.75x, and format - 1024 x 1024 pixels. Z stacks were acquired using the Leica 
Application Suite X to determine the optimal number of slices per cell for offline 3D 
reconstruction. The top and bottom of each stack was carefully set to ensure none of the 
cell was lost, which would negatively influence later morphometric analyses. 
 Flow cytometry 
Fixed and stained cells in suspension (PBS) were analysed with the Amnis ® 
ImageStreamx Mk2. Cells were detected using lasers at 488nm (GFP, green) and 561nm 
(Alexa Fluor 555, red). This method was unsuccessful. 
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2.8 Image Processing 
 Fluorescence intensity analysis 
Relative expression levels of individual proteins were analysed semi-quantitatively 
through calculation of the relative fluorescence density of immunofluorescently stained 
cells using FIJI ImageJ (Schindelin et al., 2012, Rueden et al., 2017). Fluorescence 
density was measured from at least ten cells (selected at random in the DAPI channel) 
from a minimum of three separate experiments. Individual cells were selected using the 
freehand selection tool to draw around the entire cell. The measure tool was then used to 
calculate cell area and integrated pixel density (conceptually equivalent to ‘total 
fluorescence’) per selected cell. Background fluorescence was calculated from a 
minimum of five fields of view from unstained control cell coverslips. Fluorescence 
intensity was corrected for background levels as follows: 
Corrected integrated density = measured integrated density – (area of selected cell x mean 
background fluorescence). 
 Morphological analysis 
Morphological analysis of transfected normal human astrocytes was performed by 
visually binning observed cells into four categories: fibroblast-like cells; polarised cells; 
arborised cells; and atrophic cells. Each category was defined as outlined in Table 2.3. 
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Table 2.3 Astrocyte morphology types 
Morphological type Characteristics 
Fibroblast-like Flattened, process-devoid, oblong to 
triangular shape 
Polarised Elongated, polarised apical domains, 
process-devoid 
Arborised Process bearing, > three branching 
processes 
Atrophic Process-devoid or elongated with soma 
width < 20µm 
 
Binning was carried out in a blinded manner. Microscope slide annotations (indicating 
transfection conditions) were obscured by an independent third party prior to visualisation 
and binning. 
 Morphometric quantification 
Confocal z stacks of individual cells were assessed with IMARIS 9.1 (Bitplane AG, 
Zurich, Switzerland) as described by Jones et al. (2017). 3D isosurface renders were 
created based on the extent of GFP within the cell (to reveal the entire cell morphology) 
or immunofluorescent staining of GFAP (to reveal the GFAP cytoskeleton morphology, 
as per Olabarria et al., 2010 and related methods). The edges of the fluorescence signal 
were carefully demarcated to include the entire cell and voxels were removed. These 3D 
renders then allowed the calculation of morphometric measurements including surface 
area, volume, axis lengths and sphericity. Analysis were carried out on CASS4 and 
NEDD9 overexpression and knock-down models of normal human astrocytes together 
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with controls, for comparison. A minimum of 10 cells were analysed per experiment with 
three individual experiments carried out for each of the three NHA donors per transfection 
condition. 
 
2.9 Protein Biochemistry 
 Whole cell lysate preparation 
Cells were detached with trypsin (as for the start of the cell culture protocol, section 2.3) 
and pelleted at 800 xg for 5 minutes, washed with cold PBS and pelleted 14,000 xg for 1 
minute. The pellet was placed on ice and resuspended in cold RIPA buffer supplemented 
with EDTA-free Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher, 
Altrincham, UK). The cell suspension was kept on ice for 30 minutes whilst being 
vortexed every 5 minutes to allow for lysis. Lysates were spun in a pre-cooled (4˚C) 
centrifuge at 16,000 xg for 20 minutes to remove unlysed cells and large membrane 
fragments. Protein-containing supernatants were collected and stored at -20 °C. Protein 
content was measures just prior to use with Pierce BCA Protein Assay Kit. 
 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using the Bio-Rad Mini-PROTEAN® vertical electrophoresis system and 
PowerPac Basic power supply with pre-cast 10 % mini-PROTEAN® TGX acrylamide 
gels (Bio-Rad, Watford, UK). Whole cell lysates were mixed with 2x Laemmili loading 
buffer (1:1, v/v) and boiled to 95 °C for 5 minutes prior to loading. 5-20 µg of lysate were 
loaded per well. Running buffer (25mM Tris, 190mM glycine, 0.1% SDS) was added to 
the gel tank and the apparatus checked for leaks. Gels were run at 50 V for 5 minutes to 
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allow the proteins to pass the stacking gel, followed by a constant of 100 V for 80 minutes 
to achieve protein separation. 
 Western blotting 
Transfer of resolved proteins to nitrocellulose was achieved at 300 mA for 80 minutes in 
transfer buffer using the Bio-Rad Mini Trans-Blot® Module. Membranes were 
subsequently treated with blocking buffer (5 % milk in TBS-T) for 1 hour at RT and then 
incubated with appropriate primary antibody diluted as per Table 2.2 in blocking buffer 
overnight at 4°C.  After three 10 minute washes TBS-T, primary antibodies were detected 
using species-matched horseradish peroxidase (HRP)-conjugated secondary antibodies, 
diluted 1:5000 in blocking buffer, for one hour at room temperature. The immunoblot 
membranes were then washed extensively with TBS-T. Blots were developed using the 
SuperSignal™ West Pico PLUS Chemiluminescent ECL kit (Thermo Scientific, 
Loughborough, UK). The membrane was imaged with a Bio-Rad ChemiDoc XRS+, 
equipped with Image Lab™ Software. Membranes were stripped with a mild stripping 
buffer (0.2 M glycine, 3.5 mM SDS, 0.1% (v/v) Tween, pH 2.2), re-blocked in 5% 
milk/TBS-T and re-probed for β-actin as a loading control. 
 Densitometric analysis 
Densitometric analysis of Western blots was performed with FIJI ImageJ. Images were 
converted to 8-bit grey scale prior to measuring relative band intensities. Relative 
densities of target proteins were calculated by dividing measured intensities by intensity 
of the β actin loading control. 
2.10 Statistical analysis 
Statistical analyses were performed using IBM SPSS 22 (IBM Corporation, Armonk, 
USA). Data are presented as mean ± SEM unless otherwise stated. SEM is preferred over 
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SD when comparing populations (Altman and Bland, 2005). A p-value of ≤ 0.05 was 
considered significant throughout this thesis. All data sets were tested for normality using 
the Shapiro-Wilks test prior to selection of the appropriate statistical test. 
 Comparison of fluorescence intensities 
Comparison of integrated fluorescence densities between overexpression and blank-
transfected cells or knock-down vs scramble cells was carried out via independent sample 
Student’s t-tests. 
 Comparison of morphometric measurements 
Comparison between groups was carried out by either Kruskal-Wallis, followed by 
pairwise comparison via Dunn-Bonferroni method (where data were found to be non-
parametric) or one-way ANOVA (for parametric data), followed by Tukey-HSD (equal 
variance) or Games-Howell (non-equal variance) post hoc to identify significant 
differences. The Levene’s F test was used for testing homogeneity of variance between 
groups. 
 Comparison of density measurements 
Comparison of normalised values (density) of Western blot bands from overexpression 
and knock-down experiments was carried out via independent sample Student’s t-tests. 
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Chapter 3 
Endogenous expression of NEDD9 and CASS4  
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3 Chapter 3 – RESULTS: Endogenous expression of CASS4 
and NEDD9  
3.1 Background 
While endogenous expression of CASS4 and NEDD9 in adult human astrocytes is 
predicted by several studies, confirmation of Cas-protein expression is lacking in the 
literature. As outlined in the introduction to this thesis, no studies have confirmed 
expression in astrocytes to date and expression in the adult brain varies between studies 
(Law et al., 1998). Hence, at the outset of this thesis it was necessary to undertake 
experiments to detect CASS4 and NEDD9 via western blot and immunocytochemistry in 
glial cell lines, primary human astrocytes to determine which cell line is most suited for 
further investigations. Additionally, NEDD9 and CASS4 expression was tested in adult 
mouse brain tissues to validate expression in the adult brain, as this has previously been 
challenged. Ideally, human brain tissue should be tested, but was not available for this 
thesis. 
 NEDD9 expression 
The majority of published studies related to NEDD9 have focused on its role as a 
promoter of metastasis in cancer (Beck et al., 2014, Shagisultanova et al., 2015). As such, 
the expression of NEDD9 has been demonstrated in numerous cancers including 
leukaemia, lymphoma, breast cancer, lung cancer, and brain tumours including 
glioblastoma and neuroblastoma (Shagisultanova et al., 2015, Jurcic et al., 2019, 
Gabbasov et al., 2018, Xu et al., 2019). These studies have revealed that NEDD9 has 
influences in both cancer initiation and progression, implicating a correlation between 
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NEDD9 expression and cellular changes (Izumchenko et al., 2009, Li et al., 2011, Deng 
et al., 2013, Wang et al., 2017). Given the robust expression of NEDD9 in most cancers, 
it is unsurprising that it has been detected in many cancer cell lines, including HeLa cells 
(Sima et al., 2013), offering another means for experimentation which was exploited 
within this thesis. 
Unlike its paralogue CASS4, much more is known about NEDD9 expression and the 
protein is abundant in many tissues (Fashena et al., 2002, Minegishi et al., 1996), 
including the brain, where it has been shown to regulate neural crest cell migration during 
embryogenesis, a process vital for proper brain development (Aquino et al., 2008).  
NEDD9 is believed to be highly expressed during development but has been suggested 
to be downregulated in the adult brain (Kumar et al., 1992, Law et al., 1996); hence its 
name ‘neurally-expressed, developmentally-downregulated 9’. These findings, however, 
are based only on mRNA expression rather than actual protein expression. It is known 
that cellular protein levels can differ markedly from transcript levels (Liu et al., 2016). 
This is attributed to a number of factors including the predominant control of protein 
expression at the level of translation and highly variable protein half-lives 
(Schwanhausser et al., 2011). Accordingly, Li et al., 2008, determined significant 
NEDD9 expression in adult human brain tissue via immunohistochemistry, although they 
did not explore expression in glia. 
 
 CASS4 expression 
CASS4 is the most recent addition to the Cas-proteins family, hence relatively little is 
known about its canonical functions or tissue expression (Singh et al., 2008). CASS4 
shares much structural homology with NEDD9 and other members of the Cas-proteins 
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family (Beck et al., 2014). While its exact functions or expression patterns remain largely 
unknown, its activity is believed to be dependent on the presence of other Cas-protein 
(Deneka et al., 2015), suggesting expression in similar tissues. 
During the initial identification of CASS4, RT-PCR revealed high expression of  mRNA 
in the spleen and lungs as well as in leukaemia and ovarian cancer (Singh et al., 2008). 
CASS4 transcripts have since been detected in a number of other tissues, including the 
cerebral cortex and hippocampus; albeit at rather low levels (Kim et al., 2014). As 
discussed above, although a correlation between mRNA levels and protein expression is 
often assumed, mechanisms involved in translation are complex; hence cellular protein 
levels are difficult to predict from mRNA transcript levels (Greenbaum et al., 2003, Liu 
et al., 2016). 
 
3.2 Results 
 Basal expression of CASS4 & NEDD9 in cell lines 
 HeLa - cervical cancer cell line 
Given the reported expression of both CASS4 and NEDD9 in a number of cancers, 
including gliomas, initial confirmation of expression was undertaken in the astroglial cell 
line 1321N1 (human stage 2 astrocytoma). The SVG p12 human foetal astrocyte cell line, 
which is also an astroglial cell line, was tested alongside. The HeLa (human epithelial 
cervical adenocarcinoma) has previously been shown to express NEDD9 (Sima et al., 
2013) and hence was employed as both a positive control and as a non-glial control cell 
line. 
Western blotting (WB) of HeLa lysates using an anti-NEDD9 antibody revealed two 
bands at 65 kDa and 55 kDa (Figure 3.1, A). Protein loads between 5 and 20 µg were 
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trialled, with both bands being visible at all loads, suggesting a robust expression of 
NEDD9 in HeLa cells, as expected. Both visible bands correlate with known isoforms of 
NEDD9, which are cleaved from the full length protein (93 kDa) (Deneka et al., 2015, 
Law et al., 1998). Full-length NEDD9 is known to undergo post-translational 
modifications, particularly phosphorylation, leading to two species of 105 kDa and 115 
kDa; however, these two bands were not seen in HeLa cell lysates. 
 
 
Figure 3.1 Western blotting of HeLa whole-cell lysates confirms expression of both NEDD9 
and CASS4 
Following separation by SDS-PAGE and blotting, two bands for were apparent 
using antibodies against NEDD9 (55 kDa, 65 kDa) (A) and two bands using anti-
CASS4 antibodies (76 kDa, 230 kDa) (B), confirming expression of both proteins 
in this cell type. Actin used as loading control. N=3. 
 
 
Western blotting for CASS4 at revealed two bands at 230 kDa and 76 kDa in the HeLa 
cell lysates (Figure 3.1, B). 76 kDa coincides with the size of a known isoform of CASS4 
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(isoform 2). 230 kDa does not correlate with any known CASS4 isoform and may be the 
result of dimerisation and/or post translational modifications, such as glycosylation or 
phosphorylation. Bands were not seen at 87 kDa or 38 kDa, which are other known 
isoforms of CASS4. As with NEDD9, bands were visible at protein loads as low as 5-10 
µg, suggesting a robust expression of CASS4 in HeLa cells. This is in keeping with the 
prediction that CASS4 expression follows that of its paralogue, NEDD9. 
To further validate the expression of NEDD9 in HeLa cells, immunofluorescence staining 
was undertaken with the same NEDD9 primary antibody together with an Alexa Fluor 
555 secondary antibody (Figure 3.2). Fluorescence imaging revealed fluorescence in all 
cells, indicating the expression of NEDD9. The pattern of fluorescence was slightly 
punctate and extended throughout the entire cell, consistent with expected cytosolic 
localisation of NEDD9. Omission of the primary antibody revealed no fluorescence, 
confirming that the staining observed was due to the specificity of the primary antibody. 
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Figure 3.2 Immunofluorescence staining of HeLa cervical cancer cells reveals NEDD9 
expression. 
HeLa cells were stained using a primary antibody against NEDD9 followed by 
an Alexa Fluor 555 secondary antibody, revealing a slightly punctate pattern 
of staining throughout the cell (Left). Secondary antibody (only) used as control 
(Right). N=3. Scale bar = 20µm. 
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The expression of CASS4 was also established via immunofluorescence staining using 
the same antibody as for the Western blot, followed by an Alexa Fluor 555 secondary 
antibody (Figure 3.3). As expected, based upon the Western blot, fluorescence imaging 
revealed CASS4 expression within the HeLa cells. This followed a similar pattern to 
NEDD9, with the addition of some small cellular inclusions, which may possibly be 
related to the unknown higher molecular weight species (230 kDa) seen on the blot 
(Figure 3.1, B). 
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Figure 3.3 Immunofluorescence of fixed HeLa cervical cancer cells validates CASS4 
expression. 
Fixed HeLa cells were stained using an anti-CASS4 primary antibody followed 
by Alexa Fluor 555 secondary revealing a punctate pattern of staining 
throughout the cell with small intracellular inclusions (Left). Secondary 
antibody (only) used as control (Right). N=3. Scale bar = 20µm. 
71 
 
 
 1321N1 – astrocytoma cell line 
Western blotting of 1321N1 whole-cell lysates and probing for CASS4 and NEDD9 
revealed that both Cas-proteins are expressed in 1321N1 cells (Figure 3.4). In the case of 
NEDD9 (Figure 3.4, A), two bands were clearly visible corresponding with the known 
cleaved isoforms at 55 kDa and 65 kDa. Neither the full-length protein (93 kDa) nor its 
phosphorylated forms (105 kDa and 115 kDa) were seen in the 1321N1 lysates. This is 
in keeping with the result obtained for the HeLa cell line. Blotting for CASS4 revealed 
the 76 kDa isoform 2 and the unexplained heavy band of 230 kDa, again echoing the 
results from the HeLa cells. These bands were visible with as little as 5 µg protein load, 
suggesting a robust expression of CASS4 in this astrocytoma cell line. 
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Figure 3.4 Western blotting of 1321N1 human astrocytoma whole-cell lysates confirms 
expression of both NEDD9 and CASS4. 
Following separation by SDS-PAGE and blotting, two bands for were apparent 
using antibodies against NEDD9 (55 kDa, 65 kDa) (A) and two bands using 
anti-CASS4 antibodies (76 kDa, 230 kDa) (B), confirming expression of both 
proteins in this cell type. Actin used as loading control. N=3. 
 
 
 
To further validate NEDD9 expression in the 1321N1 cell line, immunofluorescence 
staining was undertaken (Figure 3.5). This revealed the same slightly punctate pattern of 
NEDD9 staining throughout the entire cell as was seen in HeLa cells, consistent with 
expected cytosolic localisation. Omission of the primary antibody revealed no 
fluorescence, confirming that the staining observed was due to the specificity of the 
primary antibody. 
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Figure 3.5 Immunofluorescence staining of 1321N1 human astrocytoma cells validates 
NEDD9 expression. 
Fixed 1321N1 cells were stained for NEDD9 followed by Alexa Fluor 555 
secondary antibody revealing a slightly punctate pattern of staining throughout 
the cell (Left). Secondary antibody (only) used as control (Right). N=3. Scale 
bar = 20µm. 
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Immunofluorescence staining using the CASS4 antibody followed by an Alexa Fluor 555 
secondary antibody was also used to validate the expression of CASS4 in the 1321N1 
cells (Figure 3.6). A slightly punctate pattern of staining was evident in all cells. Many 
cells also exhibited small cellular CASS4+ inclusions towards the centre of the cell. 
Omission of the primary antibody revealed no fluorescence. 
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Figure 3.6 Immunofluorescence image of 1321N1 cells, showing CASS4 expression. 
1321N1 cells were stained using an anti-CASS4 antibody, followed by Alexa Fluor 
555 secondary antibody revealing a slightly punctate pattern of staining 
throughout the cell (Left). Secondary antibody (only) used as control (Right). 
N=3. Scale bar = 20µm. 
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 SVG p12 – Human foetal glial cell line 
Western blotting of SVG p12 lysates using the NEDD9 antibody revealed two bands at 
65 kDa and 55 kDa (Figure 3.7, A), correlating to the known isoforms seen in HeLa and 
1321N1 cell lysates. These bands were clearly visible at loads as low as 5 µg. Again, full-
length (93 kDa) and phosphorylated forms (105 kDa and 115 kDa) of NEDD9 were 
absent in the SVG p12 lysates. 
 
 
Figure 3.7 Western blotting of SVGp12 lysates, using antibodies to NEDD9 and CASS4. 
Following separation by SDS-PAGE and blotting, two bands for were apparent 
using antibodies against NEDD9 (55 kDa, 65 kDa) (A) and two bands using anti-
CASS4 antibodies (76 kDa, 230 kDa) (B), confirming expression of both proteins 
in this cell type. Actin used as loading control. N=3. 
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Blotting for CASS4 revealed a large sized doublet at around 230 kDa (Figure 3.7, B), 
which was not seen in any of the cancer cell lines. The lower molecular weight isoform 2 
band (76 kDa) seen in both HeLa and 1321N1 lysates was absent in this human foetal 
astrocyte cell line. These findings suggest some cell-type specific isoform expression. 
 
To further validate the expression of NEDD9 in the foetal astrocyte cell line SVGp12, 
immunofluorescence staining with the same NEDD9 antibody was undertaken (Figure 
3.8). This revealed a slightly punctate pattern of NEDD9 staining throughout the entire 
cell, consistent with the cytosolic localisation seen in the other cell lines. Omission of the 
primary antibody revealed no fluorescence, confirming that the staining observed was 
due to the specificity of the primary antibody. 
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Figure 3.8  Immunofluorescence staining of SVG p12 cells reveals NEDD9 expression. 
SVG p12 cells were fixed and stained with an anti-NEDD9 primary antibody, 
followed by an Alexa Fluor 555 secondary antibody, revealing a slightly 
punctate pattern of staining throughout the cell (Left, arrow). Secondary 
antibody (only) used as control (Right). N=3. Scale bar = 20µm. 
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CASS4 expression in SVG p12 cells could also be validated using immunofluorescence 
staining of fixed cells (Figure 3.9). As seen in other cell lines, CASS4 revealed a similar 
punctuate pattern of staining as for NEDD9 with the addition of a number of small cellular 
inclusions, towards the centre of the cells. A negative control by omission of the primary 
antibody exhibited no fluorescence. 
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Figure 3.9 Immunofluorescence staining of SVG p12 human foetal glial cells confirms 
CASS4 expression. 
Fixed SVG p12 cells were immunofluorescently stained using an anti-CASS4 
antibody, followed by Alexa Fluor 555 secondary antibody, revealing a slightly 
punctate pattern of staining throughout the cell (Left). Secondary antibody 
(only) used as control (Right). N=3. Scale bar = 20µm. 
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 Basal expression in primary human astrocytes 
Although expression of the Cas-protein was confirmed in the astroglial cell lines SVGp12 
and 1321N1, expression profiles often differ markedly between cell lines and primary 
cells (Pan et al., 2009). NEDD9 and CASS4 expression was thus next examined in 
primary human cortical astrocytes (NHA). Expression of the Cas-protein was determined 
in NHAs from three separate male donors; representative results are shown. 
 
Western blotting of NHA whole-cell lysates for NEDD9 revealed three bands at 65 kDa, 
105 kDa and 115kDa, all correlating with known isoforms (Law et al., 1998) (Figure 
3.10, A). The 65 kDa band was rather faint and only visible at a high protein load of 20 
µg. This band corresponds to the cleaved isoform which was previously found in the cell 
lines. The 55 kDa band seen in all the cell lines was absent from the NHA lysates. The 
105 kDa band was most evident on the blot and, along with the fainter 115 kDa band, 
corresponds to phosphorylated forms of the full-length protein. These two bands were not 
seen in any of the cell lines. These results suggest that NEDD9 expression differs 
substantially in primary human astrocytes in comparison to the astroglial cell lines. 
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Figure 3.10 Western blotting of NHA lysates reveals expression of NEDD9 and CASS4. 
Following separation by SDS-PAGE and blotting, three bands for were apparent 
using antibodies against NEDD9 (65 kDa, 105 kDa, 115 kDa) (A) and two bands 
using anti-CASS4 antibodies (76 kDa, 230 kDa) (B), confirming expression of 
both proteins in this cell type. Actin used as loading control. N=3. 
 
Western blotting of NHA lysates for CASS4 revealed two bands of 76 kDa and 230 kDa 
(Figure 3.10, B), which had also been seen in the cell lines. As with the cell lines, protein 
loads between 5 and 20 µg were trialled, with both bands being visible in all cases, 
suggesting a robust expression of CASS4 in primary human astrocytes.  
 
To further validate NEDD9 expression in primary human astrocytes, 
immunofluorescence staining was performed using the same antibody as for the Western 
blot (Figure 3.11). This revealed a slightly punctate pattern of NEDD9 staining which 
extended throughout the entire cell, consistent with expected cytosolic localisation. All 
cells observed exhibited NEDD9 staining. Omission of the primary antibody revealed no 
fluorescence, confirming the specificity of the primary antibody. 
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Figure 3.11 Immunofluorescence staining of primary human astrocytes (NHA) confirms 
NEDD9 expression. 
Fixed NHA were stained using an anti-NEDD9 primary antibody, followed by 
Alexa Fluor 555 secondary antibody revealing a slightly punctate pattern of 
staining throughout the cell (Left). Secondary antibody (only) used as control 
(Right). N=3. Scale bar = 20µm. 
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Immunofluorescence staining of primary human astrocytes with CASS4 revealed a 
similar punctuate cytosolic pattern as for NEDD9, although somewhat fainter (Figure 
3.12). The small cellular inclusions seen in the cell lines, were clearly visible in this cell 
type and appear more frequent than in the cell lines, suggesting that CASS4 localisation 
may differ in primary human astrocytes. Omission of the primary antibody revealed no 
fluorescence. 
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Figure 3.12  Immunofluorescence staining of primary human astrocytes (NHA) reveals 
expression of CASS4. 
Fixed NHA were stained using a primary antibody for CASS4 followed by an 
Alexa Fluor 555 secondary antibody revealing a slightly punctate pattern of 
staining throughout the cell and numerous cellular inclusions (Left). Secondary 
antibody (only) used as control (Right). N=3. Scale bar = 20µm. 
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 Basal expression in the adult mouse brain 
Expression of CASS4 and NEDD9 was clearly evident in the cell lines tested and in 
normal human astrocytes. Notwithstanding, it could be argued that the cells types tested 
were of an ‘immature’ form. For example, cancer cells tend to revert back to stem-cell 
like states (Holmberg et al., 2011, Hattermann et al., 2016), and the NHAs utilised are 
derived from foetuses. Thus, to overcome the claims that NEDD9 (and by association, 
CASS4) is not expressed in the adult brain, it was necessary to test for expression in the 
adult brain. 
As there were no human brain samples available to the project, expression of both CASS4 
and NEDD9 was examined in adult mouse brain. Specifically, expression in the 
entorhinal cortex was tested as it is one of the primary regions which exhibits astrocytic 
atrophy in the 3xTg-AD mouse model (Yeh et al., 2011). 
Western blotting was carried out on pooled mouse entorhinal cortex lysates from three 
animals aged between three and four months. Staining of the blot with antibodies against 
NEDD9 revealed four bands at 19 kDa, 70 kDa, 105 kDa and 115 kDa (Figure 3.13, A). 
The two larger bands correlated with the phosphorylated forms of the full-length protein 
which were also found in the NHA lysates. The band at around 19 kDa likely corresponds 
to NEDD9 isoform 2. This band was not seen in any of the cell types. The final 70 kDa 
band had previously not been found in any of the cell lines or the primary human 
astrocytes but is likely a post-translationally modified version of the cleaved 65 kDa 
isoform.  
 
 
87 
 
 
 
Figure 3.13 Western blotting of Mouse entorhinal cortex lysates reveals expression of 
various NEDD9 and CASS4 isoforms. 
Following separation by SDS-PAGE and blotting, four bands were seen using 
antibodies against NEDD9 (19 kDa, 70 kDa, 105 kDa, 115 kDa) (A), and two 
bands using anti-CASS4 antibodies (76 kDa, 230 kDa) (B), confirming 
expression of both proteins in the adult mouse brain. Actin used as loading 
control. Pooled lysates from N=3 mice. 
 
 
 
Western blotting of mouse entorhinal cortex lysates for CASS4 revealed a doublet at 
around 76 kDa and a single, fainter band at 230 kDa (Figure 3.13, B). While the 
unexplained 230 kDa band had been seen in all blots from the cell lines and human 
astrocytes, the usual single band at 76 kDa (corresponding to CASS4 isoform 2) was 
replaced by a doublet, potentially indicating some alteration of post-translational 
processing. As with cell lines and NHAs, protein loads between 5 and 20 µg total protein 
were trialled, with bands being visible in all cases, suggesting a robust expression of 
CASS4 in the entorhinal cortex of the adult mouse brain. Notably, the smaller isoform 
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(76 kDa) appears to be stronger expressed than the unexplained larger form (230 kDa), 
contrary to the findings in human cells, where the larger form appeared to be the more 
prominent.  
 
 
3.3 Discussion 
While NEDD9 and CASS4 have previously been reported to be expressed in many tissues 
(Deneka et al., 2015), the evidence from the brain has been limited. NEDD9 was found 
to be expressed in neural progenitor cells in the mouse brain (Aquino et al., 2008, Kumar 
et al., 1992), but these and other earlier studies found that NEDD9 was absent or 
downregulated in the adult brain (Kumar et al., 1992, Law et al., 1996). CASS4 
expression in the brain has also been dismissed as almost negligible (Kim et al., 2014). 
Yet, these adult brain findings have been based on mRNA expression alone. The 
correlation between mRNA and protein expression is not straight forward and involves 
complex translational mechanisms, which are varied and hence difficult to predict 
(Greenbaum et al., 2003, Liu et al., 2016). Only one study to date found NEDD9 
expression in human brain tissue (Li et al., 2008) and no study has explored CASS4 
expression in the human brain. Furthermore, expression of neither of the Cas-protein had 
not been confirmed in astrocytes. 
Here it was found that both Cas-protein are expressed in cancer-derived cells (HeLa & 
1321N1) as well as foetal human astrocytes (SVG p12), normal human astrocytes and the 
entorhinal cortex of the adult mouse brain. Basal expression was confirmed via 
immunocytochemistry and western blotting. 
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Western blotting for NEDD9, which has an actual molecular weight of 93 kDa, but exists 
as phosphorylated versions of 105kDa and 115kDa (Singh et al., 2007) revealed muliple 
bands of different weights. In addition to the full length versions, a band of 65 kDa, 
correlating with the size of a known isoform (Deneka et al., 2015) and a 55kDa band, 
correlating with a splice variant (Law et al., 2000) that was observed in all cell line 
lysates. 
Blotting of NHA lysates also revealed the 55 kDa NEDD9 band, as well as two additional 
bands at around 105 kDa and 115k Da. The bands of 105 kDa and 115 kDa correspond 
to phosphorylated isoforms of the full-length protein, which had previously been 
identified (Law et al., 1998, Bradshaw et al., 2011). The 65 kDa isoform, however, was 
not present. This reveals key differences between the immortalised glial cell lines and the 
primary astrocytes. It is unclear why these differences, particularly between the 
immortalised cell lines and primary astrocytes, occur, but different NEDD9 splice 
variants might serve different roles within each cell type and might arise from cell type-
specific post-translational modifications. This indicates that glial cell lines are likely not 
suitable for the investigation of the role of NEDD9 in astrocyte atrophy and that NHAs 
themselves are likely the best model for the investigation as primary cells are more likely 
to resemble cells in vivo. 
Blotting of adult mouse entorhinal cortex lysates revealed the two phosphorylated forms 
(105 kDa and 115 kDa) of the full-length NEDD9 protein as was seen in the NHAs, as 
well as a band at 70 kDa, which is likely a phosphorylated version of the 65 kDa isoform 
(not present in the NHAs). Additionally, a 19 kDa band was found in the mouse lysate, 
which had not been found in any human cell types. This corresponds to the NEDD9 
isoform 2 and as Cas-protein are known to undergo extensive phosphorylation (Singh et 
al., 2007), this could lead to these heavier forms of the protein. The myriad of NEDD9 
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isoforms is regulated by cell cycle phases and influenced by integrin binding (Law et al., 
1998, Singh et al., 2007). It is hence impossible to establish which forms may be 
expressed in a cell population or tissue at any given time. However, the varied expression 
of NEDD9 isoforms in different tissues, suggests that the protein expression is also tissue 
specific. 
In the case of CASS4, two bands were consistently seen in all cell lines, NHAs and in 
mouse brain tissue. The first band of 76 kDa corresponds with a known isoform of the 
protein appeared as a single strong band in all cases, with the exception of the mouse 
brain tissue, where it appeared as a doublet. This might suggest that there is some 
additional modification in brain tissue, or it might be a form which is seen in non-
astrocyte cell type, such as neurones, as whole tissue lysates were used. Determining 
astrocyte specific expression of CASS4 (or NEDD9) in the adult mouse brain would 
require immunohistochemistry. This would allow to use double staining, to identify 
astrocytes in situ and determine Cas-protein expression of this specific cell type in the 
adult mouse brain. Immunohistochemistry was not within the scope of this thesis but 
could be beneficial, particularly for human brain tissue, to further validate the Cas-protein 
expression in the future. 
A second CASS4 band was observed at 230 kDa in all lysates. This does not correlate 
with any known isoform of CASS4, nor to the full-length protein (87 kDa). Given the 
very large molecular weight of this band, it is unlikely that this is due to phosphorylation 
or other post-translational modifications and is more likely a complex, although it did 
resist attempts to break up with harsher denaturing conditions. Intriguingly, this heavier 
CASS4 band has also been observed in the laboratories of Dr Mahendra Singh and Prof 
Erica Golemis (personal correspondence). One possibility is that the band might be a 
tightly-bound complex of CASS4 with an associated kinase such as Abelson murine 
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leukaemia (Abl) kinase (Witte et al., 1980, Shagisultanova et al., 2015), which would 
require further research. 
 
 
Despite the fact that the large size of CASS4 remains unexplained and the expression of 
NEDD9 isoforms varies, these results nonetheless confirm: 
a) NEDD9 and CASS4 are expressed in cell lines of different tissue origin (cervical 
cancer, astrocytoma, foetal astrocytes) 
b) NEDD9 and CASS4 are expressed in primary cortical human astrocytes 
c) NEDD9 and CASS4 are expressed in the adult mouse brain (entorhinal cortex) 
 
Although immortalised cell lines can often provide a good basis for an in vitro model, as 
they are robust, highly proliferative and easy to culture, they have been shown to differ 
genotypically and phenotypically from the tissue origin (Alge et al., 2006, Pan et al., 
2009). Primary cells are only maintained in culture for a relatively short period of time, 
in order to retain native phenotype and are hence more reflective of an in vivo 
environment. While the CASS4 results were similar across all cells/tissues tested, the 
expression results from NEDD9 show marked differences in protein isoforms present in 
the cell lines compared to the primary astrocytes. Thus, the remainder of this thesis will 
utilise NHAs as a model for the investigation of the influence of the Cas-proteins in 
astrocyte morphology and function. 
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Chapter 4 
Overexpression and knock-down models of NEDD9 & 
CASS4 in normal human astrocytes 
  
93 
 
 
4 Chapter 4 – RESULTS: Overexpression and knock-down 
models of NEDD9 & CASS4 in normal human astrocytes 
4.1 Background 
Several GWAS studies have found that several SNPs in the genes NEDD9 (Li et al., 
2008) and CASS4 (Lambert et al., 2013), which encode the Cas-proteins NEDD9 and 
CASS4, are associated with a risk of developing AD. Follow-up studies tested the 
significance of these SNPs and found that NEDD9 SNP rs760678 showed the strongest 
association with LOAD development (Li et al., 2008, Fu et al., 2012, Xing et al., 2011). 
In 2013, Lambert et al. found that SNP rs7274581 of the CASS4 gene reached genome-
wide significance. Two more susceptibility loci were since added to the list of CASS4 
LOAD risk variants, rs16979934 (Wang et al., 2015) and rs6024870 (Rosenthal et al., 
2014). The SNPs in both NEDD9 and CASS4 are not within exons, suggesting that the 
gene products are not affected; the proteins are not mutated and retain normal biological 
function. Instead, the SNPs are found in transcription factor (TF) binding sites (Chapuis 
et al., 2008, Rosenthal and Kamboh, 2014). Specifically, the rs760678 polymorphism of 
NEDD9 maps near a GATA1 transcription factor binding site (Li et al., 2008). SNPs in 
this region would be expected to lead to a decrease in expression if a transcription factor 
(TF) cannot bind or an increase if a TF repressor cannot bind (Beck et al., 2014, Gan et 
al., 2018, Kamanu et al., 2012, Tugrul et al., 2015). Based on this, both, overexpression 
and knock-down models of NEDD9 and CASS4 in primary human astrocytes were 
generated to investigate the effect of altered expression of the Cas-proteins on astrocytes. 
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Mammalian overexpression systems generally rely on the use of a plasmid expression 
vector containing the gene of interest (GOI); here, NEDD9 or CASS4, together with a 
strong promoter to drive expression. The expression vectors used in this thesis were based 
on a commercially-available pLenti-GIII-CMV-GFP-2A-Puro backbone which has 
several advantageous features: (1) A cytomegalovirus (CMV) promoter; a long-
established method to drive robust expression of the GOI (Rotonardo et al., 1996); (2) An 
internal ribosomal entry site (IRES) to allow bicistronic expression of the GOI alongside 
a reporter gene (Mansouri et al., 2016, Kim et al., 2004); (3) a soluble green fluorescent 
protein (GFP) in the form of CopGFP (also known as ppluGFP2) (Shagin et al., 2004) to 
both signal which cells have taken up the vector and serve as a means to fluorescently 
visualise the cell; (4) a puromycin resistance gene, allowing selection of transfected cells 
where necessary; and, (5) lentiviral vector packaging signals to permit the plasmid to be 
used to create lentiviral vector particles for virus-mediated gene delivery, if necessary 
(Follenzi and Naldini, 2002). 
Primary cells, particularly neural cells, are notoriously difficult to transfect (Gresch and 
Altrogge, 2012, Alabdullah et al., 2019). Viral delivery methods, such as lentiviral 
transduction, have shown to yield high efficiencies in primary cells and allow to produce 
stable transfection of the target gene (Jakobsson et al., 2006, Merienne et al., 2013, 
Fassler et al., 2013). This method is not without pitfalls, as it can introduce insertions and 
lead to inactivation of tumour suppressor genes (Bett et al., 1993, Shearer and Saunders, 
2015). Furthermore, viral delivery systems are time consuming, require specific 
laboratory safety procedures and are subject to a limited cargo load (Mansouri et al., 
2016). Hence, viral delivery methods should only be utilised where needed. On the 
contrary, while transient transfection methods, particularly lipid-mediated delivery, yield 
generally lower transfection efficiencies in primary cells, they do not require extensive 
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safety procedures, are less time consuming and easily reproducible (Shi et al., 2018, 
Alabdullah et al., 2019). Based on this, transient transfection via lipid-mediated delivery 
was initially trialled to achieve overexpression Cas-proteins. 
A well-established method of depleting levels of a protein of interest in target cells is to 
utilise RNA-interference (RNAi). RNAi is a process in eukaryotes that regulates silencing 
of genes post transcription by utilising double stranded RNA (dsRNA). The dsRNA is 
then cleaved into a shorter, small interfering RNA (siRNA) by the RNase III 
endonuclease Dicer (Zhang et al., 2004). The dicer complex then aids the small siRNAs 
to bind to other proteins, including Ago-2, an argonaute protein which harbours a catalytic 
domain for cleavage of the RNA (Meister et al., 2004), to form a multiprotein complex, 
RISC. Through Ago-2 activity, the double stranded siRNA is unwound into single 
stranded RNA with a high binding affinity for the target gene mRNA. The RISC complex 
then targets the complementary mRNA and silences the gene by inducing cleavage and 
degradation of the transcript (mRNA) (Almeida and Allshire, 2005). This biological 
process can be ‘hijacked’ and used to silence genes of interest through the introduction 
of exogenous siRNAs. This can be achieved via direct transfection of cells with siRNA 
which produces transient gene silencing, or by transfection with a siRNA-encoding 
expression vector. Using a vector is superior in that it produces longer-lasting effects 
(since the siRNA will be produced for as long at the expression plasmid remains in the 
cell), and selection markers and fluorescent transporters can be inserted into the vector to 
co-express alongside the siRNA. Simultaneous transfection of several vectors which 
encode siRNAs complimentary to various target sequences within the same transcript are 
known to provide enhanced gene silencing (Parsons et al., 2009). SiRNA vectors built on 
the same pLenti-GIII-CMV-GFP-2A-Puro backbone as the overexpression vector were 
employed, whose GOI was either siRNA against NEDD9 or CASS4. In all cases, pools 
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of vectors encoding four siRNAs targeted against different regions of each Cas-protein 
transcript were transiently transfected into the NHAs using a lipofection method, as it has 
been shown to yield positive results in astrocytes (Ishii et al., 2017, Youn et al., 2015). 
Each siRNA was transfected at a relatively low level to minimise off-target effects. 
 
4.2 Results 
 Cas-protein overexpression models 
Overexpression of the Cas-proteins in NHAs in vitro was achieved via transiently 
transfecting CASS4 or NEDD9 encoding plasmids (pLenti-GIII-CMV-GFP-2A-Puro), 
which are driven by CMV promoters to induce overexpression of the Cas-proteins. An 
empty/blank pLenti-GIII-CMV-GFP-2A-Puro vector was transiently transfected into 
control NHAs. Biscistronic expression of GFP alongside the target gene which permitted 
confirmation of transfection as well as the visualisation of entire cells for subsequent 
morphometric analysis. Immunofluorescent staining with primary antibodies against 
CASS4 or NEDD9 followed by an Alexa Fluor 555 (red) secondary antibody permitted 
assessment of intracellular levels of the Cas-proteins. Cells were counted and assessed in 
20 random fields of view at x40 magnification in three repeats of the experiment (N=3). 
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Overexpression model of NEDD9 in normal human astrocytes 
Transfection of NHAs with Cas gene-containing LV-CMV vectors yielded comparable 
results as transfection with the GFP-only blank vector, in that GFP spread through the 
entire cell, permitting visualisation of cell morphologies. Transfection efficiencies also 
averaged 30-50% with no signs of toxicity. There is no standard for sufficient transfection 
efficiencies. Although on the lower end of the spectrum, the achieved 30-50% were 
sufficient to visualise cells via microscopy, as transfected cells are GFP positive and could 
thus be chosen for analysis. Transient transfection of the LV-CMV vectors for NEDD9 
and CASS4 via lipid-mediated delivery was thus deemed suitable for undertaking the 
planned experiments for this thesis. 
NHAs transfected with the NEDD9 LV-CMV overexpression vector or blank vector 
control were immunostained for NEDD9 (Figure 4.1). Fluorescence imaging revealed a 
slightly punctate staining pattern throughout the cytosol for NEDD9 in both transfection 
conditions, consistent with that observed in non-transfected cells (Chapter 3). An increase 
in NEDD9 fluorescence could be visually observed in the NHAs transfected with a 
NEDD9 overexpression vector in comparison to control cells (Figure 4.1). 
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Figure 4.1 Fluorescence of NEDD9 is increased in NHAs transfected with the NEDD9 LV-
CMV vector in comparison to the blank vector control. 
Fixed NHA were stained using a primary antibody for NEDD9 followed by an 
Alexa Fluor 555 secondary antibody revealing increased NEDD9 fluorescence 
in the cells transfected with NEDD LV-CMV in comparison to the blank vector 
transfected control. N=3 (donors), three technical repeats. Scale bar = 20µm. 
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Fluorescence intensities (NEDD9) of NHAs transfected with NEDD9 LV-CMV and a 
blank vector control were measured and compared (Figure 4.2). An independent-samples 
t-test showed that there was a significant increase of fluorescence t(4)= 12.485, P< 0.001) 
between the cells, transfected with a blank vector control (M= 135.66, SD= 8.36)  and the 
cells, transfected with NEDD9 LV-CMV (M= 471.67, SD= 45.85), indicating that 
transfection of NHAS with NEDD9 LV-CMV induces increased NEDD9 expression. 
 
 
 
Figure 4.2 Transfection of NHAs with NEDD9 LV-CMV leads to increased fluorescence 
Fluorescent images of NHAs, transfected with either NEDD9 LV-CMV or a 
blank vector control were analysed with ImageJ. Measured fluorescence 
intensity was compared between the two groups, showing a significant increase 
in the NEDD9 LV-CMV cells. N=3, three technical repeats. Error bars ± 2 
SEM. *** p≤ 0.001 
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To further validate the overexpression of NEDD9, Western blotting of whole-cell lysates 
from NHAs transfected with the NEDD9 LV-CMV or blank vector, was performed, 
followed by densitometric analysis with ImageJ. Relative density data were normalised 
to the β- actin loading control and statistically compared. All bands previously identified 
as endogenously expressed in NHAs (65, 105 and 115 kDa) were still evident in the 
NEDD9 LV-CMV transfected NHAs (Figure 4.3, A). All bands appeared to be enriched 
in the NEDD9 LV-CMV transfected cells compared to controls. This was particularly 
clear for the 115 kDa isoform band. Following normalisation, densitometric analysis of 
all bands together revealed a significant increase of NEDD9 expression is NHAs  
transfected with NEDD9 LV-CMV (M= 1.45, SD= 0.079) in comparison to the NHAs, 
transfected with the blank vector control (M= 0.58, SD= 0.02) (t(4)=18.16, P<0.001; 
Figure 4.3, B) suggesting that overexpression of NEDD9 was achieved. 
 
 
 
 
Figure 4.3 Overexpression of NEDD9 was achieved in normal human astrocytes 
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Western blotting of lysates from NHAs, transfected with NEDD9 LV-CMV show 
a visible stronger band at 115kDa comparison to lysates from cells transfected 
with a blank vector control; loading control: β actin (A) Densitometric analysis 
revealed a significant increase of density in the NEDD9 LV-CMV band in 
comparison to the control band (B). Error bars ±  SEM. *** p≤ 0.001 
 
 
Overexpression model of CASS4 in normal human astrocytes 
NHAs transfected with the CASS4 LV-CMV overexpression vector or blank vector 
control were immunostained for CASS4 (Figure 4.3). Fluorescence imaging revealed a 
staining pattern throughout the cytoplasm for CASS4 in both transfection conditions, 
consistent with that observed in non-transfected cells (Chapter 3). A clear increase in 
CASS4 fluorescence was observed in the NHAs transfected with a CASS4 
overexpression vector in comparison to control cells (Figure 4.4). 
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Figure 4.4 Fluorescence of CASS4 is increased in NHAs transfected with the CASS4 LV-
CMV vector in comparison to the blank vector control. 
Fixed NHA were stained using a primary antibody for CASS4 followed by an 
Alexa Fluor 555 secondary antibody revealing increased CASS4 fluorescence 
in the cells transfected with CASS4 LV-CMV   in comparison to the blank vector 
transfected control. N=3, three technical repeats. Scale bar = 20µm. 
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Image analysis, measuring integrated density of cells in both transfection conditions 
revealed a rise in fluorescence for NHAs, transfected with CASS4 LV-CMV. When 
compared to blank vector transfected control cells, CASS4 LV-CMV transfected cells 
showed a significantly higher amount of CASS4 fluorescence intensity (Figure 4.5). 
Independent-sample t-Test; CASS4 LV-CMV cells (M= 529.17, SD= 27.83) versus blank 
vector transfected control (M= 135.66, SD= 8.36); t(4)= 23.542, P= <0.001, suggesting 
that transfection of NHAs with CASS4 LV-CMV induces increased expression of 
CASS4. 
 
 
Figure 4.5 Transfection of NHAs with CASS4 LV-CMV leads to increased fluorescence 
Fluorescent images of NHAs, transfected with either CASS4 LV-CMV or a 
blank vector control were analysed with ImageJ. Measured fluorescence 
intensity was compared between the two groups, showing a significant increase 
in the CASS4 LV-CMV cells. N=3, three technical repeats. Error bars ± 2 SEM. 
*** p≤ 0.001 
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To further validate the overexpression of CASS4, Western blotting of whole-cell lysates 
from NHAs transfected with the CASS4 LV CMV or blank vector was performed, 
followed by densitometry analysis with ImageJ. Relative density data were normalised to 
the loading control (β-actin) and compared. Both bands previously identified as 
endogenously expressed (76 and 230 kDa), but only the 230kDa was seen to become 
thickened in the CASS4 LV-CMV transfected cells (Figure 4.6, A). Densitometry 
analysis of all bands revealed a significant increase of expression of CASS4 for NHAs 
transfected with CASS4 LV-CMV (M= 1.49, SD= 0.49) compared to NHAs transfected 
with the blank vector control (M= 0.46, SD= 0.11) (t(4)=14.59, P<0.001; Figure 4.6, B), 
suggesting that overexpression of CASS4 in primary astrocytes was achieved and 
confirming the immunofluorescence analysis results. 
 
 
Figure 4.6 Overexpression of CASS4 was achieved in normal human astrocytes 
Western blotting of lysates from NHAs, transfected with CASS4 LV-CMV show 
a visible stronger band at 115kDa comparison to lysates from cells transfected 
with a blank vector control; loading control: β actin (A) Densitometric analysis 
revealed a significant increase of density in the CASS4 LV-CMV band in 
comparison to the control band (B). Error bars ±  SE. *** p≤ 0.001 
 
105 
 
 
 Cas-protein knock-down models 
Depletion of Cas-protein expression was achieved by transiently transfecting a set of four 
piLenti-siRNA-GFP vectors encoding siRNAs targeted to NEDD9 or CASS4 transcripts. 
The siRNA vectors were bicistronic; expressing GFP alongside the siRNA to allow for 
visualisation of the entire cell. A vector encoding a scramble siRNA designed not to target 
any cellular transcript was used as a control. Cells were immunofluorescently stained for 
CASS4 and NEDD9 to assess whether knock down of CASS4 or NEDD9 had been 
achieved. Cells were counted and assessed in 20 random fields of view at x40 
magnification in three repeats of the experiment (N=3). Image analysis with ImageJ was 
performed to measure fluorescence intensity and compare the NEDD9 and CASS4 KD 
cells to cells, transfected with a scramble control. 
 
Knock-down model of NEDD9 
Transient transfection of NHAs with a NEDD9 siRNA-encoding plasmids induced no 
change in the subcellular distribution of NEDD9 (Figure 4.7). A reduction in NEDD9 
fluorescence intensity in comparison to the control cells transfected with a scramble 
control, suggesting a downregulation of NEDD9 expression. Of further note was that by 
48 hours of transfection cells transfected with NEDD9 siRNA had begun to detach from 
the cultureware, limiting the ability to maintain them in culture for any prolonged period 
of time. 
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Figure 4.7 Fluorescence of NEDD9 is reduced in NHAs transfected with the NEDD9 siRNA 
in comparison to the scramble control. 
Fixed NHA were stained using a primary antibody for NEDD9 followed by an 
Alexa Fluor 555 secondary antibody revealing reduced NEDD9 fluorescence 
in the cells transfected with NEDD siRNA in comparison to the scramble 
transfected control. N=3, three technical repeats. Scale bar = 20µm. 
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Comparing integrated density measurements of NEDD9 immunofluorescence in NHAs 
transfected with NEDD9 siRNA or a scramble control revealed a significant reduction of 
NEDD9 fluorescence intensity in the NEDD9 siRNA transfected cells (M=27.38, 
SD=1.87) in comparison to the scramble control (M=124.74 , SD=5.23) (t(4)= 30.338, 
P< 0.001; Figure 4.8), indicating that transfection with a set of NEDD9 siRNA encoding 
vectors induced a reduction of NEDD9 expression. 
 
 
Figure 4.8 Transfection of NHAs with NEDD9 siRNA leads to reduction of fluorescence 
Fluorescent images of NHAs, transfected with either NEDD9 siRNA or a 
scramble control were analysed with ImageJ. Measured fluorescence intensity 
was compared between the two groups, showing a significant decrease in the 
NEDD9 siRNA cells. N=3, three technical repeats. Error bars ± 2 SEM. *** 
p≤ 0.001 
 
 
To further validate these findings, Western blotting of lysates from NHAs, transfected 
with NEDD9 siRNA encoding vectors or a scramble control and enriched via puromycin 
selection, were performed, followed by densitometric analysis. Initially, the transfection 
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efficiency achieved by transient transfection proved problematic as endogenous Cas-
protein expression in un-transfected cells masked the knock-down, since WB is not 
sensitive enough to pick up modest changes in expression levels. In order to achieve 
unambiguous results, enrichment of transfected (i.e. knocked-down) cells via puromycin 
selection was performed. Cells were exposed to medium, supplemented with puromycin 
for 24 hours to reduce the number of non-transfected cells, which caused an adequate 
reduction of non-transfected cells to detect the knock-down. To establish the optimal 
concentration of puromycin to select transfected cells, a dose response experiment 
(puromycin kill curve) was conducted (Figure 4.9).  
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Figure 4.9 Growth curve for NHA in presence of increasing concentrations of puromycin 
Increasing concentrations of puromycin (0-5µg/ml) were added to cell medium. 
Cells were counted at 24, 48 and 72 hours. N=3, three technical repeats. Error 
bars= SEM 
 
All concentrations of puromycin tested were effective in reducing the growth of NHAs in 
culture in a dose-dependent manner. Both 4 µg/ml and 5 µg/ml had all but killed all NHAs 
within 48 hours. As outlined above, by 48 hours NEDD9 siRNA transfected NHAs had 
started to detach from the growth surface and hence could not be grown for this period. 
Hence a concentration of 5 µg/ml was chosen, as this induced an adequate effect after 
only 24 hours, reducing non-transfected cells sufficiently to conduct WB. 
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Western blotting of lysates from NHAs transfected with a scramble control showed two 
bands for NEDD9 (115 kDa and 105 kDa); both bands are visibly fainter in the NEDD9 
siRNA lysates. The NHA NEDD9 siRNA lysates unusually revealed the known isoform 
of 65kDa, which was absent in the control (Figure 4.10, A) and only faintly visible in the 
endogenous expression experiments (Chapter 3). Densitometric analysis of the combined 
bands in the blots showed a significant decrease of expression between in the NEDD9 
siRNA NHAs (M= 0.47, SD= 0.545) compared to the scramble control (M= 2.51, SD= 
0.103) (t(4)= 3.404, P= 0.027; Figure 4.10, B), suggesting that a NEDD9 knock-down 
was achieved in normal human astrocytes. The large error bars of the scramble 
densitometric data reflects the variation of Cas-protein expression in the NHA control 
cell population. 
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Figure 4.10 Knock-down of NEDD9 was achieved in normal human astrocytes 
WB of lysates from NHAs, transfected with NEDD9 siRNA show a visibly lighter 
band at 115kDa comparison to lysates from cells transfected with a scramble 
control which also showed the 105kDa isoform; loading control: β actin (A) 
Densitometric analysis revealed a significant decrease of density in the NEDD9 
siRNA band in comparison to the control band (B). Error bars ± 2 SEM. * p≤ 
0.05 
 
 
 
Knock-down-model of CASS4 
Transient transfection of NHAs with a CASS4 siRNA-encoding plasmids induced no 
change in the subcellular distribution of CASS4 (Figure 4.11). A decrease in CASS4 
fluorescence intensity in comparison to the control cells transfected with a scramble 
control, suggesting a downregulation of CASS4 expression. Of further note, as was the 
case in the NEDD9 knock-down cells, by 48 hours of CASS4 siRNA transfection, cells 
had begun to detach from the growth surface, limiting the ability to maintain them in 
culture for any prolonged period of time. 
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Figure 4.11 Fluorescence of CASS4 is reduced in NHAs transfected with the CASS4 siRNA 
vectors in comparison to the scramble control. 
Fixed NHA were stained using a primary antibody for CASS4 followed by an 
Alexa Fluor 555 secondary antibody (red) revealing decreased CASS4 
fluorescence in the cells transfected with CASS4 siRNA in comparison to the 
scramble transfected control. Transfected GFP+ cells, green. N=3, three 
technical repeats. Scale bar = 20µm. 
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Comparing measurements of CASS4 fluorescence in NHAs transfected with either 
CASS4 siRNA encoding vectors or a scramble control, revealed a significant reduction 
of CASS4 fluorescence intensity in the CASS4 siRNA transfected cells (M=26.60, 
SD=0.92) in comparison to the scramble control (M=124.74, SD=5.23); t(4)= 31.987, 
P<0.001;Figure 4.12), indicating that transfection with a set of CASS4 siRNA encoding 
vectors induced a reduction of CASS4 expression. 
 
 
 
Figure 4.12 Transfection of NHAs with CASS4 siRNA leads to a reduction of fluorescence 
Fluorescent images of NHAs, transfected with either CASS4 siRNA or a 
scramble control were analysed with ImageJ. Measured fluorescence intensity 
was compared between the two groups, showing a significant decrease in the 
CASS4 siRNA cells. N=3, technical repeats. Error bars ±  SEM. *** p≤ 0.001 
 
 
To further validate these findings, WB of lysates from NHAs, transfected with CASS4 
siRNA encoding vectors or a scramble control and enriched via puromycin selection, 
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were performed, followed by densitometric analysis. Western blotting of the scramble 
control revealed two bands for CASS4 (230 kDa and 76 kDa; Figure 4.13, A), as was 
seen in the endogenous expression chapters (Chapter 3). The same bands were also in the 
lysates from NHAs transfected with CASS4 siRNA, although they were fainter than in 
the control. Comparison of density revealed a significant reduction between the scramble 
control (M= 1.19, SD= 0.045) and the CASS4 knock-down cells (M= 0.76, SD= 0.036) 
(t(4)= 12.553, P< 0.001; Figure 4.13, B) indicating that a CASS4 knock-down was 
successfully achieved. 
 
 
 
Figure 4.13 Knock-down of CASS4 was achieved in normal human astrocytes 
WB of lysates from NHAs, transfected with CASS4 siRNA show a visibly lighter 
band at 230kDa comparison to lysates from cells transfected with a scramble 
control; loading control: β actin (A) Densitometric analysis revealed a 
significant decrease of density in the CASS4 siRNA band in comparison to the 
control band (B). Error bars ± 2 SEM. *** p≤ 0.001 
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4.3 Discussion 
The main aim of this thesis was to investigate the effect of altered NEDD9 or CASS4 
expression on astrocyte morphology and function in vitro. In order to undertake such 
assessments, NEDD9 and CASS4 overexpression and knock-down models in normal 
human astrocytes were designed. As outlined in the introduction to this chapter, primary 
cells are difficult to transfect (Alabdullah et al., 2019, Gresch and Altrogge, 2012) but 
based on the findings of the previous chapter, primary human astrocytes delivered the 
only viable model for this investigation. 
Transient lipid-mediated transfection yielded sufficient transfection efficiencies to 
validate both overexpression and knock-down via immunocytochemistry, as transfected 
cells express GFP and could hence be visualised and selected for analysis, even with low 
transfection efficiencies. This revealed a significant increase of NEDD9 or CASS4 
expression in the cells transfected with the LV-CMV overexpression vectors and a 
significant reduction of expression in the cells transfected with the siRNA-encoding 
vectors. As the measurement of immunofluorescence is only a semi-quantitative measure 
for protein expression, confirmation of overexpression and knock-down was also 
conducted via Western blotting. Here the relatively low transfection efficiency (30%) led 
to complications. With non-transfected cells forming the majority of the NHA population 
used for producing lysates, WB was not initially able to reveal modest changes in overall 
expression levels (i.e. the endogenous expression of the Cas-proteins in the non-
transfected cells masked the knock-down). Puromycin selection for 24 hours was 
sufficient to reduce the number of non-transfected cells low enough to detect the knock-
down. Densitometric analysis of the blots revealed significant reductions in Cas-protein 
expression in the transfected cells in comparison to the control cells transfected with 
scramble RNA. 
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Validation of overexpression and knock-down via immunocytochemistry is a relatively 
simple and fast way to get an indication of expression changes and is often paired with 
Western blotting, which is a standard and commonly used method to validate 
overexpression or knock-down (Erustes et al., 2018, Kikuno et al., 2007, LaRocca et al., 
2019, Liu et al., 2009). Both immunocytochemistry and WB delivered agreeing results 
here, with a knockdown of 48% for CASS4 and 88% for NEDD9. Transient knockdown 
at the protein level is highly variable, depending on the affinity of siRNA to the target 
sequence and protein turnover times but should be sufficient to explore the consequences, 
such as morphological and functional changes (Mocellin and Provenzano, 2004, Abel and 
Redersdorff, 2015). Knockdown efficiencies can thus vary greatly and reach from 20-
90% (Pachernegg et al., 2018, Burnell et al., 2018, Wu et al, 2004), placing the 
knockdown efficiencies of this thesis within the acceptable spectrum. Comparison of 
expression in transfected cells versus non-transfected cells was not undertaken. Although 
this would be of interest, the blank vector and scramble controls deliver a better base line 
for comparison, as these cells were treated with the same reagents under the same 
conditions as the overexpression and knockdown cells.  
Overexpression and knock-down are also routinely validated using qRT-PCR (Sato et al., 
2018, Zhao et al., 2018), which could add to the validation of the NHA models. However, 
as outlined in the introduction to the previous chapter, this method cannot predict actual 
protein expression (Greenbaum et al., 2003, Liu et al., 2016) due to control of protein 
expression at the level of translation and highly variable protein half-lives 
(Schwanhausser et al., 2011). Moreover, since qRT-PCR-based methods have previously 
concluded that NEDD9 is absent from the adult brain, a result contradicted by the 
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endogenous expression experiments presented in Chapter 3, this method was not 
considered to be suitable for the purpose of this project. 
 
The combined results of this chapter confirm that: 
a) Overexpression of both NEDD9 and CASS4 was achieved in primary human 
astrocytes in vitro via transient transfection cells with CMV promoter driven 
vectors. 
b) Knock-down of both NEDD9 and CASS4 was achieved via transient transfection 
of NHAs in vitro with a set of four siRNA encoding bicistronic vectors. 
c) Overexpression and KD models of NEDD9 and CASS4 in human astrocytes were 
successfully created and could be used as a model to investigate Cas-protein 
effects on astrocyte morphology and function. 
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Chapter 5 
Morphological analyses 
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5 Chapter 5 – RESULTS: Morphological analyses 
5.1 Background 
As outlined earlier, astrocytes are the most abundant and heterogeneous cells in the 
human brain. Astrocyte morphogenesis and the development from radial glial precursor 
cells to complex mature astrocytes remains incompletely understood (Zhou et al., 2019) 
but requires extensive cytoskeletal remodelling (Schiweck et al., 2018). Most of what is 
known is based on animal models, which delivers another challenge as human astrocytes 
differ greatly to rodent or murine astrocytes (Oberheim et al., 2009, Verkhatsky et al., 
2019). The unique astrocyte morphology is integral to copious functions in the central 
nervous system (CNS). Owing to this exceptional morphology, it is speculated that a 
single astrocyte may contact over 2 million synapses (Oberheim et al., 2009). Moreover, 
each astrocyte forms many gap junctions with other astrocytes to form functional 
syncytia, able to integrate and carry information from synapse to synapse outside of the 
neurone (Mohamet et al., 2018). As part of the tripartite synapse, astrocytes support and 
maintain synaptic plasticity, required for learning and memory formation (Zovkic et al., 
2013, Zorec et al., 2015). To fulfil synaptic requirements, astrocytes exhibit enormous 
structural plasticity, allowing these cells to remodel cell processes rapidly (Perez-Alvarez 
et al., 2014). Such structural plasticity requires extensive intracellular signalling inducing 
cytoskeletal rearrangement (Heller and Rusakov, 2015, Schiweck et al., 2018a); a 
process, as mentioned in the previous chapter, which involves scaffolding proteins such 
as NEDD9 and CASS4. 
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Given the above, it is not surprising that aberrant astrocyte morphologies have been linked 
to several neurological pathologies, including Amyotrophic Lateral Sclerosis, 
Parkinson’s disease and AD (Kohutnicka et al., 1998, Verkhratsky et al., 2014, 
Yamanaka and Komine, 2018). Aberrant astrocyte morphology will inevitably have 
functional consequences as aberrant cells are likely unable to maintain homeostasis of 
neurotransmitters, amyloid clearance and lose control of neuronal synaptic transmission, 
leading to neurotoxicity and hence synaptic loss (Hefendehl et al., 2016, Woltjer et al., 
2010).  
Two morphological phenomena of astrocytes are present in the AD brain: 
reactive/hypertrophic astrocytes and atrophic astrocytes (Olabarria et al., 2010). 
Hypertrophic astrocytes are characterised by enlarged somata and thicker membrane 
processes and have been found in in vitro studies, animal models (e.g. 3xTg-AD) and 
post-mortem brain samples of AD patients (Olabarria et al., 2010, Verkhratsky et al., 
2016, Vijayan et al., 1991). Astrocytes become activated/hypertrophic as a result to 
injury, which can be in form of a traumatic brain injury (Robinson et al., 2016), oxidative 
stress and inflammation (Gonzales-Reyes et al., 2017).  The exact mechanisms remain 
largely unknown, but Notch signalling, the NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells) pathway and MAPK (mitogen-activated protein kinase) 
activation are likely to play a role (Acaz-Fonseca et al., 2019). In AD 
reactivity/hypertrophy is believed to be induced by the presence of Aβ plaques (Abramov 
et al., 2003, Grolla et al., 2013), but has been shown to have a neurotoxic as well as a 
neuroprotective role (Liddelow et al., 2017). Hypertrophic astrocytes are evident only in 
the later stages of AD (Olabarria et al., 2010, Rodriguez-Arellano et al., 2016, Sofroniew 
and Vinters, 2010).  
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More recent studies focus on the presence of atrophic astrocytes in AD. These precede 
amyloid plaques and neurodegeneration, manifesting during the early stages of AD, as 
found in the 3xTg-AD mouse model and iPSC-derived astrocytes from AD patients 
(Jones et al., 2017, Verkhratsky et al., 2016, Yeh et al., 2011).  
Atrophic astrocytes are characterised by somata and process shrinkage. IPSC studies have 
revealed that these are cell autonomous effects, but what exactly leads to this aberrant 
astrocyte morphology remains unknown (Jones et al., 2017). As atrophic astrocytes 
present with a decreased level of glial fibrillary acidic protein (GFAP), as well as other 
cytoskeletal proteins (Olabarria et al., 2010, Rodriguez-Arellano et al., 2016), 
mechanisms involved in cytoskeletal structure and motility may be affected in AD. 
As mentioned above, NEDD9 and CASS4 have been implicated in such pathways. 
Appropriate microtubule assembly is essential to maintain structural plasticity. NEDD9 
interacts with AURKA responsible for microtubule assembly and mitotic spindle 
organisation (Nikonova et al., 2013, Pugacheva and Golemis, 2005). Further, studies have 
shown how overexpression of NEDD9 promotes process formation in epithelial derived 
cancer cells (Bargon et al., 2005) and, during preliminary experiments, we found 
overexpression of both NEDD9 and CASS4 induced morphological changes in epithelial 
cells, generating processes atypical for this cell type (Ulzheimer & Jones, 2016; 
unpublished data). 
Only one study to date has investigated the effect of NEDD9 on brain function; finding 
that NEDD9 knock-out mice suffer extensive dendritic spine loss in the dentate gyrus and 
CA1 regions of the hippocampus (Knutson et al., 2016). Consequently, these NEDD9 
null mice displayed deficits in learning and memory via the Morris water maze test. 
Unfortunately, astroglial function was not directly assessed in this study. However, it is 
clear that a NEDD9 knock out alters synaptic integrity; a process heavily shaped by 
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astrocytes. Altered expression of NEDD9 or its paralogue CASS4 are likely to induce 
morphological changes in astrocytes and based on the evidence above, could be involved 
in aberrant astrocyte morphology in AD, identifying a new mechanism of morphological 
control in these cells. Identifying pathways, leading to aberrant astrocyte morphology, 
could lead to the identification of new therapeutic targets. 
 
5.2 Heterogeneous morphology of astrocytes in vitro 
Astrocytes are known to be highly heterogeneous in vivo (Miller, 2018, Matyash and 
Kettenmann, 2010, Olude et al., 2015), but it is unknown if the normal human astrocytes 
exhibit the same heterogeneity in a 2D culture. To test the morphological characteristics 
in vitro, normal human astrocytes were transiently transfected with pEGFP-C1 (a vector 
expressing only EGFP) to permit visualisation of the full extent of the cell. Untransfected 
cells are difficult to assess, as no stain allows visualisation of entire cell morphology 
comparable to GFP. Brightfield microscopy or a cell membrane stain could be used, to 
visualise untransfected cells, but such methods are not suitable for morphometric 
quantification and hence unsuitable for this thesis.  
The gross morphology of fixed primary human astrocytes was assessed in 20 random 
fields of view each from three separate donor pools. As expected, EGFP filled the entire 
cell, including all processes and soma (Figure 5.1). Four distinct morphologies were 
evident, and cells were thus binned into four categories: fibroblast-like (A - large >20 µm, 
process-devoid), polarised (B - exhibiting a single, usually thick, process), arborised (C - 
consisting of a small soma with multiple ramified processes), and atrophic (D - process-
devoid with reduced soma width, <10 µm). 
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Figure 5.1 NHAs transfected with pEGFP-C1 exhibit four distinct morphological types. 
Representative images of Fibroblast-like, process devoid cells (A), polarised, 
asymmetric cells (B), arborised cells (C) and atrophic cells with reduced soma 
width (D). Scale bar = 20µm 
 
The populations of astrocytes transfected with pEGFP-C1 revealed an uneven distribution 
of morphologies, whereby most cells exhibited fibroblast-like morphology 37.7±0.9 % or 
polarised morphology 36.7±1.2 %.  Fewer arborised cells 18.0±0.8 % were seen, and only 
a small number of cells with an atrophic morphology 7.5±1.1 % could be observed in this 
cell population (Figure 5.1), indicating that, although some heterogeneity exists, healthy, 
untreated human astrocytes in vitro display primarily fibroblast-like and polarised 
morphologies.  
 
124 
 
 
Figure 5.2 NHA distribution of morphologies in vitro 
Astrocytes in vitro display mainly fibroblast-like 37.7±0.9 % and polarised 
36.7±1.4 % morphologies. Arborised cells made up 18.0±0.8 % and few 
atrophic cells 7.5±1.1 % were found in NHAs transfected with a GFP 
expressing plasmid (control group), N=3, three repeats per N. Error bars ± 
SEM. 
 
 
The visual binning of NHAs into morphological groups reveals that these cells exhibit 
heterogeneity in vitro. Although most cells displayed a fibroblast-like morphology, as can 
be expected in 2D cultures, almost as many cells revealed a polarised shape and just over 
a quarter of cells exhibiting different morphologies, showing how diverse astrocytes are, 
even grown in culture.  
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5.3 Overexpression of the Cas-proteins in normal human astrocytes 
 Morphological distribution in NEDD9 and CASS4 overexpression 
models 
To determine the effect of overexpressing the Cas-proteins on primary human astrocyte 
morphology, fixed primary astrocytes, which had been transfected with NEDD9 LV-
CMV, CASS4 LV-CMV or the blank GFP-only vector were visually binned into the 
previously established morphological categories. Importantly, the LV-CMV expression 
vectors bicistronically co-express a GFP (CopGFP2) alongside either NEDD9 or CASS4 
to permit both the identification of transfected cells and the visualisation of the entire cell. 
The gross morphology of fixed primary human astrocytes was assessed in 20 random 
fields of view each from three separate donor pools for each of the transfection conditions. 
Analysis was undertaken in a blinded manner (a third party obscuring all slide labels) to 
avoid any bias. 
The control group (Blank GFP-only LV vector) exhibited each of the four morphologies 
identified with the pEGFP-C1-transfected cells. Again, the distribution of morphologies 
was uneven and was indistinguishable to that seen with pEGFP-C1 (Figure 5.2), 
suggesting that the CopGFP2-expressing vector did not cause any morphological changes 
to the NHAs compared to the more widely utilised pEGPF-C1. Specifically, the blank 
vector transfected cells comprised predominantly fibroblast-like (37.7±0.4 %) (Figure 
5.3) and polarised cell (34.3± 1.5 %) morphologies, with significantly fewer arborised 
(19.3 ±1.5 %) and atrophic (9.3 ±0.6 %) cells (Kruskal-Wallis; H(3)= 88.021, P<0.001; 
Dunn-Bonferroni pairwise comparisons; fibroblast vs arborised or atrophic, P<0.001; 
polarised polarised vs arborised or atrophic, P< 0.001). It was vital to establish the 
statistical significance between the morphology groups within the control cell population 
in order to compare these findings with the data of NEDD9 or CASS4 overexpressing or 
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depleted cell populations. This allows a comparison of morphology distributions within 
and across populations and whether the differences are statistically significant. 
 
Figure 5.3 Distribution of morphologies in the blank vector control group 
Visual binning into morphological categories and comparison of the distribution 
revealed that populations of NHAs, transfected with a blank vector display 
significantly fewer arborised and atrophic cells than fibroblast-like and polarised 
cells. N=3 donors, three repeats per N. Error bars ± SEM. *** p≤ 0.001.  
 
 
 
 
 
 
As with the blank GFP-only transfected cells, the CopGFP2 expressed alongside either 
NEDD9 or CASS4 from the LV-CMV expression vectors filled the entire cell and 
permitted visualisation of all processes (e.g. Figure 5.1). 
Cells overexpressing NEDD9 retained heterogeneity of morphology, exhibiting all four 
morphological classifications (Figure 5.4). Similar to control cells, the distribution of 
these morphologies was not even (Kruskal-Wallis; H(3)=35.7, P<0.001), however the 
NEDD9 overexpressing NHAs were predominantly arborised (36.1±1.3 %), with a 
significantly greater proportion compared to fibroblast-like (19.9±1.0 %) cells (Dunn-
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Bonferroni pairwise comparison, P= 0.005). There were also significantly fewer atrophic 
cells (7.3±1.3 %) than any other morphological type (Dunn-Bonferroni pairwise 
comparison, P<0.001, all other morphology groups). 
 
 
 
Figure 5.4 Distribution of morphologies in NHAs overexpressing NEDD9 
Visual binning into morphological categories and comparison of the 
distribution revealed that populations of NHAs, overexpressing NEDD9 display 
significantly fewer fibroblast-like cells and significantly more arborised cell.s 
N=3 donors, three repeats per N. Error bars ± SEM.  ** p≤ 0.01, *** p≤ 0.001. 
 
 
 
 
 
Astrocytes overexpressing CASS4 also retained a heterogenous set of morphologies 
(Figure 5.5; Kruskal-Wallis; H(3)=48.485, P< 0.001). Crucially, this distribution of 
morphologies was distinct to that of the blank control cells; but very similar to the NEDD9 
overexpressing cells. Again, like the NEDD9 overexpressing cells, CASS4 
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overexpression induced a predominantly arborised morphology (Figure 5.5), with a 
significantly greater proportion of these cells compared to fibroblast-like cells (Dunn-
Bonferroni pairwise comparison, P< 0.001). Conversely, there was a significantly 
reduced number of atrophic cells compared to all other morphological categories (Dunn-
Bonferroni pairwise comparison, P< 0.001). 
 
 
Figure 5.5 Distribution of morphologies in NHAs overexpressing CASS4 
Visual binning into morphology categories and comparison of the distribution 
revealed that populations of NHAs, overexpressing CASS4 display significantly 
less fibroblast-like cells and significantly more arborised cells. N=3, with three 
repeats per N. Error bars ± SEM. *** p≤ 0.001 
 
 
The above data suggested that NEDD9- and CASS4-overexpressing cells exhibited 
patterns of morphologies which were similar to one another and clearly distinct from 
control cells. To investigate, the relative proportions of each morphological type were 
compared across each of the transfection groups (Figure 5.6).  
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It was found that the distribution differed between the groups (ANOVA; F(2,6)= 134.945, 
P< 0.001), suggesting that CASS4 and NEDD9 expression plays a role in astrocyte 
morphology. The control blank vector group comprised a significantly greater number of 
fibroblast-like cells than the cells overexpressing either CASS4 or NEDD9 (Tukey post 
hoc, P <0.001, for both). No significant difference in the distribution of polarised or 
atrophic cells was seen across the transfection groups (Tukey post hoc, P= NS, for all 
comparisons). NEDD9 and CASS4 overexpression did induce a significant increase in 
the proportions of arborised NHA cells in comparison to the control group (Tukey post 
hoc, P= 0.015 and P= 0.045, respectively), suggesting that overexpression of the Cas-
protein is capable of promoting process formation in astrocytes in vitro. 
 
. 
 
Figure 5.6 Distribution of morphologies of cells overexpressing NEDD9 or CASS4 differs 
significantly from the blank vector control population.  
Distribution of morphologies was compared across groups, showing a 
decreased number of fibroblast-like and polarised cells and an increase of 
arborised cells in populations overexpressing NEDD9 or CASS4 compared to 
the blank vector transfected control population. Error bars ± SEM. *p≤ 0.05; 
*** p≤ 0.001  
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 Morphometric analysis of NEDD9 & CASS4 overexpression models 
Although bias was avoided by numbering slides whilst assessing the distribution of 
morphologies under different transfection conditions, this method of morphological 
assessment remains somewhat subjective and is only semi-quantitative. To quantify any 
morphological changes induced by the overexpression of NEDD9 or CASS4, 
overexpressing NHAs and control cells were imaged using confocal microscopy to 
generate 3D images suitable for morphometric analyses. In all cases, z-stacks of entire 
cells were collected from a minimum of 20 cells from each of three separate donor NHA 
pools. This permitted the creation of 3D isosurface renders, which could be analysed for 
morphometric characteristics. 
Initial visualisation of 3D isosurface renders of cells overexpressing NEDD9 or CASS4 
appeared markedly larger in comparison to the blank vector transfected control, although 
the tendency towards arborisation was not as readily apparent (Figure 5.7). 
 
 
Figure 5.7 Overexpression of NEDD9 or CASS4 induces larger cells sizes compared to 
controls 
Representative 3D isosurface renders of transfected NHAs expressing GFP 
permitted visualisation of the entire cell. Optical z-stacks were compared to 3D 
vectors and revealed an increase in size of NHAs overexpressing NEDD9 (B) 
or CASS4 (C) in comparison to the blank vector control (A). Scale bar = 20µm.  
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Morphometric analysis of 3D isosurface renders from normal human astrocytes, 
overexpressing NEDD9 revealed a significant increase in both cell surface area 
(ANOVA, F(2,6)= 14.041, P= 0.005) and a Tukey post hoc test revealed that cell surface 
area of cells overexpressing NEDD9 (13740.66±1077.79 µ2) was significantly larger (P= 
0.008) than the blank vector transfected control (5817.56±472.61 µ2). There was also a 
significant difference of volume (ANOVA, F(2,6)= 10.097, P= 0.12) and a Tukey post 
hoc test revealed that cell volume of cells overexpressing NEDD9 (17356.31±1392.75 
µ3)  was also significantly increased (P= 0.01) versus blank vector transfected control 
NHAs (8027.5±1674.8 µ3), (Figure 5.10). The same was found for CASS4 
overexpressing cells, which also showed significant increases in both cell surface area 
(13549.4±1725.9 µ2 ) and volume (13543.4±1338.3 µ3 ) versus blank vector transfected 
control NHAs (5817.5±472.6 µ2 and 8027.5±1674.8 µ3, respectively) (Figure 5.10; P= 
0.009 and P= 0.029). Taken together this finding suggests that both Cas-proteins are able 
to influence astrocyte morphology when overexpressed.  
A comparison of cell surface area to volume (SA:V) ratio revealed no significant changes 
between cells overexpressing either of the Cas-protein in comparison to the blank vector 
transfected controls (Figure 5.8, C), suggesting that surface area and volume increase in 
relation; overexpression of CASS4 and NEDD9 produces proportionately larger cells. 
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Figure 5.8 Overexpression of NEDD9 or CASS4 increases cell surface are and volume 
Morphometric analyses of 3D isosurface renders of NEDD9 or CASS4 
overexpressing NHAs showed that cell surface area and volume are 
significantly increased in the NHAs overexpressing either of the Cas-protein in 
comparison to control NHAs. Surface to volume ratio remained the same across 
all transfection groups. N=3 donors, two technical repeats.  Error bars ± SEM. 
*p≤ 0.05; ** p≤ 0.01.  
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5.4 Knock-down model 
 Morphology distribution in NEDD9 & CASS4 knock-down models 
To determine the effect of NEDD9 or CASS4 knock-down on primary human astrocyte 
morphology, fixed primary astrocytes (N=3) were assessed in >20 random fields of view. 
Prior to analysis, transfection conditions were obscured by randomly numbering all slides 
to avoid any bias. The distribution of morphologies within groups of transfection 
conditions a) Scramble RNA, b) NEDD9 siRNA, c) CASS4 siRNA was assessed and 
compared to determine the how knock-down of the Cas-proteins affects astrocyte 
morphology in vitro. 
The control group (scramble) presented with a heterogeneous distribution (Figure 5.9) of 
morphologies but presenting with a large number of fibroblast-like (34.2±1.9 %) and 
polarised cells (39.7±0.8 %) and significantly less arborised (16.9±2.2 %) and atrophic 
cells (9.1±0.6 %) (Kruskal-Wallis; H(3)= 44.985, P<0.001), reflecting the discrepancies 
between fibroblast-like and arborised or atrophic cells (Dunn-Bonferroni pairwise 
comparison, P= 0.022, P= 0.003; respectively). As well as significantly less arborised 
and atrophic cells in comparison to polarised cells (Dunn-Bonferroni pairwise 
comparison, P< 0.001; both), reflecting the distribution of morphologies in the blank 
vector control group in the overexpression experiment. 
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Figure 5.9 Distribution of NHA morphologies in the scramble control group 
Visual binning into morphology categories and comparison of the distribution 
revealed that populations of NHAs, transfected with a scramble control display 
significantly less arborised and atrophic cells than fibroblast-like and polarised 
cells. N=3 donors, two technical repeats. Error bars ± SEM. *p≤ 0.05; ** p≤ 
0.01. 
 
 
NEDD9 knock-down NHAs presented with a distribution of morphologies distinctly 
different from the scramble control group (Figure 5.10). Although all four morphologies 
were still evident (Kruskal-Wallis; H(3)= 9.801, P= 0.02), the atrophic morphological 
phenotype predominated. A significant increase of atrophic cells (39.1±0.7 %) could be 
found in comparison to fibroblast-like (15.8±1.6 %) or arborised cells (18.8±0.8 %). 
(Dunn-Bonferroni pairwise comparison, P= 0.002 and P< 0.001, respectively). These 
data suggest that knock-down of NEDD9 promotes atrophic morphologies in astrocytes. 
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Figure 5.10 NEDD9 knock-down leads to a significant increase of atrophic cells 
Visual binning into morphology categories and comparison of the distribution 
revealed that populations of NHAs, depleted of NEDD9 display significantly 
more atrophic cells and significantly less of any other morphology type. N=3 
donors, two technical repeats. Error bars ± 2 SE.  ** p≤ 0.01; *** p≤ 0.001 
 
 
 
CASS4 knock-down NHAs demonstrated a similar distribution as for NEDD9 knock-
down; specifically a robust shift towards atrophic morphologies (Figure 5.11). 
Comparison of morphologies across the CASS4 knock-down group were revealed a 
significantly uneven distribution (Kruskal-Wallis; H(3)= 48.2, P< 0.001), indicating that 
morphological heterogeneity persisted. A significantly increased number of atrophic cells 
(39.7±1.1 %) was found in comparison to the other morphology types of fibroblast-like 
(18.5±0.7 %), polarised (24.7±1.2 %) and arborised (17.0±1.0 %) (Dunn-Bonferroni 
pairwise comparison, P< 0.001; for all), suggesting that CASS4 depletion promotes an 
atrophic morphology of astrocytes, similar to its paralogue NEDD9. 
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Figure 5.11 CASS4 knock-down leads to a significant increase of atrophic cells 
Visual binning into morphological categories and comparison of relative 
proportions revealed that populations of NHAs depleted of CASS4 display 
significantly more atrophic phenotypes and significantly fewer of any other 
morphology type. N=3 donors, two technical repeats. Error bars ± SEM.  *** 
p≤ 0.001 
 
 
As was seen with the overexpression studies, these data suggested that knock-down of 
NEDD9 and CASS4 in NHAs induce similar morphological changes (i.e. a shift towards 
the atrophic cellular phenotype), which are markedly distinct from scramble cells. To 
investigate, the relative proportions of each morphological type were compared across 
each of the transfection groups (Figure 5.12; ANOVA; F(2,6)= 55.732, P< 0.001).  
The number of fibroblast-like cells was significantly reduced upon knock-down of either 
NEDD9 or CASS4 compared to scramble controls (Tukey post hoc, P< 0.001 for both). 
A similar pattern was seen for polarised cells, the proportions of which were significantly 
decreased in either Cas-protein knock-down versus the scramble control (Tukey post hoc, 
P< 0.001 for both). This indicated that depletion of the Cas-proteins drives reduction of 
the two dominant NHA morphologies, fibroblast-like and polarised, found predominantly 
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in control NHA groups. No significant difference of distribution of arborised cells was 
found across the groups. As anticipated, a significant difference was found in the 
distribution of atrophic cells, which had been near absent in the control NHAs, but 
predominated in either NEDD9 or CASS4 knock-down cells (Tukey post hoc, P< 0.001 
for both). Taken together these data suggest that depletion of either Cas-proteins leads to 
a rise of atrophic astrocyte profiles. 
 
 
 
Figure 5.12 Distribution of morphologies of cells depleted of NEDD9 or CASS4 differs 
significantly from the control population. 
The distribution of morphologies was compared across groups, showing a 
significant increase of atrophic cells in the populations depleted of NEDD9 or 
CASS4 in comparison to the scramble transfected control population. Error 
bars ±  SEM.  *** p≤ 0.001 
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 Morphometric analysis of NEDD9 & CASS4 knock-down model 
As outlined in the previous section, it is impossible to completely avoid any bias when 
assessing morphologies via visual binning; the method only delivers semi-quantitative 
results. To quantify any morphological changes, induced by the knock-down of NEDD9 
or CASS4, Z-stack images of cells (>10 fields of view, N=3) were taken. This permitted 
the creation of 3D isosurface renders, which could be analysed for morphometric 
characteristics. 
Observations of NEDD9 and CASS4 KD cells revealed a great amount of small atrophic 
cells, as found in the previous experiment of binning cells based on morphology. NHAs, 
depleted of NEDD9 or CASS4 appeared process-devoid and atrophic in comparison to 
the scramble control cells (Figure 5.13). 
 
 
Figure 5.13 Knock-down of NEDD9 or CASS4 induces small, process-devoid cells compared 
to scramble controls 
Representative 3D isosurface renders of optical stacks reveal a decrease in 
surface area and volume in NHAs depleted of NEDD9 (B) or CASS4 (C) in 
comparison to the scramble control (A). Scale bar = 20µm 
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Morphometric analysis revealed a difference of cell surface area and cell volume between 
groups (ANOVA, F(2,6)= 12.8, P= 0.007). Although there was a tendency towards a 
reduction in cell surface area (40.68±849.34 µ2) and volume (5247.41±1027.60 µ3) in 
NHAs depleted for NEDD9 compared to the scramble control (6961.49±12.41 µ2 and 
8344.13±43.44 µ3, respectively), these reductions did not reach statistical significance 
(Games-Howell post hoc, P= 0.136 and P= 0.167, respectively). On the other hand, 
analysis of NHAs with a CASS4 knock-down did reveal significant decreases in cell 
surface area (3761.99±93.87 µ2; P=0.001) and cell volume (4893.0.1±129.93 µ3; 
P=0.001) in comparison to cells transfected with a scramble control. Although no 
significant difference was found between KD CASS4 astrocytes and KD NEDD9 
astrocytes in cell surface area (P= 0.901) or cell volume (P= 0.909), this suggests that 
depletion of CASS4 is capable of inducing morphological changes in astrocytes and may 
do so a greater extent than NEDD9 depletion.  
A comparison of surface to volume ratio revealed no significant differences between the 
Cas-proteins knock-downs and the scramble control, suggesting a proportionate 
relationship between cell surface and cell volume. This might suggest that depletion of 
CASS4, and to some degree NEDD9, leads to proportionately smaller cells. 
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Figure 5.14 Knock-down of NEDD9 or CASS4 reduces cell surface are and volume 
Morphometric analyses of 3D isosurface renders showed an increase of small, 
process-devoid cells in the KD models in comparison to the control population. 
Cell surface area and volume are significantly decreased in the NHAs depleted 
of the Cas-protein in comparison to the control. Surface to volume ratio 
remained the same across populations. N=3 donors, two technical repeats. 
Error bars ± 2 SEM.  ** p≤ 0.01 
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5.5 Discussion 
Previous studies have shown that altered expression of NEDD9 and CASS4 affect 
essential cellular mechanisms, including cell growth, migration and adhesion (Beck et al., 
2014, Singh et al., 2008, Tikhmyanova et al., 2010). Upregulation of the Cas-protein have 
been shown to promote migration, metastasis and invasion in numerous cancers (Zhou et 
al., 2017, Li et al., 2016, Wang et al., 2017), including epithelial to mesenchymal 
transition in mammary epithelial cells (Kong et al., 2011). All of these cellular processes 
exploit the Cas-protein abilities to induce changes in cellular morphology.  
Here it was found that overexpression of either NEDD9 or CASS4 is capable of directing 
astrocyte morphology, a phenomenon not previously demonstrated, implicating a new 
role for the Cas-proteins in the regulation of astrocyte morphology. This indicates, that 
the proteins may play a role in astrocyte dystrophy in AD and could unearth mechanisms, 
which could be exploited as therapeutic targets.  
Initially, the changes found between NEDD9 and CASS4 overexpression promoted a shift 
towards an arborised cell phenotype and a decrease in fibroblast-like cells. This is in 
keeping with previous findings that upregulation of NEDD9 promotes process formation 
in epithelial cancer cells (Bargon et al., 2005), albeit under different conditions (in 
presence of Rho inhibitor) and in non-glial cells. Although the findings of this work 
suggest overexpression of the Cas-proteins promotes process formation in astrocytes and 
thus increasing the arborised cell types, the method of visually assessing cell morphology 
is limited by subjectively categorising cell morphologies.  
On the contrary, the morphometric quantitative analysis revealed that overexpression of 
both, NEDD9 and CASS4 leads to generally larger cells, based on the measurements of 
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volume and cell surface. Yet no significant difference in surface to volume ratio was 
found, which indicates that the morphology is not necessarily more complex in the 
overexpressing cells, compared to the control group; a small soma with several processes 
would lead to a higher surface to volume ratio in comparison to cells of a less complex 
nature as fibroblast-like cells. As mentioned earlier, the initial assessment of 
morphologies revealed that overexpression of the Cas-proteins promoted process 
formation, leading to an increase of arborised cells in these populations, yet the surface 
to volume ratio comparison does not reflect these results. This may be as a result of some 
overlapping between the morphology categories or due to cells appearing more/less 
complex in 2D images than the actual 3D shape; isosurface renders used for 
morphometric analysis reflect the actual cell shape to a greater degree. On the contrary, 
software to create isosurface renders of cells may be unable to detect finer processes, 
which can be detected by the human eye. Both methods were used to gain a broader 
perspective on the morphological changes induced by NEDD9 and CASS4. To answer 
the question whether the Cas-proteins induce process formation, a third method, a 
modified method (ImageJ) of Scholl analysis was trialled. Scholl analysis is a quantitative 
method, which was originally used to assess neuron morphology, measuring dendritic 
processes and the number and size of branching processes to assess arborisation (Longair 
et al., 2011, Sholl, 1953).  This method proved to be unsuitable for the assessment of 
astrocytic processes in 2D culture. Although a modified Sholl method has recently been 
applied to astrocytes, this was in whole tissue sections; where astrocytes exhibit native 
3D conformations that include much finer processes emanating in all dimensions 
(Tavares et al., 2017).  
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Morphological analyses of the NEDD9/CASS4 knock-down model also confirmed that 
altered expression of the Cas-protein induces changes in astrocyte morphology. The 
results show that depletion of either of the proteins promotes atrophic cellular phenotypes. 
Morphometric quantitative analysis reflected these results, although depletion of CASS4 
had a greater effect. In either case there was a tendency for the morphological 
heterogeneity of the cell population to be reduced in comparison to the control population. 
It had previously been shown that depletion of NEDD9 induces cell rounding in mouse 
embryo fibroblasts (Zhong et al., 2012) and is capable of inducing dendritic spine loss of 
hippocampal neurons in mice (Knutson et al., 2016).  
These studies indicate that depletion of NEDD9 can inhibit the formation or maintenance 
of membrane protrusions, such as processes, as seen here. Intriguingly, these atrophic 
cells mimic the atrophic phenotype of astrocytes found in AD models of astrocytes (Jones 
et al., 2017, Verkhratsky et al., 2016, Yeh et al., 2011). 3D isosurface renders of NHAs, 
depleted of NEDD9 and CASS4 (representative exemplar shown, Figure 5.15) display 
the same aberrant morphology as iPSC derived astrocytes of patients, carrying either 
EOAD (PSEN1 M146L) or LOAD (ApoE4+/+ ) mutations (Figure 5.15). 
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Figure 5.15 NHAs depleted of NEDD9 or CASS4 mimic atrophic phenotype of astrocytes 
found in AD models of astrocytes 
Exemplar 3D isosurface renders constructed from serial confocal z-stacks of 
NHAs depleted of NEDD9 or CASS4 (top) display the same aberrant 
morphology found by Jones et al., 2017 in iPSC derived astrocytes of 
PSEN1 M146L LOAD and ApoE4+/+ EOAD patients (bottom). Scale bar (top) 
= 20µm; Scale bar (bottom) = 10µm.  
 
 
The NHAs, depleted of NEDD9 or CASS4 display a morphology almost 
indistinguishable from the iPSPC derived astrocytes. Both are characterised by soma 
shrinkage and complete loss of cellular processes.  
The iSPC model Jones et al. (2017) employed, originates from patients with mutations 
known to cause AD. Yet it is unclear how and if these mutations lead directly to this 
(atrophic) phenotype. In LOAD, only around 50% of patients are homozygous for the 
APOE ε4 allele (Huang et al., 2004), so it is unclear whether astrocyte atrophy would be 
present in patients with LOAD who do not carry the gene. Testing this, is currently not 
145 
 
possible due to atrophy manifesting prior to symptoms; brain samples from deceased 
patients and hence late stage disease development would not display this astrocyte 
phenotype. Although an in vivo model of NEDD9-/- or CASS4 -/- may deliver some vital 
clues, as knock-down of the proteins alone caused clear phenotypical changes in this 
model. Furthermore, testing the expression levels of NEDD9 and CASS4 in iPSC derived 
astrocytes, originating from AD patients could indicate whether the Cas-proteins play an 
additional role. 
 
Although it remains unknown how exactly altered expression of NEDD9 and CASS4 
induces changes in astrocyte morphology, these results show that: 
a) Both NEDD9 and CASS4 direct astrocyte morphology in vitro 
b) Overexpression of the Cas-proteins leads to larger, possibly more arborsied cells 
c) Depletion of CASS4 leads to atrophic astrocyte morphology (and NEDD9 
depleted astrocytes tend towards being atrophic) 
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Chapter 6 
Analyses of functional markers 
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6 Chapter 6 – RESULTS: Analysis of astrocyte functional 
markers  
6.1 Background 
Astrocyte morphology and function are inexorably connected. As proper morphology is 
vital to astrocyte function, astrocyte dystrophy coincides with aberrant cell function 
(Dossi et al., 2018, Matias et al., 2019, Zhou et al., 2019). In order to indicate altered 
astrocytic function, several functional markers may be assayed, such as glial fibrillary 
acidic protein (GFAP), s100 calcium-binding protein B (S100B) and transporters such as 
the excitatory amino acid transporter 2 (EAAT2). An increase of s100B could initiate 
proliferation and inflammatory responses, similar to GFAP, but has also been shown to 
induce apoptosis in other cell types (Xia et al., 2018). A downregulation of s100B has 
been indicated in a reduced inflammatory response (Ohtaki et al., 2007), suggesting that 
a decrease of s100B in astrocytes may hamper the neuroprotective role of astrocytes to 
brain insults, such as amyloid plaques or NFTs. Downregulation of the glutamate 
transporter EAAT2, which is responsible for removing excess glutamate from the 
synaptic cleft, would lead to a glutamate ‘overspill’, inducing neurotoxicity and thereby 
synaptic loss.  
To investigate the astrocyte function in the model of this thesis, functional tests would be 
required, but were not within the scope of this thesis. Furthermore, as it is not known 
which functions may be affected, assessing the expression and localization of key markers 
could identify which functional tests should be undertaken in follow-up experiments. An 
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increase of functional markers, such as GFAP is a feature of reactive/hypertrophic 
astrocytes, which are a typical manifestation in neurodegenerative diseases such as AD. 
GFAP is an intermediate filament and expressed almost exclusively in astrocytes 
(Brenner, 1994, Hol and Pekny, 2015, Sofroniew and Vinters, 2010). This protein is 
widely established as the typical marker for astroglia (Janke et al., 2001, Moon et al., 
2011, Schitine et al., 2015). Changes in the expression of GFAP have been linked to 
numerous neurological disorders such as schizophrenia, (Johnston-Wilson et al., 2000), 
Parkinson’s disease (Tong et al., 2015), amyotrophic lateral sclerosis (Benninger et al., 
2016). Upregulation of GFAP is a typical hallmark of astrogliosis (Yang and Wang, 2015, 
Wakasa et al., 2009), an ill-defined yet ubiquitous context-dependent defensive process 
in which astrocytes adopt a so-called ‘reactive’ phenotype that includes hypertrophic 
cellular re-modelling and altered gene expression, outlined in the previous chapter 
(Liddelow et al., 2017, Pekny and Pekna, 2004). This astrocyte response is established 
with the later, symptomatic stages of AD (Osborn et al., 2016, Colangelo et al., 2014). 
Although found in some other cells, S100B is primarily produced in astrocytes in the CNS 
(Donato et al., 2013, Yardan et al., 2011). Not all functions of S100B are known, but it is 
believed to be involved in cell proliferation, migration and differentiation, and as an 
inhibitor of apoptosis (Brozzi et al., 2009, Lin et al., 2010, Raponi et al., 2007). In 
astrocytes, it has been shown to stimulate proliferation and inflammatory responses when 
overexpressed (Van Eldik and Wainwright, 2003) and altered expression has been 
implicated in several inflammatory and psychiatric diseases neurodegenerative disorders 
(Sathe et al., 2012, Yardan et al., 2011). 
Glutamate is the principle excitatory neurotransmitter of the brain. Astrocytes play a 
crucial role in the production of glutamate; supplying neurones with the precursor 
glutamine via the glutamate-glutamine shuttle (Hertz, 2013). Moreover, astrocytes 
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rapidly scavenge glutamate from the synaptic cleft via several specific transporters, 
protecting neurons from excitotoxicity. EAAT2 is specifically expressed on astrocytic 
processes which ensheath synapses (Holmseth et al., 2009) and is responsible for around 
90% of glutamate uptake from the synaptic cleft (Kim et al., 2011, Nedergaard et al., 
2002), meaning altered expression of this transporter will inevitably therefore lead to 
unbalancing glutamate homeostasis in the brain. Indeed, altered expression has been 
linked to several diseases, such as amyotrophic lateral sclerosis (Rattray and Bendotti, 
2006), Huntington’s disease (Arzberger et al., 1997) and AD (Garcia-Esparcia et al., 
2018). It is hence of interest to establish if altered expression of NEDD9 or CASS4 and 
the corresponding morphological changes lead to a change of EAAT2 expression. 
Altered expression of a wide array of functional astrocyte markers have been suggested 
to play a role in AD. Studies of AD murine models has identified variously changing 
astroglial profiles during different stages of AD (3, 9, 18 and 24 months disease 
development). Yeh et al (2011) reported alterations in GFAP, glutamine synthetase (GS) 
and S100B expression in 3xTg-AD mice, implicating astrocyte functional changes in AD. 
Furthermore, a recent study by Jones et al. (2017) established a change in key markers of 
induced pluripotent stem cell (iPSC)-derived astrocytes from AD patients, detecting 
decreased GFAP, excitatory amino acid transporter-1 (EAAT1) and GS compared to 
controls. Altered expression of key markers in AD astrocytes imply aberrant function, 
which is particularly interesting as the iPSC astrocytes were investigated in an 
autonomous culture, hence free of any environmental influences, such as dysfunctional 
neurons or aberrant proteins. The mechanisms underlying such changes are as-yet 
unexplored. Given that altered expression of NEDD9 and CASS4 are sufficient to 
recapitulate some of the aberrant morphological changes associated with AD, 
experiments were undertaken to establish whether the Cas-proteins were capable of 
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influencing established markers of aberrant function (namely GFAP, S100B and EAAT 
2) also.  
In addition to GFAP, S100B and EAAT 2, the expression of cytoskeletal proteins β-actin 
and α-tubulin was assessed. As outlined in the previous chapter, Cas-proteins are known 
to play a role in cytoskeletal arrangement. NEDD9 activates AURKA, which leads to 
microtubule assembly and mitotic spindle arrangement (Pugacheva et al., 2007) and 
depletion of NEDD9 has been shown to downregulate AURKA, hence leading to 
destabilisation of the cytoskeleton (Ice et al., 2013). Furthermore, NEDD9 regulates 
remodelling of microtubules neurite extension via AURKA activation, (Mori et al., 2009, 
Pugacheva and Golemis, 2005), whereby depletion of NEDD9, demonstrated in a murine 
knockout study, causes dendritic spine loss (Knutson et al., 2016). Also unknown to date, 
CASS4 is a paralogue of NEDD9 and is likely to have similar functions in the regulation 
of the cytoskeleton.  
Actin filaments and microtubules are considered the master regulators of cell 
morphogenesis (Bouchet and Akhmanova, 2017). The actin cytoskeleton, composed of 
various distinct arrays of branched actin filaments, is considered the primary driver of 
cellular morphology. Growth of these filaments beneath the plasma membrane exerts a 
physical force which drives the production of protrusions, such as lamellipodia (Pollard 
and Borisy, 2003). Microtubules are rigid, hollow tubes composed of α- and β-tubulin 
heterodimers. The integrity of the microtubule network is considered secondary to that of 
actin; coordinating actin filament assembly, especially during cell migration (Etienne-
Manneville, 2013). Interestingly, however, in some cell types, including human 
glioblastoma cells, cell motility occurs independently of actin, with the microtubule 
network playing the dominant role (Panopoulos et al., 2011). Moreover, microtubules 
have specifically been shown to be responsible for generating membrane protrusions in 
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primary rodent astrocytes (Ellenbroek et al., 2012, Etienne-Manneville and Hall, 2001) 
although the exact mechanisms underlying astrocyte protrusion formation remain 
unexplored. 
The involvement of NEDD9 in cytoskeletal arrangement and the morphological changes 
in both, the overexpression and KD model are likely to influence cytoskeletal structure in 
astrocytes. The effect on the cytoskeleton and its major components, tubulin and actin, 
has not been investigated to date. Astrocyte dystrophy is likely linked to cytoskeletal 
arrangement. Unearthing mechanisms, leading to astrocyte atrophy in AD, could aid the 
hunt for new and much needed therapeutic targets in AD. 
 
 
6.2 Results 
To assess the expression of astroglial functional markers, NHAs overexpressing either 
NEDD9 or CASS4, and NHAs depleted of NEDD9 or CASS4 were fixed and immuno-
stained with target-specific primary antibodies (against GFAP, S100B, EAAT1, EAAT2 
and GS) together with an Alexa Fluor 555 secondary antibody. Omission of the primary 
antibody was used as control to confirm the specificity of the primary antibody. As 
outlined in chapter four, co-expression of GFP permitted the identification of transfected 
cells. Transfected cells were imaged at x40 magnification in >10 random fields of view 
per experiment, for a total of three experiments each for three separate donor pools. 
Fluorescence intensity measurements of each marker were calculated using FIJI ImageJ. 
Despite adherence to published protocols (e.g. Jones et al., 2017) and subsequent attempts 
at optimisation; immunofluorescent staining for EAAT1 and GS was ultimately 
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unsuccessful. Limitations in the availability of the primary NHAs meant that further 
attempts at optimising the staining protocol were not possible. 
 
 Glial fibrillary acidic protein 
Immunocytochemical staining of NHAs with anti-GFAP revealed a pattern of 
fluorescence which localised to filamentous structures throughout the entire cell, 
consistent with its expected localisation to intermediate filaments. No difference of GFAP 
localisation could be detected in NHAs overexpressing NEDD9 or CASS4 compared to 
the blank vector control group (Figure 6.1). 
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Figure 6.1 Overexpression of NEDD9 or CASS4 has no effect on GFAP fluorescence or 
localisation 
Fixed NHAs were stained using an anti-GFAP primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing slightly striated staining 
throughout the cell consistent with localisation to intermediate filaments. No 
alteration in staining was evident in cells overexpressing NEDD9 or CASS4 
compared to blank vector controls. GFP+ transfected cells, green. N=3 donors. 
Scale bar = 20µm. 
 
GFAP fluorescence intensities were calculated and compared between the blank control 
cells (1073.83±43.14 a.u.) and cells overexpressing NEDD9 (993.72±24.61 a.u.) or 
CASS4 (988.56±9.31 a.u.) (Figure 6.2). No significant difference of fluorescence 
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intensity was found (ANOVA, F(2,6)= 2.685, P= 0.147), suggesting that overexpression 
of the Cas-proteins does not influence GFAP expression in these astrocytes. 
 
 
Figure 6.2 Overexpression of NEDD9 or CASS4 has no effect on GFAP expression 
Mean fluorescence intensity of GFAP staining in NEDD9 or CASS4 
overexpressing NHAs in comparison to the blank vector control. Error bars ±  
SEM. N=3 donors. P=NS. 
 
 
 
As discussed in Chapter 5, NHAs depleted of NEDD9 or CASS4 exhibit reduced size, 
complicating comparison of the pattern of GFAP staining in comparison to scramble 
siRNA transfected controls. Nonetheless, a faint filamentous pattern of staining could be 
seen in those cells which had some form of process (e.g. polarised cells), (Figure 6.3). 
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Figure 6.3 GFAP fluorescence is reduced in NHAs depleted of NEDD9 or CASS4  
Fixed NHAs were stained using an anti-GFAP primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing slightly striated staining 
throughout the cell in the control and reduced staining in the KD cells. GFP+ 
transfected cells, green N=3 donors. Scale bar = 20µm. 
 
 
Initial observations seemed to indicate that GFAP fluorescence was less intense in the 
Cas-protein-depleted cells compared to the scramble control. Hence, quantification and 
comparison of fluorescence was undertaken (Figure 6.4). It should be noted that the 
method of quantification employed takes into account the size of each cell, such that there 
156 
 
is no bias against smaller cells. This analysis revealed a significant reduction of GFAP 
fluorescence in both the NEDD9 (137.87±6.34 a.u.) and CASS4 (133.62±3.28 a.u.) 
depleted cells compared to the scrambled control (970.97±40.18 a.u.),  (ANOVA, F(2,6)= 
418.826, P< 0.001; Tukey post hoc P< 0.001 for both); indicating that depletion of either 
of the Cas-proteins induces reduced GFAP expression in primary human astrocytes in 
vitro. 
 
 
 
Figure 6.4 Knock-down of NEDD9 and CASS4 induces down regulation of GFAP 
Mean fluorescence intensity of GFAP in NEDD9- and CASS4-depleted NHAs 
in comparison to the scramble control. Error bars ±  SEM. N=3 donors. *** 
p≤ 0.001 
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 S100 calcium-binding protein B  
Fluorescence imaging of NHAs immunocytochemically treated with an anti-S100B 
antibody revealed staining throughout the cytosol, consistent with the expected 
localisation of S100B. As with GFAP, no difference of S100B localisation could be 
detected between the blank vector control and the NHAs, overexpressing either NEDD9 
or CASS4. (Figure 6.5). 
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Figure 6.5 Overexpression of NEDD9 or CASS4 has no effect on S100B fluorescence or 
localisation 
Fixed NHAs were stained using an anti-S100B primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing slightly punctate staining 
throughout the cell under all transfection conditions. GFP+ transfected cells, 
green N=3 donors. Scale bar = 20µm. 
 
Comparison of the S100B fluorescence between the blank vector control cells 
(656.35±17.96 a.u.) and cells overexpressing either NEDD9 (630.13±24.87 a.u.) or 
CASS4 (637.00±43.37 a.u.) revealed no significant difference (ANOVA, F(2,6)= 0.197, 
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P= 0.827) of S100B fluorescence (Figure 6.6), suggesting that overexpression of the Cas-
protein has no effect on S100B expression in astrocytes. 
 
 
Figure 6.6 Overexpression of NEDD9 or CASS4 has no effect on S100B expression 
Mean fluorescence intensity of S100B in NEDD9 or CASS4 overexpressing 
NHAs in comparison to the blank vector control. Error bars ±  SEM. N=3 
donors. P=NS.  
 
 
On the contrary, a marked reduction of  S100B fluorescence was observed between the 
scramble control cells and the NEDD9 KD or CASS4 KD population, presenting with a 
reduction of S100B fluorescence in both KD populations (Figure 6.7). 
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Figure 6.7 Knock-down of NEDD9 or CASS4 shows a reduction of S100B fluorescence  
Fixed NHAs were stained using an anti-S100B primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing slightly punctate staining 
throughout the cell under control conditions and staining adjacent to the nuclei 
in both KD populations. GFP+ transfected cells, green. N=3. Scale bar = 
20µm. 
 
 
Additionally, an unusual cellular localisation of S100B could be observed in both knock-
down populations when observed by high-resolution confocal microscopy (Figure 6.8). 
S100B ordinarily localises throughout the cytosol, which could be observed in the NHAs 
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transfected with the scramble control (red, left panel). Yet in the cells depleted of NEDD9 
or CASS4, S100B appears to localise in a distinctive ring shape around the nucleus (red, 
centre and right panels, respectively), suggesting that depletion of the Cas-proteins may 
induce re-localisation of the calcium binding protein, possibly to the nuclear envelope. 
 
 
Figure 6.8 NEDD9 and CASS4 knock-out induce aberrant subcellular localisation of S100B 
Fixed NHAs were stained using an anti-S100B primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing punctate staining in the 
control and aberrant circular staining, adjacent to the nuclei (arrows) in both 
KD populations. GFP+ transfected cells, green. Scale bar = 10µm. N=3 
donors. 
 
 
Fluorescence intensities of S100B staining were quantified and compared between NHAs 
depleted of NEDD9 or CASS4 and the scramble control (Figure 6.9). A significant 
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reduction of S100B fluorescence was revealed in the NEDD9 (132.48±5.45 a.u.) and 
CASS4 knock-down (150.38±2.30 a.u.) NHAs compared to scrambled controls 
(675.16±5.97 a.u.),  (ANOVA, F(2,6)= 4027.529, P< 0.001; Tukey post hoc P< 0.001 for 
both), suggesting that KD of NEDD9 or CASS4 downregulates S100B expression in 
primary human astrocytes in vitro. 
 
 
 
Figure 6.9 Knock-down of NEDD9 and CASS4 downregulates S100B expression 
Mean fluorescence intensity of S100B is significantly reduced in NEDD9 or 
CASS4 knock-down NHAs in comparison to the scramble control. Error bars ± 
2 SEM. N=3 donors *** p≤ 0.001. 
 
 
 
 Excitatory amino acid transporter 2 
Fluorescence imaging of NHAs immunocytochemically stained for EAAT 2 revealed a 
slightly punctate pattern of staining throughout the cell, consistent with its expected 
localisation in the cytosol. No difference of subcellular localisation or fluorescence could 
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be observed between cells overexpressing NEDD9 or CASS4 in comparison to the blank 
vector control (Figure 6.10). 
 
 
Figure 6.10 Overexpression of NEDD9 or CASS4 has no effect on EAAT2 fluorescence or 
localisation 
Fixed NHAs were stained using an anti-EAAT2 primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing staining throughout the 
cell. GFP+ transfected cells, green. N=3 donors. Scale bar = 20µm 
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Quantification and comparison of EAAT2 fluorescence revealed no significant difference 
between cells overexpressing either NEDD9 (262.67±4.89 a.u.) or CASS4 (249.79±1.27 
a.u.) and the blank vector control (271.11±10.06 a.u.) (ANOVA, F(2,6)= 5.422, P= 
0.147), suggesting that overexpression of the Cas-proteins has no effect on EAAT2 
expression in astrocytes (Figure 6.11). 
 
 
Figure 6.11 Overexpression of NEDD9 or CASS4 do not affect EAAT2 fluorescence 
Mean fluorescence intensity of EAAT2 in NEDD9 and CASS4 overexpressing 
NHAs in comparison to the blank vector control. N=3 donors. Error bars ± 2 
SEM. P=NS 
 
 
In contrast to the overexpression model, a reduction of EAAT2 fluorescence could be 
observed in the NEDD9 (118.01±1.51 a.u.) or CASS4 (162.97±8.58 a.u.) knock-down 
NHAs when compared with the scramble control (263.40±5.29 a.u.), (Figure 6.12). 
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Figure 6.12 Knock-down of NEDD9 or CASS4 shows a reduction of EAAT2 fluorescence  
Fixed NHA were stained using an anti-EAAT2 primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing staining throughout the 
cell. GFP+ transfected cells, green. N=3 donors. Scale bar = 20µm. 
 
 
Comparing measurements of EAAT2 fluorescence in these cells revealed that this 
reduction was statistically significant (Figure 6.13; ANOVA, F(2,6)= 159.709, P< 0.001; 
Tukey post hoc P< 0.001 for both). This suggests that depletion of either of these Cas-
proteins stimulates a downregulation of this glutamate transporter in human astrocytes in 
vitro. 
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Figure 6.13 Knock-down of NEDD9 and CASS4 downregulates EAAT2 expression 
Mean fluorescence intensity of EAAT2 is significantly reduced in NEDD9 and 
CASS4 knock-down NHAs in comparison to the scramble control. N=3 donors. 
Error bars ± 2 SEM. *** p≤ 0.001. 
 
 
 
 β Actin 
Fluorescence imaging of NHAs stained for β-actin revealed striated staining throughout 
the cytosol and enriched in various stretches of the cell membrane, consistent with its 
cytoskeletal localisation (Figure 6.14). A difference of β-actin fluorescence or localisation 
could not be seen between the cells overexpressing NEDD9 or CASS4 and the blank 
vector control. 
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Figure 6.14 Overexpression of NEDD9 or CASS4 has no effect on βactin fluorescence or 
localisation 
Fixed NHA were stained using an anti-βactin primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing slightly striated staining 
throughout the cell. GFP+ transfected cells, green. N=3 donors. Scale bar = 
20µm. 
 
Quantification and comparison of β-actin fluorescence revealed no significant changes 
between the overexpressing population (NEDD9 217.42±19.46; CASS4 304.17±15.05 
a.u.) and the control population (216.57±36.77 a.u.) of NHAs (Figure 6.15; ANOVA, 
F(2,6)= 3.881, P= 0.083), suggesting that overexpression of the Cas-proteins does not 
influence expression of the actin filament. 
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Figure 6.15 Overexpression of NEDD9 or CASS4 has no effect on βactin expression 
Mean fluorescence intensity of β-actin in NEDD9 or CASS4 overexpressing 
cells in comparison to the blank vector control. Error bars ± 2 SEM. N=3 
donors. P=NS.  
 
 
As seen in the overexpression cells, NEDD9 or CASS4 KD did not appear to change β-
actin fluorescence or cellular localisation in NHAs, depleted of either NEDD9 or CASS4 
in comparison to the scramble control (Figure 6.16). 
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Figure 6.16 Knock-down of NEDD9 or CASS4 has no effect on βactin fluorescence or 
localisation 
Fixed NHAs were stained using an anti-βactin primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing slightly striated staining 
throughout the cell. GFP+ transfected cells, green. N=3 donors. Scale bar = 
20µm. 
 
Comparing β-actin fluorescence of NHAs depleted of NEDD9 (242.57±43.30 a.u.) or 
CASS4 (214.13±31.73 a.u.) to the scramble control (272.72±4.064 a.u.) revealed no 
significant changes between these populations (Figure 6.17; ANOVA, F(2,6)= 0.568, P= 
0.595), suggesting that depletion of NEDD9 or CASS4 does not affect β-actin expression 
in these astrocytes. 
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Figure 6.17 Knock-down of NEDD9 or CASS4 does not affect βactin fluorescence 
Mean fluorescence intensity of β-actin in NEDD9 and CASS4 depleted NHAs 
in comparison to the blank vector control. Error bars ±  SEM. N=3 donors 
 
 
 α Tubulin 
Fluorescence imaging of NHAs immunocytochemically stained for α-tubulin revealed a 
striated pattern of staining, similar to β-actin, throughout the cytosol, consistent with the 
expected cytoskeletal localisation of this tubulin. Cells overexpressing NEDD9 or CASS4 
appeared to display a slightly increased α-tubulin fluorescence in comparison to the blank 
vector control but with no apparent change in subcellular localisation (Figure 6.18). 
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Figure 6.18 Overexpression of NEDD9 or CASS4 leads to an increase of α tubulin 
fluorescence 
Fixed NHA were stained using an anti-tubulin primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing slightly striated staining 
throughout the cell under all transfection conditions. GFP+ transfected cells, 
green. N=3 donors. Scale bar = 20µm. 
 
Quantification and subsequent comparison of α-tubulin immunofluorescence revealed 
that the increase in fluorescence upon NEDD9 (2003.81±58.97 a.u.) or CASS4 
(2290.29±45.53 a.u.) overexpression was statistically significant (Figure 6.19; ANOVA, 
F(2,6)= 68.184, P< 0.001; Tukey post hoc, P≤ 0.001) in comparison to the blank vector 
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control (1537.32±31.32 a.u.) suggesting that both NEDD9 and CASS4 are influencing α 
tubulin expression in these NHAs. 
 
 
Figure 6.19 Overexpression of NEDD9 and CASS4 upregulates α tubulin expression 
Mean fluorescence intensity of α-tubulin is significantly increased in NEDD9 
and CASS4 overexpressing NHAs in comparison to the blank vector control. 
N=3 donors. Error bars ±  SEM. ** p≤ 0.01; *** p≤ 0.001 
 
 
Fluorescence imaging of the KD NHA groups stained for α tubulin revealed a slightly 
reduced fluorescence for the globular protein in cells, depleted of CASS4 in comparison 
to the cells depleted of NEDD9 and the scramble control (Figure 6.20). 
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Figure 6.20 Knock-down of CASS4 shows a reduction of αtubulin fluorescence  
Fixed NHAs were stained using an anti-αtubulin primary antibody, followed by 
Alexa Fluor 555 secondary antibody (red) revealing slightly striated staining 
throughout the cell and a reduction of α-tubulin in the CASS4 KD cells (arrow). 
GFP+ transfected cells, green. N=3. Scale bar = 20µm. 
 
 
Comparison of the measured α-tubulin fluorescence confirmed that there was a significant 
reduction in fluorescence in the CASS4 (722.74±12.34 a.u.) depleted NHAs compared to 
scrambled controls (1507.65±248.88 a.u.) (ANOVA, F(2,6)= 8.444, P= 0.018; Tukey 
post hoc, P= 0.024) but not for the NEDD9 knock-down (1457.98±81.11 a.u.) (Tukey 
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post hoc, P= 0.917) in comparison to the scramble control cells (Figure 6.21), indicating 
that only CASS4 has an effect on α tubulin expression when depleted. 
 
 
Figure 6.21 Knock-down of CASS4 downregulates αtubulin expression 
Mean fluorescence intensity of α-tubulin is significantly reduced in CASS4 
depleted cells in comparison to the scramble control. NEDD9 knock-down 
NHAs show no change in α-tubulin levels. N=3 donors. Error bars ± 2 SEM. 
*p≤ 0.05. 
 
 
6.3 Discussion 
As outlined previously, cell morphology and function are not separate entities but rather 
a unified system in which one influences the other. While overexpression of NEDD9 and 
CASS4 promoted an increase of cell volume and surface area; it had no effect on β-actin 
localisation or expression. Only α-tubulin was altered, with astrocytes overexpressing 
either NEDD9 or CASS4 experiencing increased expression of α-tubulin (although no 
change in subcellular distribution was evident). This may be in keeping with the earlier 
findings that the microtubule network, rather than actin filaments, play a particular role 
in morphological changes in astrocytes and glial cell lines (Ellenbroek et al., 2012, 
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Etienne-Manneville and Hall, 2001, Panopoulos et al., 2011). Development of the 
microtubule network is necessary for cells to increase in size (Lacroix et al., 2018). As 
one of the two major components of microtubules, enhanced expression of α-tubulin 
would be expected in larger cells. Moreover, changes of the microtubule network would 
be expected to occur due to the role of Cas-proteins in cytoskeletal arrangement: NEDD9 
has been shown to regulate AURKA (Bargon et al., 2005), which in turn controls 
microtubule remodelling (Yamada et al., 2010); and both NEDD9 and CASS4 are also 
known to have roles in mediating integrin-dependent signalling, maintaining focal 
adhesion integrity and regulating cell spreading and migration (Singh et al., 2008). This 
finding suggests, that overexpression of the Cas-proteins promotes astrocyte process 
formation and could hence even have a protective role in synapse support. Process 
formation is vital for contact with pre- and postsynaptic membrane, building the tripartite 
synapse, enabling bidirectional communication between neurons and astrocytes (Zovkic 
et al., 2013, Zorec et al., 2015). To investigate the effects of the larger astrocytes and the 
upregulation of tubulin on neuronal function would require co-cultures. Measuring 
neuron function in presence of NEDD9/CASS4 overexpressing astrocytes could provide 
evidence for a protective or damaging role. 
Interestingly, in the knock-down model, only depletion of CASS4 led to decreased levels 
of α-tubulin; NEDD9 depletion did not alter α-tubulin expression. This finding is 
somewhat at odds with reports that CASS4 may be less biologically active than NEDD9 
in mediating integrin-dependent signalling (Singh et al., 2008), possibly due to reduced 
Src binding (Tachibana et al., 1997). The relative activities of the Cas-proteins in 
astrocytes have not yet been explored, however, so this could potentially be reflective of 
an astrocyte-specific preference. Decreased expression of tubulin coincides with the loss 
of processes seen in the KD model and may reflect the inability of these cells to maintain 
176 
 
the tripartite synapse and hence loss of synaptic support, which could contribute to 
synaptic loss in the early stages of AD. 
Notably, overexpression of the Cas-proteins did not induce an increase of GFAP, 
suggesting that the increased cell size and process formation seen in the previous chapter 
was not due to an induction of reactivity, as outlined in the introduction, 
reactive/hypertrophic astrocytes present with increased GFAP expression and are a direct 
result to injury (Robinson et al., 2016, Gonzales-Reyes et al., 2017), such as amyloid 
plaques.  
Depletion of NEDD9 and CASS4, on the other hand, induced a marked decrease in GFAP 
expression. Although upregulation of GFAP as part of the astroglial reactive response is 
a hallmark of several neurodegenerative diseases (Pekny and Pekna, 2004, Ross et al., 
2003, Yang and Wang, 2015, Verkhratsky et al., 2013); in AD, reactive astrocytes are 
only evident during later symptomatic stages of the disease (Verkhratsky et al., 2017). 
During the early, asymptomatic stages of AD, astrocytes exhibit atrophy and present with 
a decreased GFAP expression (Beauquis et al., 2014, Jones et al., 2017, Olabarria et al., 
2010). Hence, NEDD9- or CASS4-induced reduction in GFAP concurrent with decreased 
cell size and arborisation in NHAs mirrors the early AD astrocyte phenotype. 
Neither overexpression of NEDD9 or CASS4 showed a significant difference in s100B 
or EAAT2 expression or localisation. Conversely, in Cas-protein-depleted cells, both of 
these markers were significantly downregulated. Reduced expression of the glutamate 
transporter EAAT2 could be a direct consequence of knock-down induced atrophy but 
may also be a result of reduced GFAP expression, as GFAP has previously been 
implicated as a regulator of EAAT2 (Hughes et al., 2004, Simpson et al., 2010). This is 
contrary to the finding that the mouse orthologue of EAAT2, GLT1, only displayed a 
slight, non-significant reduction in astrocytes of the prefrontal cortex in the 3xTg-AD 
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murine model (Kulijewicz-Nawrot et al., 2013), despite the pronounced atrophy evident 
in these cells (Kulijewicz-Nawrot et al., 2012). This disparity might be due to differences 
in the brain regions tested as the NHAs utilised herein being harvested from across the 
cortex, while Kulijewicz-Nawrot and colleagues specifically focused on the medial 
prefrontal cortex. Additionally, GFAP expression in 2D culture of astrocytes can vary 
greatly, depending on culture methods, from their counterparts in vivo (Lange et al., 
2012). This is a limitation of cells in 2D culture but alternatively, it may simply be due to 
inherent differences between mouse and human astrocytes (Mohamet et al., 2018). 
Although in vivo models are generally superior to in vitro, murine astrocytes differ greatly 
to human astrocytes (Zhang et al., 2013, Vasile et al., 2017, Verkahratsky et al., 2017), 
suggesting that primary astrocyte models are a more viable option for this investigation. 
Jones et al. (2017) previously reported reduced expression of another member of the 
EAAT family of glutamate transporters, EAAT1, in human astrocytes derived from AD 
patients. EAAT1 and EAAT2 share significant sequence homology (Arriza et al., 1994) 
and are both found almost exclusively on astrocyte processes which ensheath synapses, 
although they may exhibit some functional differences and brain region-specific 
expression variation (Valtcheva and Venance, 2019). Unfortunately, EAAT1 expression 
could not be tested in this thesis owing to the technical difficulties with the staining and 
a limited number of primary astrocytes available for optimisation. In the absence of any 
published literature suggesting otherwise, it is reasonable to speculate that the factors 
which impact upon the expression of one paralogue will have a similar effect on the other. 
Parallels may thus be drawn between the downregulation of EAAT1 seen in AD patient-
derived astrocytes and the downregulation of EAAT2 induced by NEDD9 or CASS4 
depletion. In both cases, loss of synapse-associated astrocytic glutamate transporters 
could be indicators of impaired synaptic glutamate homeostasis. 
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S100B was also significantly downregulated in NHAs depleted of either NEDD9 or 
CASS4. Reduced expression of s100B has previously been reported in iPSC-derived 
astrocytes of AD patients (both LOAD and EOAD) (Jones et al., 2017). The atrophic 
astrocytes also displayed a nuclear localisation of s100B, which was exclusively detected 
in the nucleolar region instead of the usual cytoplasmic subcellular localisation. A similar, 
though less extreme, mis-localisation of S100B was observed in the cells depleted of 
NEDD9 or CASS4, wherein the protein localised in a ring shape surrounding the nuclei 
with reduced prevalence in the cytoplasm. Nuclear accumulation of s100B has been 
reported in astrocytes previously, and also in adult oligodendrocyte progenitor cells, 
where those which exhibit nuclear S100B immunoreactivity go on to produce dense 
processes, while those which do not express S100B fail to achieve stellation (Deloulme 
et al., 2004). Depletion of s100B has previously been reported to result in a loss of typical 
morphology and the development of a fibroblast-like shape in the rat C6 glioma cell line 
and the GL15 astrocytoma cell lines, akin to that seen upon Cas-protein depletion (Brozzi 
et al., 2009, Selinfreund et al., 1991). Selinfreund and colleagues suggested that S100B 
might play a role maintaining proper astrocyte stellation through its interaction with Src 
kinase. As Src is a known binding partner of NEDD9 and CASS4, this might be another 
potential mechanism through which the Cas-proteins can exert influence on astrocyte 
morphology. Expression of s100B may also be linked to calcium signalling, but remains 
a limited aspect of such and further functional testing is required to determine the effects 
on calcium signalling in this model; this could be done with calcium labelling and live 
cell imaging. But s100B is also implicated in cell migration, proliferation and 
inflammatory response, whereby s100B downregulation reduces these effects (Xia et al., 
2018). Hence cells, depleted of s100B, are unable to respond to brain insults, suggesting, 
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that these astrocytes may not be able to deal with accumulating plaques and NFTs, leading 
to disease progression in AD.  
Overall, the changes of astrocyte functional markers in the NEDD9/CASS4 
overexpression model have been minimal and clearly coincide with the increased cell 
size, as cytoskeletal protein tubulin is expected to increase with increasing cell size and 
might even provide protective properties. Contrary to this, the KD model presented with 
drastic changes in functional markers, which as outlined above, suggests that the 
physiological functions of these cells are impaired. This is likely to lead to loss of the 
neuroprotective role of astrocytes to injury, such as plaques, and the role in homeostasis, 
such as clearing glutamate from the synaptic cleft. Protein aggregates, such as amyloid or 
tau, and loss of synapses are known AD pathologies and based on the above, atrophic 
astrocytes may be an early contributor to these manifestations. If further tests confirm 
NEDD9 and CASS4 as regulators of astrocyte atrophy in AD, the Cas-proteins could be 
used as therapeutic targets in the future.  
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Chapter 7 
General discussion 
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7 Discussion 
The overall aim of this thesis was to investigate whether altered expression of NEDD9 
and CASS4 induce morpho-functional changes in astrocytes and to explore if the altered 
expression links to a role in astrocyte dystrophy in AD. Initially it was necessary to 
confirm endogenous expression of these proteins, as this had previously not been 
demonstrated. Robust expression of both NEDD9 and CASS4 was confirmed via 
immunocytochemistry and Western blotting in glial cell lines and in primary human 
cortical astrocytes. Ideally, expression would also have been determined in the human 
adult brain, which had only been demonstrated in one previous study (Li et al., 2008), as 
the primary astrocytes used for this thesis are derived from foetal sources. 
Notwithstanding, the NHAs employed did express mature astrocyte markers, including 
s100B which has been reported to be a marker for terminally differentiated cortical 
astrocytes (Raponi et al., 2007). Human brain tissue was not available for this 
investigation (although ethical approvals are being sought to undertake this work, see 
future directions section), however expression was confirmed in the entorhinal cortex of 
adult mice. As the whole brain homogenate contains all brain cell types, conclusions may 
not be drawn about astrocyte expression in isolation. Nonetheless, these data indicate that 
both Cas-proteins are expressed in the mature murine brain. Taken together with the data 
from individual primary astrocyte cultures, it is highly likely, that the proteins are 
expressed in mature astrocytes in situ.  
Normal human astrocytes were selected as the model system in which to test the effects 
of the Cas-proteins. Although CASS4 isoforms were consistent across glial cell lines and 
the primary human astrocytes, blotting of whole cell lysates for NEDD9 revealed key 
differences in the expression of NEDD9 isoforms between the cell lines and primary 
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astrocytes. While cell lines expressed two cleaved forms of the full-length protein (55 
kDa and 65 kDa), NHA lysates contained only one of these isoforms (55 kDa) together 
with two phosphorylated isoforms of the full-length protein (105 kDa and 115k Da) 
(Bradshaw et al., 2011, Law et al., 1998). It may be that these differences are part of the 
altered NEDD9 expression profiles in the cancer cells from which the cell lines are 
derived (Gabbasov et al., 2018, Feng et al., 2015, Li et al., 2011, Izumchenko et al., 
2009). Although, as outlined in chapter four, primary cells are difficult to transfect 
(Alabdullah et al., 2019, Gresch and Altrogge, 2012), it is likely that the different NEDD9 
splice variants may serve different roles and might arise from cell type-specific post-
translational modifications. These differences meant that the primary human astrocytes 
were a superior option on which to base the expression models to permit better translation 
of findings to humans. Hence, immortalised cell lines were omitted from further 
experiments. 
When blotting cell lysates for CASS4, a band was never seen at the predicted size of 87 
kDa in any cell type. Instead, the truncated isoform 2 (76 kDa) was evident, together with 
an unusually large band at 230 kDa was seen in all cell types. This large molecular weight 
species does not correlate with any known isoform of the protein; however, it was 
consistently observed in all lysates, including the cell lines, NHA and mouse brain, 
indicating that the band is representative of CASS4 expression. Additionally, as 
previously indicated, this heavier CASS4 band has also been observed in the laboratories 
of Dr Mahendra Singh and Prof Erica Golemis (personal correspondence), although they 
have never published this finding. Although Cas-proteins undergo extensive 
phosphorylation, the very large size makes this unlikely to explain this size difference. 
The protein may form homo- or heterodimers via the C-terminal domain, as has been 
previously reported for NEDD9 (Law et al., 1999), although the size would be closer to 
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a trimerization, which has not been described for these proteins previously. Alternatively, 
this might represent a complex of CASS4 with one of its larger binding partners, such as 
Abl, which at 123 kDa would provide roughly the correct size band (Shagisultanova et 
al., 2015, Witte et al., 1980). Notwithstanding, this large molecular weight species 
resisted all attempts at disruption, including exposure to heat, additional reducing agents 
and chemical denaturants including urea. Interestingly, it was this band which was 
primarily enriched upon overexpression of CASS4 and knocked-down by siRNA; 
isoform 2 was largely unchanged in either case. This would indicate that a change in 
expression does not influence binding of CASS4 to its ‘mysterious’ binding partner. 
Identifying this binding partner may reveal new insights into CASS4-specific functions, 
since NEDD9 does not appear to form this same complex. Unfortunately, preliminary 
attempts at immunoprecipitation were unsuccessful and, since they were not a central 
objective of this thesis, will have to be left for future work. 
 
The NEDD9 and CASS4 overexpression and knock-down models in NHAs were created 
via transient transfection. This was initially considered to provide a sufficient transfection 
efficiency for subsequent experiments including the planned morphometric analyses. 
Stable transfection of NHAs may have aided this work as a continuous stock could have 
been created, readily available for follow-up experiments and longer-term experiments 
could have been undertaken (although maintenance of primary cells in culture for 
extended periods is not recommended as they become ‘culture adapted’ and start to 
exhibit altered phenotypes (Hayflick, 1979). The procedures of viral design and 
establishing stable transfection, however, are time consuming and require specific safety 
requirements, which would have limited the scope of this project. The transfection 
efficiency was suitable for preliminary validation of overexpression and knock-down via 
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immunocytochemistry. Western blotting, however, is the gold-standard and most 
commonly used method to validate overexpression and knock-down (Kikuno et al., 2007, 
LaRocca et al., 2019, Liu et al., 2009, Zhao et al., 2018). A stable line may have been 
advantageous in this validation via Western blot, as the relatively low transfection 
efficiency generated by the transient transfections meant that endogenous expression of 
the Cas-proteins in the non-transfected cell pool masked the knock-down. This was 
overcome by enrichment via puromycin selection for 24 hours, which produced sufficient 
enrichment by killing off the non-transfected cells in the culture, permitting knock-down 
confirmation. Selection of transfected cells via fluorescence-activated cell sorting 
(FACS) was also trialled, however both the low total numbers of primary cells available 
and the larger-than-average size of the NHAs meant that this method was unsuccessful 
and without results. Given more time for optimisation, FACS would be a suitable method 
to further validate KD and overexpression and improve this model. Other means to 
confirm the knock-down could have included qRT-PCR to quantify NEDD9 or CASS4 
mRNA levels; although this method only indicates the level of the transcript which, as 
described earlier, may not be a reliable indicator of the level of the protein product (Liu 
et al., 2016, Schwanhausser et al., 2011). Nevertheless, the combined results of 
confirmation via quantification of immunofluorescence and Western blot, combined with 
the observation of clear phenotypic changes in the transfected NHAs from three different 
donors, provided sufficient validation of Cas-protein overexpression and knock-down 
within the scope of this project. This thesis is the first study to create overexpression and 
knock-down models of the Cas-proteins in astrocytes as their effect on this cell type, or 
any neuronal cells, has not been tested to date. This permits a novel insight to regulation 
of morphology and physiology of astrocytes and a possible mechanism for astrocyte 
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atrophy in AD. Furthermore, it provides insights to the effect of GWAS identified risk 
variants on clinically relevant cells.  
 
Overexpression and knock-down experiments provided clear evidence that both NEDD9 
and CASS4 are capable of inducing morphological changes in astrocytes, achieving one 
of the main objectives of this thesis. Initial observation and visual binning of cells 
overexpressing either of the Cas-proteins showed a general shift towards a more stellate 
cell phenotype and a decrease in fibroblast-like morphologies. This is reflective of 
previous findings that upregulation of NEDD9 promotes process formation in epithelial 
cancer cells (Bargon et al., 2005). The morphometric quantitative analysis revealed that 
overexpression of NEDD9 or CASS4 leads to generally larger cells, based on the 
measurements of volume and cell surface, but no significant difference in surface to 
volume ratio was found. This would indicate, however, that the cellular morphology is 
not necessarily more complex in the overexpressing cells, compared to the control group; 
a small soma with several processes would lead to a higher surface to volume ratio in 
comparison to cells of a less complex nature as fibroblast-like cells (Jones et al., 2017). 
This discrepancy may be down to a number of factors. The method of visually assessing 
cell morphology is limited by subjectively categorising cell morphologies, whereas 
isosurface renders, used for morphometric analysis, are more quantitative and less prone 
to subjective influences. Moreover, despite best efforts at blinding when visually binning 
cell morphologies, the marked change in cell size was rather obvious to the observer, thus 
potentially compromising the blinding. However, the methodology used to image and 
render cells in 3D for the morphometric analysis could be considered less sensitive to 
detect finer processes. Such processes would contain limited amounts of GFP, making 
them relatively dim. Confocal microscopy (even the high-end systems with hybrid 
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detectors employed here) notoriously struggle to deal with low levels of fluorescence 
since the principles used to collect individual optical z-sections mean much of the light 
from the specimen fails to pass through the pinhole to the detector. A widefield 
fluorescence microscope of the sort used to conduct the visual binning experiments, 
however, collects all of the light from the specimen (even that which is out of focus) 
(Lichtman and Conchello, 2005). This combined with the cells being visualised using the 
human eye (which despite huge advances in the field is still considerably better dynamic 
range than a CCD camera or other digital detector) would offer a superior ability to 
identify fine, dim processes emanating from larger, brighter cell bodies. Alternatively, 
this difference may be the result of using a relatively crude measure of cellular complexity 
in the form of the surface area to volume ratio. It could be that a form of Sholl analysis, 
which was originally developed to quantify neuronal dendritic arborisation (Longair et 
al., 2011, Sholl, 1953), modified to take into account the thicker processes of astrocytes 
might provide a more sophisticated approach to quantifying such complex morphologies. 
Although a modified Sholl method has recently been applied to astrocytes, this was in 
mouse brain sections; where astrocytes exhibit native 3D conformations that include 
much finer processes emanating in all dimensions (Tavares et al., 2017). Attempts to 
apply the method to human astrocytes in culture during this thesis were unsuccessful, 
probably owing to differences in cellular morphology between the 2D culture system and 
the in vivo morphologies upon which the analysis method was based. Nonetheless, 
modification of this morphometric approach might prove beneficial to future studies on 
astrocytes in 2D culture. 
Morphological analyses of the NEDD9 and CASS4 knock-down model presented a 
somewhat clearer picture; visual evaluation and binning cells into morphology types and 
morphometric analysis both revealed that astrocytes depleted of either of the Cas-proteins 
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exhibit an atrophic morphology. These cells presented with a decreased somata width and 
were process devoid. Similarly, morphometric analyses showed a significant decrease in 
cell surface area and volume and no difference in surface to volume ratio, indicating that 
depletion of NEDD9 and CASS4 promotes smaller cells. This is also in keeping with 
previous findings, were NEDD9 depletion has induced cell rounding in mouse embryo 
fibroblasts (Zhong et al., 2012) and is capable of inducing dendritic spine loss of 
hippocampal neurons in mice (Knutson et al., 2016).  
Taken together these data indicate that depletion of NEDD9 and CASS4 can inhibit the 
formation and/or maintenance of membrane protrusions, such as processes, a 
phenomenon which has not previously been reported for CASS4 in any cell type.  
 
The molecular mechanisms underlying Cas-protein-induced morphological changes were 
not explored as part of this thesis, however previous studies provide some insight. 
NEDD9 is known to be involved in several signalling pathways which could lead to 
morphological changes. NEDD9 regulates AURKA activity, which is essential for proper 
arrangement of the microtubule network (Mori et al., 2009, Pugacheva and Golemis, 
2005). Microtubules, rather than the actin cytoskeleton, have previously been especially 
implicated in astrocyte morphogenesis (Ellenbroek et al., 2012, Etienne-Manneville and 
Hall, 2001, Panopoulos et al., 2011). During this process, phosphorylation of the 115 kDa 
NEDD9 isoform is increased (Sakai et al., 1994). This isoform was overexpressed in the 
NHAs transfected with NEDD9 LV-CMV and it is plausible that overexpression triggers 
a similar pathway in astrocytes, inducing process formation, discussed in in chapter 5. 
Additionally, the 115 kDa isoform was depleted in the KD cells and may inhibit such 
pathways, hence inhibit process formation. As cells depleted of CASS4 exhibit a similar 
phenotype, it is likely that the protein acts in the same manner as its paralogue. 
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Alternatively, these morphological changes might be mediated by s100B, whose levels 
appear to be influenced by the Cas-proteins via Src and has been reported to play an 
important role maintaining proper astrocyte stellation (Brozzi et al., 2009, Selinfreund et 
al., 1990). 
One particularly interesting find was that the astrocytes depleted of NEDD9 or CASS4 
mimic the atrophic phenotype of astrocytes found in both mouse and human models of 
AD (Jones et al., 2017, Kulijewicz-Nawrot et al., 2012 Olabarria et al., 2011, Yeh et al., 
2011). Cell morphology in both models are characterised by soma shrinkage and 
complete loss of cellular processes, as was the morphological phenotype induced by Cas-
protein depletion presented here. As astrocyte atrophy in AD remains unexplained and 
polymorphisms in both NEDD9 and CASS4 which likely alter expression have been 
linked to an increased risk of LOAD, it is reasonable to suggest that this might be a 
potential mechanism through which atrophy might manifest and requires further 
investigation. Atrophic, process-devoid astrocytes are likely unable to be in contact with 
synapses, hence losing the ability to support them. This could lead to an increase of toxins, 
such as glutamate, in the synaptic cleft and ultimately synaptic loss. Synaptic loss is a 
manifestation in AD, uncovering mechanisms leading to these hallmarks, such as Cas-
protein induced atrophy, could aid the understanding of pathogenesis and identify new 
therapeutic targets in the future. 
 
The change of astrocyte functional markers induced by Cas-protein depletion also 
correlated with findings from AD models. Jones et al (2017) have reported the 
downregulation of GFAP, s100B, EAAT1 and GS in their atrophic human iPSC-derived 
AD astrocytes. Here a reduction in GFAP and s100B accompanied NEDD9 or CASS4 
knock-down. Crucially, overexpression of the Cas-proteins induced no change in GFAP 
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or s100B levels, indicating that the enlarged morphological phenotype induced was not 
due to astrocyte reactivity, which is associated with upregulation of both of these proteins 
(Pekny and Pekna, 2014). Depletion of s100B has previously been reported to result in a 
loss of typical morphology and the development of a fibroblast-like shape in glial cell 
lines (Brozzi et al., 2009, Selinfreund et al., 1990). Furthermore, downregulation of 
s100B has been shown to inhibit the inflammatory response in other cell types (Ohtaki et 
al., 2007), suggesting that a decrease of s100B may hamper the ability of astrocytes to 
respond to brain insults, such as amyloid plaques or NFTs.  
The downregulation of S100B and its aberrant cellular mis-localisation provided another 
parallel to the studies of atrophic astrocytes in AD, as a reduced expression was reported 
in 3xTg-AD mice and human iPSC-derived AD astrocytes (Jones et al., 2017, Yeh et al., 
2011). The atrophic iPSC-derived AD astrocytes also displayed a mis-localisation of 
s100B, which was exclusively detected in the nuclei instead of the usual cytoplasmic 
subcellular localisation. A similar redistribution of s100B was observed in the NHAs 
depleted of NEDD9 or CASS4 here with the protein localising in a ring shape surrounding 
the nucleus. It remains unclear how the dysregulation and mis-localisation of s100B 
occurs. S100B binds to GFAP, hence the reduction of GFAP and aberrant cytoskeletal 
arrangement in the Cas-protein KD cells could potentially influence s100B localisation. 
To completely elucidate the morphological and functional changes induced by altered 
expression of the Cas-proteins will require additional research. Notwithstanding, NEDD9 
or CASS4 depletion alone appears to induce a similar s100B cellular phenotype to that 
seen in AD models.  
 
Downregulation of the astrocytic glutamate transporter EAAT2 was also reported upon 
depletion of either Cas-protein. Kulijewicz-Nawrot et al. (2013) also reported a slight 
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decrease in EAAT2 in astrocytes of the prefrontal cortex in the 3xTg-AD murine model, 
although this was deemed non-significant, and Jones and colleagues (2017) showed a 
downregulation of EAAT1, a related paralogue of EAAT1 (Arriza et al., 1994). 
Determination of EAAT1 levels in the overexpression and knock-down models was 
attempted, however it was not possible due to difficulties with the optimisation of the 
staining protocol and the limited number of primary cells. The same problem occurred 
for glutamine synthetase, which has also been reported to be reduced in AD (Jones et al., 
2017, Kulijewicz-Nawrot et al., 2013, Rodriguez-Arellano et al., 2016). Notwithstanding, 
these data point to an impairment of astrocyte functional markers upon Cas-protein 
depletion, implying a key role for both NEDD9 and CASS4 in maintaining astroglial 
functions. For example, EAAT2 is responsible for the majority of glutamate uptake by 
astrocytes (Kim et al., 2011, Nedergaard et al., 2002) and hence a reliable marker of 
astrocytic function. Altered expression of the transporter as reported here would 
inevitably lead to unbalancing glutamate homeostasis in the brain. Indeed, altered 
expression has been linked to several neurological diseases, such as amyotrophic lateral 
sclerosis (Rattray and Bendotti, 2006), Huntington’s disease (Arzberger et al., 1997) and 
AD (Garcia-Esparcia et al., 2018). The reduction of EAAT2 could be a direct 
consequence of KD-induced atrophy but may also be a result of reduced GFAP 
expression, as GFAP has previously been implicated as a regulator of EAAT2 (Hughes 
et al., 2004, Simpson et al., 2010). A downregulation of EAAT2 would indicate that 
glutamate transport of the KD cells is affected and may hence lead to unbalanced 
glutamate homeostasis and reduced uptake at the synapse, potentially exposing neurons 
to excitotoxic damage (Kim et al., 2011, Nedergaard et al., 2002). Collectively, the 
dysregulation, particularly the downregulation of functional markers in the KD 
astrocytes, give imply that the function of these cells is affected. This downregulation 
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mirrors the atrophic AD phenotype, identified in earlier studies (Jones et al., 2017), 
further implicating altered expression of the Cas-proteins as a possible mechanism in 
astrocyte atrophy in AD. However, immunocytochemistry alone is not sufficient and 
direct functional assessments, such as glutamate uptake assays, should be employed to 
validate these findings.  
Collectively, the functions of atrophic astrocytes, such as the NEDD9/CASS4 KD model, 
are likely to be impaired and play a role in AD pathogenesis. The downregulation of 
glutamate transporters could ultimately lead to synaptic loss due to glutamate 
neurotoxicity, but the mechanisms by which early synaptic impairment is caused in AD 
remain elusive, however given the dependence of many synapses on close physical 
contact with astrocytes (Hama et al., 2004, Hennenberger et al., 2010), astroglial atrophy 
is likely be a contributing factor in synaptic dysfunction in AD. Furthermore, atrophic 
astrocytes are likely unable to deal with amyloid or NFT load, hence contributing to AD 
pathology. It remains unclear if atrophic astrocytes become reactive during later stages of 
the disease but are likely an independent early hallmark and hence playing a different, yet 
unknown role in disease progression.  
While the mechanisms are not yet fully understood, this thesis demonstrates, that altered 
expression of the Cas-proteins, NEDD9 and CASS4 (implied by GWAS as a risk factor 
for AD) are capable of recapitulating many of the morphological and functional deficits 
seen in atrophic astrocytes in AD. These results build upon the astrocyte atrophy during 
early, asymptomatic AD stages, identified by Jones et al. (2017) and propose a new 
mechanism for this manifestation.  
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7.1 Concluding statement 
In summary, this work provides valuable insights of how NEDD9 and CASS4 may be 
involved in astrocyte pathology and provides solid grounds for further research. This 
work confirms that altered expression of the Cas-proteins leads to morpho-functional 
changes in astrocytes, which may uncover mechanisms leading to astrocyte atrophy in 
AD. This thesis is a step towards elucidating pathologies in AD but harbours some 
limitations, such as the NHA model of foetal tissue origin. Although there are no adult 
astrocyte models available, testing human brain samples alongside the in vitro model 
could have improved this thesis. Furthermore, much time was spent on the validation of 
the models, particularly via FACS, when validation had already been achieved via IF and 
western blotting. This time could have been used to pursue functional tests, thus greatly 
enhanced the last result chapter. Due to the novelty of this work and lack of literature, 
much optimisation was required, which limited time for testing the model. Nonetheless, 
this thesis contributes to the understanding of astrocyte dystrophy in AD and could, with 
some additional work, unearth new therapeutic targets in the future. 
 
  
193 
 
 
 
 
Chapter 8 
Future directions 
  
194 
 
 
8 Future directions 
First of all, some work of this thesis could be refined, repeated and extended, such as the 
model validation or the investigation of functional markers, however, this is already 
outlined in the general discussion. The role of NEDD9 and CASS4 in AD development 
has previously not been studied. Based on this, there is copious future work which could 
build upon the findings of this thesis 
A good starting point would be to genotype the NHAs, used in this thesis, as there is the 
possibility of the (NHA) donors carrying the SNPs indicated as LOAD risk factors. 
Although the SNPs are rare and the results have been congruent across all donors, it is a 
vital investigation, which was not possible due to lack of resources for this thesis.  
Once the absence of the indicated SNPs is established, rescue studies should be employed 
to fully exclude the possibility of off-target effects and confirm that KD of NEDD9 and 
CASS4 is indeed the cause for the atrophic phenotype. This work would require the 
development of siRNA-resistant expression vectors which would be used to rescue the 
levels of each Cas-protein following knock-down. Although this would be vital to 
validate the KD, the low transfection efficiency may lead to difficulties as a second 
transfection with siRNA-resistant vectors is unlikely to be successful in all KD cells, if at 
all. This could be overcome with stable transfection, but as outlined in this thesis, is time 
consuming and may cause further off-target effects. Nonetheless, rescue experiments 
should be trialled, including crossover studie, to see if overexpression of CASS4 could 
rescue the phenotype induced by KD of NEDD9, and vice versa. In this way overlapping 
functions could be uncovered.  
195 
 
Next functional assessment of the astrocyte models should be undertaken. The findings 
of changed marker expression, particularly the downregulation in the KD model, points 
to aberrant function of these cells. To actually determine this, functional tests could be 
performed. The downregulation of the glutamate transporter EAAT2 is likely to affect 
glutamate homeostasis; a glutamate uptake assay would be a relatively simple but 
effective way to test if glutamate uptake is impaired in these cells. Furthermore, the 
dysregulation and mislocalisation of s100B indicates that calcium signalling may also be 
affected in these cells. To determine calcium signalling in this model, calcium immuno-
labelling, such as Rhod-2, would be required for live cell imaging. Live cell imaging has 
not been undertaken, as the experiments of this thesis required fixed cells. The transient 
overexpression and knockdown would be time limiting but it would also show how these 
cells function over a, although short, time period. 
As KD of NEDD9 or CASS4 leads to smaller cells which reflects the atrophic phenotype 
found in iPSC-derived astrocytes from EOAD and LOAD patients, it would be of great 
interest to determine the expression of the Cas-proteins in these cells. This would 
conclusively establish whether there, expression of the Cas-proteins is indeed reduced in 
AD. The same phenotype had been found in transgenic mouse models of AD, it would 
thus also be of interest to test the expression of the Cas-proteins in AD mouse brain tissues 
in comparison to a wild-type control. 
Furthermore, NEDD9 and CASS4 knockout (KO) murine models would also be a valid 
path of investigation. It has previously been shown that mice null for NEDD9 display 
dendritic spine loss in neurons (Knutson et al., 2016), yet astrocytes were not investigated 
in this study and no such model exists for CASS4. Gaining access to brain tissues from 
the NEDD9 KO model and, in the longer term, establishing a CASS4 KO model would 
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provide significant insight to how altered expression of the Cas-proteins affects astrocytes 
(and other neural cells) in vivo. 
There is little knowledge on how atrophic astrocytes affect neurons. To determine this, 
growing co-cultures of primary neurons alongside astrocytes with altered 
NEDD9/CASS4 expression could give some insight and follow-up testing of neuron 
morphology and function may provide vital clues on synaptic loss in AD.  
Finally, it would be of interest to investigate the large CASS4 (230 kDa) band seen in 
WB and to establish its binding partner. This could be undertaken via 
immunoprecipitation followed by mass spectrometry. This may not relate directly to AD, 
but may yield more knowledge of the Cas-protein individual function, which would 
ultimately aid the investigation of its role in LOAD. 
If the role of NEDD9 and CASS4 in LOAD can be confirmed, it would be of interest to 
test various compounds which may reverse the phenotype caused by dysregulation 
(possibly downregulation) of the Cas- protein expression. Drugs, known to stabilise the 
cytoskeleton, such as Paclitaxel (used in cancer treatment), could also be administered to 
see if they might aid the reverse to a healthy astrocyte phenotype.  
Collectively, there is a myriad of future work which could be conducted based on the 
findings in this thesis which might provide insight into not only the specific functions of 
the Cas-proteins in astrocytes but also their role in the development of LOAD. Several 
steps must be undertaken to determine their role and definite function, but once achieved, 
the Cas-proteins could deliver new therapeutic targets for the treatment of LOAD. 
Furthermore, if the proteins indeed play a role in astrocyte atrophy during the 
asymptomatic stages of AD, they could even deliver targets for preventative measures in 
the future.  
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9 Appendices 
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9.1 Appendix 1 – Exemplar western blot including loading controls 
 
Figure 9.1 Exemplar western blot including lysis buffer controls 
All ten lanes are shown. Lane 1, protein marker (ladder); Lane 2-4, NHA lysate; 
Lane 5 and 6, lysis and loading buffer only (RIPA); Lane 7-9, NHA lysate; Lane 
10, loading buffer (Laemmli) only. Blot stained for CASS4, no visible staining 
in the lanes with lysis buffer or/and loading buffer. 
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